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Mitochondria contain their own DNA (mtDNA) which can be damaged, leading to the 
formation of mtDNA deletions (ΔmtDNA). These are particularly prominent in post mitotic 
tissues and progressively accumulate with advancing age. Within the brain, ΔmtDNA may 
reach levels of 50% and has been linked to COX-deficiency and neurodegeneration. Although 
these ΔmtDNA are well characterised, the definitive mechanism for their formation and 
accumulation to high levels is unknown. One of the suggestions for deletion formation is 
inadequate replication. This study aimed to further understand how mtDNA replication differs 
between neurons and with age, and whether such changes could be associated with the 
formation and accumulation of mtDNA deletions. 
This was investigated in different ways. Various regions of the brain differ in the levels of 
deletions. Therefore, the mtDNA replication levels in different regions were investigated via 
thymidine analogue labelling to identify any alterations. Significant differences were noticed 
between different regions with cerebellum generally presenting increased signal and the SN 
presenting the lowest. Since ageing and disease is a risk factor of ΔmtDNA accumulation, aged 
mice and PolgAmut/mut mice were used, demonstrated a general decrease in thymidine 
analogue signalling with increased age and with a replication defect. The replication levels 
obtained from this study were compared to another study from the literature investigating 
the levels of deletions from different brain regions. No correlation was observed suggesting 
that although mtDNA replication is altered within different regions in the brain, there could 
be other mechanisms effecting the formation and accumulation of ΔmtDNA.  
Additionally, the thymidine analogue labelling was developed and optimised for in vitro use 
on HeLa cells and was used to label iPSCs and differentiated neurons from a patient with a 
large scale mtDNA deletion. Two isogenic cell lines of varying heteroplasmy (>10% and 40%) 
were used for this study to see the effect of altered ΔmtDNA on replication. The methodology 
was optimised successfully for further use.    
Along with the total replication levels, the location of replication was also investigated to 
understand the impact of this on the accumulation of ΔmtDNA. This is due to previous theories 
 
 
that have suggested that since replication and mitophagy happen in close proximity to the 
nucleus and each other, this increases the chances of a dysfunctional mitochondria, containing 
ΔmtDNA, replicating. The results suggested that majority of the replication happened in the 
perinuclear region, and preliminary data on the location of mitophagy also showed a 
perinuclear increase.   
To further investigate the health and connectivity of the mitochondria in the perinuclear 
region I compared them to distal mitochondria. This novel ‘proof-of-concept’ study 
investigated the morphology and structural connectivity of mitochondria in human brain 
tissue using electron microscopy techniques. This study was successful and preliminary data 
from dopaminergic neurons are discussed.  
In conclusion although mtDNA replication levels and replication location varies between 
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PGC-1α  Peroxisome proliferator-activated receptor γ, coactivator 1α  
Pi Inorganic Phosphate      
PINK1 PTEN-induced putative kinase 1  
PM Post-mortem       
PO PolgAmut/mut old 
POLG Polymerase Gamma      
POLMRT Mitochondrial RNA polymerase     
POLRMT mtRNA polymerase 
Polγ Polymerase Gamma      
PPARγ Peroxisome Proliferator Activated Receptor Gamma  
PY PolgAmut/mut young 
Rcf Relative Centrifugal Force     
RITOLS Ribonucleotide incorporation throughout the lagging strand  
RNA Ribonucleic Acid      
ROI Region of interest 
ROS Reactive oxygen species     
RRM2B Ribonucleotide Reductase subunit M2 B   
RT Room temperature      
SBF-SEM Serial Block Face Scanning Electron Microscopy  
SD Standard Deviation      
SDH Succinate Dehydrogenase      




SLC solute carrier 
smPCR Single molecule PCR     
SN Substantia nigra 
SPATA18 Spermatogenesis Associated 18  
SPATA18 Spermatogenesis Associated 18  
T Thymidine       
TCA Tricarboxylic Acid      
TEM Transmission Elctron Microscopy     
TFAM Transcription Factor A, Mitochondrial  
TIM translocases of the inner membrane  
Tm Melting temperature      
TOM translocases of the outer membrane  
tRNA transfer ribonucleic acid     
TSFM Tu Translation Elongation Factor, Mitochondrial  
TWINKLE Twinkle helicase      
UNG Uracil-N glycoslyase      
UV ultra violet 
VDAC Voltage Dependant Anion Channel    
VGLUT Vesicular glutamate transporter     
WO wildtype old 
WT Wild-type       
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WY wildtype young 
ΔmtDNA mtDNA deletion 
μl microlitre       
















Chapter 1 : Introduction 
1.1 Origin of Mitochondria 
Mitochondria are dynamic organelles present within the cytoplasm of all mammalian 
nucleated cells. The origin of mitochondria has been theorised to arise due to an 
endosymbiotic relationship, where a primitive free-living prokaryote with the ability to utilise 
oxygen available in the atmosphere as an energy source, was engulfed by a pre-eukaryotic 
cell. This was brought to light in 1971 (Margulis, 1971), and explained that the reason for this 
symbiotic relationship was that the free-living prokaryote received a secure and stable 
environment and in return ATP (adenosine triphosphate) as the result of respiration, was 
provided for the host cell (Martin et al., 2015). The main evidence for this theory is the 
prokaryotic-like properties of the mitochondrion including its double membrane, circular 
genome, ability to undergo fission and fusion and the ability to independently synthesise 
proteins. Alongside this, a high proportion of genes required for mitochondrial structure, 
function and quality control are found in the nuclear genome (Gray, 2012, Gray et al., 1999). 
The hydrogen hypothesis theory proposes another basis for mitochondrial origin (Martin and 
Müller, 1998). This theory suggests that the host cell was a methanogenic archezoa which 
engulfed a eubacterium with the ability to produce H2 and CO2. When the host was in an 
environment with a lack of H2, a symbiotic relationship was formed between the two species. 
Selective pressures within this environment selected the host cells with this symbiotic 
relationship (Martin et al., 2001). This theory suggests that the formation of the nucleus 
occurred following this symbiotic event. However this theory is not completely accepted as a 
‘true archezoa’, a eukaryotic cell without a mitochondria, has not been identified and 
molecular analysis has identified mitochondrial genes present within the nuclear DNA of this 
group (Clark and Roger, 1995, Roger, 1999).  
The ancestor of mitochondria has been suggested to be the intracellular parasite Rickettsia 
prowazekii, identified by whole genome sequencing (Andersson et al., 1998). This analysis 
found genes encoding for components of the tricarboxylic acid (TCA) cycle and complexes of 
the respiratory chain within its genome, allowing Rickettsia prowazekii to produce ATP, similar 
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to mitochondria. However, due to inconsistencies in phylogenetic trees during analysis and a 
fast evolution rate, it has been suggested that this might not be the true ancestor of 
mitochondria but simply a lineage relative (Degli Esposti, 2018, Degli Esposti, 2016). In other 
studies, a few other organisms have been suggested to be the evolutionary ancestor of 
mitochondria (Yang et al., 1985, Atteia et al., 2009, Williams et al., 2007, Degli Esposti, 2018), 
despite this, all studies are consistent in their agreement for a prokaryotic origin for the 
mitochondrion (Gray, 2015). 
1.2 Mitochondrial Structure 
In concurrence with their prokaryote ancestors, mitochondria have been observed through 
electron microscopy as consisting of a double membrane structure with an outer 
mitochondrial (OMM) and an inner mitochondrial membrane (IMM) separated by the 
intermembrane space (Palade, 1953, Mannella et al., 1994). Figure 1.1 presents a cartoon 
illustration of a mitochondrion highlighting its integral structures (figure 1.1a), and an image 
obtained from electron microscopy (EM, figure 1.1b). Although typically illustrated as a rod 
shaped organelle (figure 1.1a), the shape and size of mitochondria vary due to their dynamic 
nature and ability to form a reticular network. Initial studies, using EM, measured 
mitochondrial length to be in the range of 1-4µm and with diameters ranging between 0.3-
0.7µm (Palade, 1953). This is consistent with the EM image (figure 1.1b) produced for the 
purpose of this thesis. Further studies looking at 3D models have demonstrated consistent 
values within the range of 0.75 to 3µm2 for the size of mitochondria (Rafelski and Marshall, 
2008, Bereiter-Hahn, 1990, Wiemerslage and Lee, 2016). The number of mitochondria per cell 
also varies depending on the cell type due to differential energy requirements (Nass, 1969). 
Analysis of five different mammalian cell types demonstrated an average of 83 mitochondria 
per cell (Robin and Wong, 1988). However, these measures are not fixed since mitochondria 




Figure 1.1 The structure of the mitochondrion. Image A presents the cartoon representation of a mitochondrion 
with its structural components labelled. Image B presents an electron microscopy image of multiple mitochondria 
presented within an axon. The image shows clearly the cristae and double membrane structures of the 
mitochondria 
The double membrane of the mitochondrion has a similar structure to the phospholipid 
bilayer of the cell membrane and functions in a similar way to allow selective permeabilisation. 
The OMM is a smooth lipid membrane separating the free flow of molecules between the 
mitochondrial interior and the cytoplasm of the cell. The membrane contains voltage-
dependent anion channels (VDAC), also known as mitochondrial porin. These channels allow 
the exchange of molecules and ions <10kDa to pass (Alberts et al., 2002, Szabo and Zoratti, 
2014). VDAC remains open at a membrane potential of 0mV, but when the potential reaches 
30mV (for both positive and negative potential), it closes (Blachly‐Dyson and Forte, 2001).  
Compared to the OMM, the IMM is highly selective in terms of permeabilisation, only allowing 
O2, CO2, H2O and NH3 to pass freely. The IMM has an increased protein to lipid ratio due to 
the presence of cardiolipin and the IMM bound oxidative phosphorylation (OXPHOS) 
complexes I – V (also termed respiratory complexes), that are required for ATP production 
(Fleischer et al., 1961). Cardiolipin is a protein required for the function of the respiratory 
chain enzymes and also provides structural support for the IMM (Pfeiffer et al., 2003). Due to 
this high protein content, the IMM is less permeable then the OMM. Alongside this, the IMM 
is also folded into convoluted structures called cristae (Frey and Mannella, 2000). The 
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convolution provides an increased surface area, which is beneficial for oxidative 
phosphorylation (OXPHOS) protein assembly and to maximise ATP production. Originally, 
according to the baffle model, the IMM was thought to be folded back on itself to form 
internal ridges with broad openings (Palade, 1953). However, with better resolution and 3D 
EM, structures termed ‘pediculi cristae’ were discovered. They demonstrated that the IMM 
contained an inner boundary membrane (IBM) and a cristae membrane (CM) that were 
connected together via narrow and tubular openings called cristae junctions (Daems and 
Wisse, 1966, Mannella et al., 1997, Frey and Mannella, 2000). As mentioned before, the IMM 
is highly selective in terms of permeabilisation, and hence for protein transport it contains 
adenine nucleotide translocator (ANT) which is responsible for the transport of ATP out of the 
mitochondrial matrix into the cytoplasm and the transport of adenosine diphosphate (ADP) 
from the cytoplasm into the matrix in a 1:1 ratio (Pfaff et al., 1969, Lauquin et al., 2017). 
Certain molecules over 10kDa, including pyruvate produced as the result of glycolysis in the 
cytoplasm and various nuclear encoded proteins, are required within mitochondria. These 
proteins contain N-terminal sequences that target them to mitochondria but they require 
assistance to cross the membranes. To facilitate this, the OMM and IMM also contain the 
translocases of the outer membrane (TOM) and inner membrane (TIM) that allow protein 
transport across the mitochondrial membranes and into the matrix (Alberts et al., 2002, Endo 
and Yamano, 2010, Ahmed and Fisher, 2009).  
Surrounded by the inner membrane, is the matrix, containing a mixture of substances that 
makes it more viscous than the cytoplasm (Palade, 1953). They included various nuclear 
encoded proteins and multiple copies of the mitochondrial DNA (mtDNA) packed together in 
nucleoids. Initially studies discovered an average of 2.6 mtDNA molecules per mitochondria, 
and within the whole cell the range was from 220-1720 in various mammalian cell types (Robin 
and Wong, 1988). In human carcinoma cell lines, for example, mtDNA copy number was 
suggested to be in the range of 1-15 mtDNA molecules or an average of 4.6 mtDNA molecules 
within each mitochondrion (Satoh and Kuroiwa, 1991). This was consistent with later studies 
using more developed techniques such as quantitative-PCR and immune-EM  which 
demonstrated a similar range of 2-10 mtDNA molecules per mitochondrion (Legros et al., 
2004, Iborra et al., 2004). 
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As mentioned above, a number of nuclear encoded proteins required for mitochondrial 
function are also transported into the matrix. This includes proteins required for the 
transcription, translation and general maintenance of the mtDNA. The majority of the proteins 
required for this purpose are coded for by the nuclear DNA and transported into the matrix. 
Mitochondria contain mitochondrial ribosomes for translation. The matrix is also the site of 
iron-sulphur cluster biogenesis, pyruvate oxidisation, β-oxidation of fatty acids and Krebs 
cycle, hence electron carriers, enzymes required for these processes and their by-products are 
also present within the matrix (McCommis and Finck, 2015, Braymer and Lill, 2017, Wanders 
et al., 2010). 
1.3 Mitochondrial dynamics 
Mitochondrial dynamics is a term that describes various characteristics of mitochondria 
including their biogenesis, fission, fusion, transport and finally their degradation, through the 
process of mitophagy.  
 Mitochondrial biogenesis  
This is the process by which, new mitochondria are formed. This normally occurs in response 
to the requirement for energy within cells, for example an increase in the demand for more 
ATP would stimulate the production of more mitochondria (Handschin and Spiegelman, 2006). 
One of the most studied proteins within the biogenesis pathway is Peroxisome Proliferator-
Activated Receptor Gamma, Coactivator 1 Alpha (PGC1α). This is activated upon 
phosphorylation by AMP-activated protein kinase (AMPK) in response to an increase in the 
AMP/ATP ratio, or by Sirtuin (SIRT1)-dependent deacetylation, which then functions to 
activate production of more PGC1α in a feedback loop (Jäger et al., 2007, Handschin et al., 
2003, Cantó et al., 2010). 
PGC1α then induces downstream production of various transcription factors that activate this 
biogenesis pathway via other signalling proteins such as Peroxisome Proliferator Activated 
Receptor Gamma (PPARγ), Nuclear respiratory factors 1 and 2 (NRF1, NRF2), Estrogen Related 
Receptor (ERR) all of which function to assist in mitochondrial biogenesis (Zong et al., 2002, 
Hardie et al., 2012, Fan and Evans, 2015, Jäger et al., 2007).  
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PGC1α deficient mice have been described as being “blunted” which includes effects such as 
a diminished mitochondrial number and respiratory capacity (Leone et al., 2005). While 
overexpression of PGC1α in vitro has demonstrated an increase in mitochondrial density, 
oxygen consumption, oxidative phosphorylation genes and mtDNA levels all indicating an 
increased level of biogenesis (Wu et al., 1999). 
A more specific discussion of mitochondrial biogenesis in neurons can be found in chapter 5. 
 Mitochondrial fusion 
As mentioned above, originally, with EM, mitochondria were observed to be simple rod 
shaped organelles and were thought to be distinct, individual mitochondrion (Palade, 1953). 
However, with advances such as live cell imaging, it was discovered that mitochondria are 
dynamic organelles that undergo simultaneous and continuous fission and fusion resulting in 
altered morphology to form complex networks with one another (Johnson et al., 1981, Rizzuto 
et al., 1996, van der Bliek et al., 2013). These mechanisms determine the shape and size of 
mitochondria. Fusion is the merging of multiple mitochondria to form the connected 
mitochondrial network observed in many cells. The main purpose of fusion is to share contents 
between mitochondria such as mtDNA and other vital molecules (including NADH, FADH and 
cAMP), to provide mtDNA stability and at times, to compensate for mitochondrial dysfunction 
and avoid degradation (Olichon et al., 2003, Twig et al., 2006, Nunnari and Suomalainen, 2012, 
Chen et al., 2010).  
This process requires the fusion of both the OMM and IMM and is mediated by mitofusin 
proteins 1 and 2 (mfn1 and mfn2) and mitochondrial dynamin like GTPase, also called opa1 
due the involvement of this gene in dominant optical atrophy, which is the neurodegeneration 
of the optic nerve (Delettre et al., 2000, Santel and Fuller, 2001). These are GTPases which 
hydrolyse guanosine triphosphate (GTP) for their energy requirements. Mfn1 and 2 mediate 
the fusion of OMM as they contain hydrophobic heptad repeats (HR) which tethers them to 
the OMM. Although the exact mechanism of fusion is unclear, the mitofusins can also bind to 
HR regions on adjacent mitochondria which eventually leads to the fusion of the phospholipid 
bilayer using the energy obtained from GTP hydrolysis (Koshiba et al., 2004, Formosa and 
Ryan, 2016, Westermann, 2010). Studies have shown that they are present together within a 
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cell and have certain structural and functional differences, however they are capable of 
facilitating successful fusion individually as well (Chen et al., 2003a). This was also highlighted 
by a study showing mRNA expression of mfn1 and mfn2 in most human tissues examined, 
including skeletal muscle, heart, brain and pancreas, however their expression levels differed 
in different tissues suggesting differential affinity for either protein based on tissue (Santel et 
al., 2003). Following OMM fusion, is the fusion of the IMM.  
The opa1 protein is involved in the fusion of IMM.  Studies have observed that OPA1 mutations 
(or their yeast orthologs), resulted in fusion of the OMM, but not the IMM (Meeusen et al., 
2006, Meeusen et al., 2004, Malka et al., 2005, Westermann, 2010). Similar to mfn1 and mfn2, 
the exact mechanism of action of opa1 is still undetermined. However, it is known that it is 
imported into the mitochondria, again due a mitochondria targeting sequence, and can be 
tethered to the IMM of both mitochondria that are undergoing fusion (Escobar-Henriques and 
Anton, 2013, Westermann, 2010). 
Although the mechanism of action is not completely clear, several studies have identified the 
importance of these proteins in mitochondrial fusion. Studies on patient fibroblasts with 
mutations in the OPA1 gene have demonstrated complete inhibition of mitochondrial fusion 
in some cases (Zanna et al., 2007). Further highlighting the importance of the fusion process 
is that mutations in the genes that code for mfn2 and opa1 are involved in neuropathies such 
as optic atrophy or axonal neuropathy (Züchner et al., 2006, Williams et al., 2010). Other 
studies have also observed a lack of tubular network and the presence of fragmented 
mitochondria in cells with mutations in mfn1, mfn2 or opa1 (Chen et al., 2003a, Olichon et al., 
2003). Alongside this, knockdowns of OPA1 using siRNA in HeLa cells has demonstrated 
increased mitochondrial fragmentation and apoptosis (Olichon et al., 2003), with Mfn1 
knockout displaying similar characteristics. Over expression of mfn1 cDNA results in a highly 
complex mitochondrial network and the presence of mfn1 containing a point mutation results 
in fragmented mitochondria in vitro (Santel et al., 2003). Over expression of Mfn2 also gives 
similar results, leading to a highly connected network of mitochondria in most cases, however 
in some cases, they also produced clusters of fragmented mitochondria within the perinuclear 
region and causing the release of cytochrome c (Huang et al., 2007). This could be because 
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Mfn2 has also been identified as being involved in the removal of damaged mitochondria and 
cellular apoptosis (Chen and Dorn, 2013, Wan-Xin et al., 2012).  
 Mitochondrial fission 
Fission is the process by which individual mitochondria separate from the network, typically 
for transport to distal regions or for degradation purposes (Simcox et al., 2013). The fission 
process of the IMM is still inconclusive, however, the main protein conducting this is dynamin-
like protein 1 (drp1), which is a GTPase (Smirnova et al., 2001). Mutations in the drp1 gene 
lead to perinuclear clusters of highly connected mitochondria as observed with 
overexpression of mfn2 (Huang et al., 2007). The method of action of this protein is to form a 
multimeric structure with itself which encloses the site of fission and allows cleavage of the 
OMM (Smirnova et al., 2001). Other proteins such as fission protein 1 (FIS1), mitochondrial 
fission factor (mff), mitochondrial dynamic proteins (MiD49 and MiD51) also have roles in 
fission by recruiting drp1 from the cytoplasm to the OMM (Losón et al., 2013, Mozdy et al., 
2000). Studies looking at knock down of fis1 in human cell lines has not demonstrated an effect 
on fission, however mff was demonstrated as having an effect on drp1 and fission, as drp1 
was not recruited to mitochondria (Otera et al., 2010).  
Knockout of drp1 in mice leads to the presence of extremely large individual mitochondria 
instead of a tubular network (Wakabayashi et al., 2009). Drp1 knockout mice in this study also 
demonstrated embryonic lethality and this was determined as being due to developmentally 
regulated apoptosis not occurring during neural tube formation. Other studies using drp1 
knockout mice have also demonstrated the need for this protein in cytochrome c release and 
apoptosis (Ishihara et al., 2009). This is because fission is required for targeted removal of 
damaged mitochondria, also termed mitophagy (Twig et al., 2008). In support of this, patient 
fibroblasts with parkin mutations (a protein involved in mitophagy, see section 1.3.5) have 
demonstrated increased mitochondrial branching, suggesting that they experienced increased 




Mitochondrial transport occurs due to the demand for ATP in various regions of a cell. 
Mitochondria move along the cytoskeleton of the cell on microtubules (MT) which have a 
negative or positive charge that facilitates the movement and transport direction of cargo. 
This movement uses ATP as an energy source and utilises the proteins kinesin, dynein and 
myosin (Frederick and Shaw, 2007). Disruption of these proteins in HeLa cells has been 
observed as causing defective mitochondrial movement leading to perinuclear clustering of 
mitochondria and formation of highly branched mitochondria (Varadi et al., 2004). 
Mitochondrial movement is particularly important in neurons due to their architecture, they 
are the longest cells in the human body and are highly branched with a number of processes 
and axons. Dopaminergic neurons, for example, can have a total length of 4.5m when all their 
processes are added up (Bolam and Pissadaki, 2012, Matsuda et al., 2009).  
Transport of mitochondria into distal regions of the neuron such as axons is termed 
anterograde and the movement back towards the cell body or the perinuclear region is 
retrograde (figure 1.2). The cytoskeletal structure of neurons is comprised of cytoskeletal 
elements termed the microtubules (MT) which consist of α and β-tubulin. Each MT has a 
negatively charged end directed towards the cell body and a positively charged end towards 
the distal regions which allows bi-directional transport based on their polarity and driven by 
the hydrolysis of ATP (Hirokawa et al., 2010). This transport is mediated by two motors: 
kinesins for anterograde movements as they travel towards the positively charged end of the 
MT, and dynein motors for retrograde movement as they travel to the negatively charged end 
(Ligon and Steward, 2000, Tanaka et al., 1998). Dynein can also mediate anterograde 
movement and kinesin is required for dynein mediated retrograde transport (Hirokawa et al., 
1990, Pilling et al., 2006, Haghnia et al., 2007). The attachment of mitochondria to these 
motors is facilitated by two proteins: Miro and Trak1 (Milton) (van Spronsen et al., 2013, 
Schwarz, 2013). These act as a connection between the motor proteins and the mitochondria, 
forming a motor-adaptor-receptor complex, allowing bi-directional movement of the 
mitochondria. Miro is a GTPase found on the OMM, which binds to Trak1 which then interacts 
with kinesins. The interaction between mitochondria and dynein remains unclear, however it 
has been suggested that dynein can bind with proteins present on the OMM, for example 
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VDAC, but it is also thought to interact with Miro as loss of Miro impacts on both anterograde 
and retrograde mitochondrial transport (Russo et al., 2009, Schwarzer et al., 2002).  
 
Mitochondria are not always moving, they can remain stationary for a period of time, in fact 
evidence suggests that the majority of the mitochondria are stationary (Sun et al., 2013). 
There have been multiple mechanisms suggested for the stalling of mitochondria, one of 
which involves syntaphilin (SNPH, figure 1.2) (Kang et al., 2008). Other suggested methods 
include anchoring to the microtubules by myosin present on the mitochondrial surface, 
inhibiting Miro or the motor complexes and disassociation from the motor complexes which 
in turn blocks the movement mediated by them (Schwarz, 2013, Sheng, 2014, Pathak et al., 
Figure 1.2 Mitochondrial transport machinery in neurons. Miro1, Trak2, Kinesin and Dynein are 
involved in the anterograde and retrograde movement of mitochondria along the microtubules 
that form the cytoskeleton of a neuron. The negative and positive charge of the microtubules is 





2010). SNPH is a protein specific to neurons and capable of binding to the MT and the OMM, 
but it is not capable of moving along the MT which in turn ‘anchors’ the mitochondria to the 
microtubule. As further evidence, knockout of this gene in mouse models has demonstrated 
an increase in mitochondrial movement (Sheng and Cai, 2012). 
 Mitochondrial degradation (Mitophagy) 
The specific degradation of mitochondria is termed mitophagy. This is the process by which 
dysfunctional mitochondria are removed from the reticular network and degraded by 
lysosomes. This process is connected to fission as this is required to remove the damaged 
mitochondria from the network in order for mitophagy to occur (Duvezin-Caubet et al., 2006, 
Frank et al., 2012). This term was coined by a study that used GFP tagged Light chain 3 (LC3) 
protein in hepatocytes (Kim et al., 2007). This study demonstrated that when cells were 
exposed to laser induced photo damaged, there was a loss of membrane potential and 
following this loss, there was an increase in GFP tagged LC3 intensity over time.  
One of the suggested pathways of mitophagy, is the PTEN-induced putative kinase 1 (PINK1) 
and parkin pathway. PINK1 contains a mitochondrial targeting sequence and localises within 
the inner membrane space. Usually in healthy mitochondria, PINK1 undergoes proteolysis by 
presenilins-associated rhomboid-like protein (PARL). In cases of mitochondrial damage such 
as a loss of membrane potential or an increase in reactive oxygen species (ROS), PARL does 
not cleave PINK1, which in turn transfers to and accumulates within the OMM (Narendra et 
al., 2008). This accumulation activates and recruits the E3 ubiqutin ligase protein, parkin, from 
the cytoplasm which ubiquitinates OMM proteins (including VDAC1 and DRP1) and recruits 
lysis proteins such as p62, LC3 and autophagosomes (Narendra et al., 2010). This relationship 
of PINK1 and parkin is further evidenced by overexpression studies, where overexpression of 
parkin in PINK1 deficient cells was beneficial, rescuing the ensuing defects, however 
overexpression of PINK1 in parkin deficient cells did not have the same effect suggesting that 
parkin was required for the recruitment of further mitophagy related proteins (Clark et al., 
2006, Exner et al., 2007, Park et al., 2006). In the absence of PINK1, it has been suggested that 
VDAC is abundant within the OMM alters to be accessible for parkin translocation and 
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mitophagy, suggesting that parkin mediated mitophagy can occur even in the absence of 
PINK1 (Geisler et al., 2010) 
Another pathway of mitophagy uses NIP3-like protein X (NIX) which has been studied in 
erythrocytes since their differentiation involves the complete removal of mitochondria and 
through the action of this pathway (Aerbajinai et al., 2003). Mice lacking NIX in these cells 
retain their mitochondria as the cells mature (Sandoval et al., 2008). In this pathway, NIX 
localises to the OMM and then in turn binds to LC3 present in the cytoplasm via the LC3-
interacting region (LIR) on the NIX. LC3 then functions to recruit autophagosomes. In mice 
with NIX deficiency, there is a decrease in mitophagy, however decreasing the membrane 
potential of the IMM by treatment with the uncoupler Carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP) can rescue mitophagy, suggesting stimulation of another pathway such as 
PINK1/Parkin (Zhang and Ney, 2009, Sandoval et al., 2008). BNIP3 has also been suggested to 
behave in a similar manner to NIX, as they both contain LIR allowing binding to LC3 
(Chinnadurai et al., 2009, Rodger et al., 2018). In vivo models with loss of BNIP3 resulted in 
lower levels of mitophagy along with an accumulation of damaged mitochondria (Chourasia 
et al., 2015) 
Mitophagy, and its importance for neurons is discussed in more detail in chapter 5. 
1.4 Mitochondrial functions 
 Tricarboxylic acid (TCA) cycle (Kreb’s cycle)  
The initiation of glucose breakdown for ATP production occurs within the cytoplasm via the 
process of glycolysis. This reaction breaks down glucose through intermediate products, into 
pyruvate producing a net yield of two adenosine triphosphate (ATP) molecules and two 
molecules of reduced Nicotinamide adenine dinucleotide (NADH) (Berg, 2011) (figure 1.3). 
When the conditions are hypoxic, this pyruvate is converted to lactic acid via anaerobic 
respiration, however in the presence of oxygen, the pyruvate is imported into the 
mitochondrial matrix and is converted into Acetyl CoA by pyruvate dehydrogenase (producing 
NADH as a by-product), which is used for the TCA cycle (Wang et al., 2010). Fatty acid 
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breakdown through the β-oxidation pathway, can also result in the production of Acetyl CoA 
for use within the TCA cycle (Houten and Wanders, 2010).  
The TCA cycle consists of a series of enzyme mediated reactions through which Acetyl CoA is 
oxidised, in turn reducing several products such as GDP, NAD+ and FAD into GTP, NADH, and 
FADH2 respectively, which are required for downstream oxidative phosphorylation (Krebs and 
Eggleston, 1940b, Krebs and Eggleston, 1940a). Figure 1.3 presents all the intermediate 
products in glycolysis and the enzymes that mediate this process. Within this cycle, 
oxaloacetate is produced, which then combines with a new molecule of Acetyl CoA to go 
through the same series of oxidative reactions again. The name citric acid cycle comes from 




Figure 1.3 The reactions of glycolysis and the TCA cycle. This presents the breakdown of glucose to pyruvate 
through glycolysis, which happens in the cytoplasm. It also presents the transport of pyruvate into the 
mitochondrial matrix, where it is converted into Acetyl CoA, and enters the TCA cycle. All the intermediates are 
named for both the processes. All the enzymes mediating the reactions are presented in blue. The green asterisks 
represent the production of NADH. The image also shows the production of FADH2 from succinate which is used 
by complex II of the OXPHOS system 
 
 Oxidative phosphorylation (OXPHOS) 
As the final process of ATP production, mitochondria contain the electron transport chain 
within their inner membrane. This enables OXPHOS, which requires complexes I – V (figure 
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1.4). The OXPHOS processes utilise redox reactions which transport electrons across the 
complexes and transfers protons into the IMS, thereby establishing a proton gradient and 
allowing the maintenance of a negative membrane potential across the IMM (Mimaki et al., 
2012). The protons are then utilised by complex V to phosphorylate ADP to form ATP.  
Complex I, or NADH ubiquinone oxidoreductase, is the largest of the 5 OXPHOS complexes 
containing around 45-46 subunits (Hirst et al., 2003, Sazanov, 2007), 7 of which are coded for 
by the mammalian mitochondrial DNA (mtDNA) (MTND1, MTND2, MTND3, MTND4L, MTND4, 
MTND5 and MTND6). The remaining subunits are encoded by the nuclear genome and 
translocate into the mitochondria to be assembled in the inner membrane, to produce the full 
enzyme complex with the mitochondrially encoded subunits. This complex oxidises NADH 
produced in the TCA cycle into NAD+ transferring four protons into the intermembrane space 
and transferring electrons to reduce Coenzyme Q (Janssen et al., 2006) (equation 1.1). This 
complex is also a site of reactive oxygen species (ROS) production, as it can produce 
superoxide radicles as a result of electron leakage (Hirst et al., 2008). 
𝑁𝐴𝐷𝐻+𝑄+5𝐻 + (matrix) →𝑁𝐴𝐷++𝑄𝐻2+4𝐻 + (IMS) 
Equation 1.1  Complex I reaction 
Complex II is also called Succinate dehydrogenase, and functions in oxidising succinate to 
fumarate (this reaction is part of the TCA cycle) and produces FADH2 (Cecchini, 2003). The 
oxidation of FADH2 into FAD, by the iron sulphur clusters within this complex, produces 
electron that are passed on reducing Coenzyme Q (equation 1.2). Complex II is the smallest of 
all the complexes and is completely coded for by the nuclear DNA.  
𝑠𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 + 𝑄 →𝑓𝑢𝑚𝑎𝑟𝑎𝑡𝑒 + 𝑄𝐻2 






Figure 1.4 Oxidative phosphorylation. Highlighted on the figure are the complexes (I-V) embedded in the inner 
mitochondrial membrane and functions within the OXPHOS system. This system functions by transporting 
electrons from complex I and II to complex IV with the help of cytochrome C. This process releases protons into 
the intermembrane space creating a proton gradient that is then utilised by complex V to convert ADP into ATP. 
More details about the individual processes are present in section 1.4.2. 
 
Electrons produced from oxidation of NADH and FADH2 from Complex I and II respectively, are 
transferred on to Coenzyme Q that is then oxidised by complex III. This complex, also known 
as ubiquinol cytochrome c oxidoreductase, consists of 11 subunits, one of which; cytochrome 
b (gene: MTCYB), is coded for by mtDNA (Schägger et al., 1995). This complex is responsible 
for transferring electrons from Coenzyme Q to cytochrome c. This complex also releases 4 
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protons into the intermembrane space (van den Heuvel and Smeitink, 2001). Cytochrome c is 
then responsible for transferring electrons from Complex III to complex IV.  
2𝑄𝐻2+𝑄+2𝐶𝑦𝑡𝑐 (𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑) +2𝐻 + (matrix) →2𝑄+𝑄𝐻2+2𝐶𝑦𝑡𝑐 (𝑟𝑒𝑑𝑢𝑐𝑒𝑑) +4𝐻 + (IMS) 
Equation 1.3 Complex III reaction 
Complex IV (Cytochrome c oxidase; COX) is comprised of 13 subunits, 3 of which; COXI, COXII 
and COXIII, are coded for by the mtDNA (van den Heuvel and Smeitink, 2001). This complex 
accepts electrons from cytochrome c and transfers them to oxygen (the terminal electron 
acceptor), producing H2O. This also releases two protons into the intermembrane space 
further adding to the proton gradient (Capaldi, 1990, Diaz, 2010).  
4𝐶𝑦𝑡𝑐 (𝑟𝑒𝑑𝑢𝑐𝑒𝑑) +8𝐻 + (matrix) + 𝑂2 →4𝐶𝑦𝑡𝑐 (𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑) +2𝐻2𝑂+4𝐻 + (IMS) 
Equation 1.4 Complex IV reaction 
The final complex, complex V is also termed ATP synthase. This contains 17 subunits, 2 of 
which; ATP6 and ATP8, are present on mtDNA. This molecule is responsible for 
phosphorylating ADP into ATP using the protons pumped out into the IMS by the other 
complexes. This protein contains two main domains: FO and F1. The protons in the 
intermembrane space travel down their concentration gradient into the matrix through the 
FO subunit of ATP synthase causing this to rotate. This leads to the rotation of the F1 subunit 
which functions to catalyses the phosphorylation of ADP into ATP and the release of this ATP 
molecule into the matrix (Boyer, 1997).  The ATP synthase can also function in reverse 
converting ATP into ADP and releasing protons to IMS in the process (Abramov et al., 2010). 
This usually occurs as a response to loss of membrane potential in order to regain this, and to 
avoid mitophagy (Gottlieb et al., 2003, Safiulina et al., 2006). 
𝐴𝐷𝑃+𝑃𝑖+2.7𝐻+ (IMS) + →𝐴𝑇𝑃+2.7𝐻 + (matrix) 




 Biogenesis of molecules in mitochondria 
Iron is transported into the mitochondria using mitoferrin present on the IMM (Shaw et al., 
2006, Zhu et al., 2016). This is used within mitochondria for haem synthesis which is a catalyst 
for redox reactions occurring in complexes I-III, by acting as an electron carrier. Iron is also 
important for the movement of electrons in the OXPHOS system as it is used for Fe-S cluster 
biogenesis. These are required within the OXPHOS complexes to accept electrons, for example 
the Fe-S cluster within Complex II accepts electrons from FADH2 (Lill et al., 2012, Wang and 
Pantopoulos, 2011). Fe-S clusters are formed and matured using various mitochondrial 
proteins (such as Isu1/2, Isa1/2, Nfu, Grx5 and Abcb7), which obtain the iron through frataxin, 
and forms Fe-S clusters. The sulphur for this process is produced from cysteine mediated by 
the enzyme cysteine disulfurase (Tong and Rouault, 2000). Mitochondria also function to 
regulate iron homeostasis within the cell (Rouault and Tong, 2005). 
Although the mechanisms remain unclear, mitochondria are also the site of steroid hormone 
synthesis from cholesterol (Miller, 2013).  
 Calcium buffering  
Mitochondria assist the cell with calcium buffering and the regulation of this ion is particularly 
important within neurons for action potential generation (Bean, 2007, Surmeier and 
Schumacker, 2013). Mitochondria contain the mitochondrial Ca2+ uniporter (MCU) in their 
IMM and VDAC on the OMM, which together are capable of importing calcium ions from the 
cytoplasm into the mitochondrial matrix regulating the calcium ion concentration within the 
cell. This is based on a calcium gradient and when there is large concentration of calcium 
within the cell, it is sequestered down its concentration gradient into mitochondria, which can 
sequester large quantities of calcium, up to 1000nmol per mitochondrion (Kirichok et al., 
2004). Ca2+ is required for various signalling pathways and functions within the cell such as 
ATP production, however at large concentrations it can be detrimental and lead to apoptosis 
of the cell (Griffiths and Rutter, 2009, Orrenius et al., 2003, Mattson and Chan, 2003). Calcium 




 Reactive oxygen species (ROS) production 
Reactive oxygen species can be produced from the mitochondrial OXPHOS system due to the 
leakage of electrons from complex I and III (Chen et al., 2003b). These electrons can react with 
oxygen molecules in the vicinity (produced from complex IV) to produce the superoxide anion 
(•O2-). Although initially thought to be detrimental, recent studies discovered that at low 
levels, ROS are beneficial for cells though various pathways such as cell signalling, 
differentiation and immunity (Sena and Chandel, 2012). However, at higher levels, ROS can 
have negative effects, and therefore the mitochondria possess antioxidant enzymes to 
minimise this risk and regulate ROS. Superoxide dismutase (SOD), present within the matrix 
and IMS, converts the •O2- into H2O2, which is then converted into H2O by gluthathione 
peroxidase (GPx) or peroxiredoxins (PRX) (Sabharwal and Schumacker, 2014). Although this 
system is beneficial, H2O2 can itself be converted into the hydroxyl radical (•OH) upon reaction 
with •O2- (Sena and Chandel, 2012). ROS scavengers such as uric acid and vitamin C can also 
function to protect from ROS related damage (Valko et al., 2007). ROS can be detrimental as 
it can also cause the oxidation of proteins, lipids and DNA within the cells and mitochondria 
(Lyras et al., 1997, Slupphaug et al., 2003). Since mitochondria are a site of ROS production, 
mtDNA can be particularly damaged due to its close proximity to the source of ROS, leading 
to mtDNA damage (Indo et al., 2007, Liang and Godley, 2003). An accumulation of this damage 
can eventually lead to apoptosis of the cell (Kim et al., 2010). 
 Apoptosis 
Cellular damage, such as oxidative stress, DNA damage and high levels of intercellular calcium 
can lead to cell death. Apoptosis is the process by which a damaged or unrequired cell is 
degraded. The IMM contains Apoptosis Inducing Factor Mitochondria Associated (AIFM1). 
This generally functions as a NADH oxidoreductase, however in the case of damage, this 
protein translocates to the nucleus in order to cause chromosome condensation and DNA 
fragmentation leading to apoptosis (Kettwig et al., 2015). This protein can also induce the 
release of cytochrome c.  
Within the IMM, cytochrome c is present and functions as an electron transporter for the 
OXPHOS system. The release of cytochrome c from the IMM is generally regulated by the Bcl-
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2 family of proteins. BNIP3L is involved in mitochondrial quality control by interacting with 
Spermatogenesis Associated 18 (SPATA18, or Mieap) which can regulate the translocation of 
lysosomal proteins into the mitochondrial matrix to degrade damaged proteins, a process 
termed Mieap-induced accumulation of lysosome-like organelles (MALM) (Nakamura and 
Arakawa, 2017). BNIP3L can also bind to Bcl-2. Bcl-2 is capable of interacting with VDAC to 
increase the membrane permeability and also influence cytochrome c release which 
induces apoptosis. This is in response to high levels of damage, where cytochrome c released 
to trigger caspase-9 leading to apoptosis (Wang and Youle, 2009, Hüttemann et al., 2011).  
1.5 Mitochondrial DNA 
Mitochondria are the only other organelle that contain their own DNA, which like the 
organelle in which is it found is maternally inherited (Giles et al., 1980). As mentioned, the 
subunits required for OXPHOS are coded for by both the nuclear and the mitochondrial 
genomes. The mtDNA of humans was first sequenced in 1981, which was later revised in 1999 
to include any polymorphisms and correct any errors (Anderson et al., 1981, Andrews et al., 
1999). MtDNA contains 37 genes coding for 13 proteins, 22 tRNA’s and 2 rRNA’s within 16,569 
base pairs (figure 1.5). It is a circular DNA molecule that consists of a heavy (H) strand on the 
outside that gets this name, as it is rich in purines, which are heavier than pyrimidines. This H 




MtDNA is supercoiled and arranged into structures called nucleoids (which average 100nm in 
diameter), within the mitochondrial matrix, causing this molecule to be highly compact (Satoh 
and Kuroiwa, 1991, Gilkerson et al., 2013). Although previous studies have eluded to a higher 
number of mtDNA molecules within these nucleoids, recent advances in electron microscopy 
discovered that each nucleoid contained an average of 1-3 mtDNA molecules (Kukat et al., 
2011, Brown et al., 2011). Super resolution fluorescence imaging was also used to identify that 
each nucleoid, in addition to mtDNA, also contains mtDNA maintenance proteins, such as 
those involved in transcription and replication (Brown et al., 2011). One such example of a 
nucleoid protein is mitochondrial transcription factor A (TFAM). This is involved in mtDNA 
transcription; however, it also has an additional function in the appropriate packaging of 
Figure 1.5 Mitochondrial DNA. Highlighted on the figure are the protein encoding genes in colour and the genes 
are stated on the image. The orange sites code for rRNAs and the green stadium shapes demonstrate the tRNAs. 




mtDNA. TFAM can generate U-shaped bends with the mtDNA, due to the presence of a high 
mobility group (HMG) box, allowing mtDNA to be compacted within the nucleoid (Alam et al., 
2003, Ngo et al., 2011b).  
MtDNA contains a non-coding displacement-loop (D-loop) which consists of the origin of 
replication (OH) for the heavy strand. For replication to initiate, a complementary strand binds 
to the D-loop displacing the H strand from the L strand. This exposes OH where replication for 
the H strand is initiated. The origin of replication for the light strand (OL) is present further 
into the strand. The region from OH to OL is the major arc and the remaining bases pairs from 
OL to OH are termed the minor arc. The 13 genes present are all essential for OXPHOS and all 
the genes are expressed as there are no introns in the mtDNA and some genes even have 
overlapping regions; therefore any damage to mtDNA could be severe. As mentioned in the 
previous section, high levels of ROS are also produced within the mitochondria from the 
OXPHOS system. As a result, mtDNA is also highly susceptible to damage which accumulates 
with age (Castro et al., 2012, Manczak et al., 2005, Corral-Debrinski et al., 1992b, Yen et al., 
1991, Fayet et al., 2002).  
Unlike the nuclear DNA, cells and indeed individual mitochondria harbour multiple copies of 
mtDNA. A single cell has been estimated to contain 103-104 copies of mtDNA, however the 
number can vary based on age, tissue and cell (Wiesner et al., 1992, Lightowlers et al., 1997, 
Miller et al., 2003). Individuals with inherited mtDNA mutations commonly harbour wild type 
and mutant genomes within most cells, a situation termed heteroplasmy. If the mtDNA 
genomes present are all the same, this is termed homoplasmy. For a mutation within mtDNA 
to have a biochemical defect, a certain threshold level of mutant mtDNA has to be achieved, 
at which point the wild type mtDNA could not compensate for the mutated mtDNA. This is 
termed the biochemical threshold effect (Rossignol et al., 2003). Due to this threshold, there 
is often some residual function of the OXPHOS system in cells harbouring mtDNA mutations, 
as wild type mtDNA might be present (Brunelle et al., 2005).  
 MtDNA replication 
MtDNA replication will be discussed in more detail in chapter 4, therefore this brief 
introduction will focus on the replication machinery and the modes of replication. 
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As mentioned before, a nucleoid contains mtDNA molecules alongside a few replication 
machinery related proteins. These include TFAM, mitochondrial transcription factor B 
(mtTFB), mtRNA polymerase (POLRMT), DNA Polymerase gamma (Polγ), mitochondrial single 
strand binding protein (mtSSB), Twinkle and Mitochondrial Lon peptidase (LONP) 
(Bogenhagen et al., 2008, Gilkerson et al., 2013). TFAM, as discussed above, is involved in 
transcription and packaging of mtDNA. TFAM, mtTFB and POLRMT are involved in mtDNA 
transcription (section 1.5.2). POLRMT also has roles in replication initiation by providing RNA 
primers at the at the site of OH (Fuste et al., 2010). Polγ is the DNA polymerase, specific to 
mitochondria, that carries out mtDNA synthesis based on template sequence and is also 
suggested to have roles in repair. The importance of Polγ was noticed when transgen ic 
knockdown mice displayed an accelerated ageing phenotype and when a number of diseases 
were associated with Polγ mutations (Trifunovic et al., 2004, Wong et al., 2008). MtSSB is a 
single strand DNA binding protein, and has been thought to provide stability to single stranded 
mtDNA during replication. An increase in mtDNA replication was associated with an increase 
in mtSBB protein levels indicating this is involved in mtDNA replication and repair (Schultz et 
al., 1998, Ruhanen et al., 2010). Twinkle is a mtDNA helicase capable of unwinding short 
stretches of DNA in a 5’ to 3’ direction in response to stimulation from mtSSB, and mutations 
within this gene are associated with mtDNA deletions (ΔmtDNA) and multiple disease 
conditions (Korhonen et al., 2003, Goffart et al., 2008, Tyynismaa et al., 2005). LONP is a 
protease and functions to degrade damaged nucleotides (Lu et al., 2007). 
Although the definitive mechanism of replication is uncertain, a few theories exist, which have 
postulated potential mechanisms. The first theory to be proposed suggests that mtDNA 
replication occurs through the strand-displacement method (SDM). This mechanism was 
initially described in a paper looking at mouse mitochondria isolated using caesium chloride 
density centrifugation (Kasamatsu and Vinograd, 1973). This led to the development of the 
SDM model of replication which has also been referred to as the asynchronous model of 
mtDNA replication (Clayton, 1982). The SDM mechanism suggests that replication begins at 
‘OH’ of the leading strand (heavy strand), as the D-loop is displaced. This heavy strand is then 
replicated from 5’ to 3’, once approximately 2/3rd of the strand has been replicated, ‘OL’, the 
origin of replication of the lagging strand (light strand) becomes exposed. This allows 
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replication of the lagging strand to begin (Krishnan et al., 2008) in an opposing direction from 
5’ to 3’ until both strands have been replicated (figure 1.6). Further evidence supporting this 
was obtained when the origin of replication sites OH and OL were found on opposite strands 
with a distance of over 11kb between them (Clayton, 1982). This suggests that replication is 
initiated at different locations within both the strands. The 11kb distance supports the original 
idea that 2/3rd of the H strand is replicated before replication begins at the L strand.  
Another proposed theory is the coupled leading-lagging-strand replication (Holt et al., 2000) 
also termed the synchronous model which was observed using 2D-neutral agarose gel 
electrophoresis. This theory suggests that replication is initiated at the zone of replication 
(OriZ) that is present at the same loci for both the leading and the lagging strand. This region 
is broad and said to be between the bases 12337 and 15887 containing the genes ND5, ND6 
and CYB. In this model, replication proceeds bidirectionally (Bowmaker et al., 2003). However, 
the coupled leading-lagging theory was observed after mtDNA in human cultured cells was 
depleted using 2’3’ dideoxycytidine (ddC) or ethidium bromide, hence this mode of replication 
could be the result of damage. This study also investigated an untreated control cell line which 
presented with a different replication intermediate to the ddC or ethidium bromide 
treatments. This suggested that multiple modes of replication could exist.  
Nonetheless this, and SDM, have been challenged by the discovery of multiple ‘OL’ sites within 
the L strand suggesting multiple origins of replication (Brown et al., 2005). Another challenge 
for the SDM model came when mitochondrial RNA polymerase was found to have RNA 
primase activity in the mitochondria and to be capable of producing primers for the OL region. 
This can initiate replication of the L strand even without H strand exposing the OL site as 
suggested by SDM (Fusté et al., 2010). This primase can start replication at any one of the 
multiple OL sites and the gap between these strands can then be filled in by polγ (Wanrooij et 
al., 2008). As mentioned above, the study (Holt et al., 2000) discovered two replication 
intermediates, one with and one without mtDNA depletion, one of these was vulnerable to 
single stranded nuclease digestion as suggested by SDM, which was initially used to support 
SDM and couple-leading lagging theory co-existing (Holt et al., 2000). However upon further 
study using a purer preparation of mitochondria, these single stranded intermediates were 
found to not be DNA but RNA:DNA hybrids (Yang et al., 2002, Yasukawa et al., 2006). The led 
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to the postulation of the ‘RNA incorporation throughout the lagging strand’ model (the RITOLS 
model) (figure 1.6) (Holt and Reyes, 2012, Yasukawa et al., 2006). This is similar to the SDM 
method where the H strand replicates as normal from OH, whereas the single stranded L 
strand replicates as segments of RNA of about 2.5kb in length, which hybridises with the H 
strand, and is then matured into DNA.  
Recently a ‘bootlace’ mechanism of replication was also put forward after analysis of 
replication forks on 2D gel electrophoresis (Reyes et al., 2013). This theory is similar to RITOLS, 
however it suggests that RNA transcripts complementary to the L-strand are produced prior 
to replication. This was verified as RNA chain terminators did not block the labelling of mtDNA 
replication intermediates however DNA chain terminators did, hence RNA transcripts was 
produced beforehand. Once the D-loop is displaced and DNA synthesis begins at ‘OH’ on the 
H strand, these RNA transcripts bind to the L strand discontinuously. This is later processed 
into DNA through a maturation process which is as yet unclear. This  also explains the single 
stranded regions noticed by (Holt et al., 2000) as the RNA transcripts are discontinuous, 










 MtDNA repair 
DNA can undergo various chemical modifications that result in damage. Over the evolutionary 
period, sufficient repair mechanisms have been developed to combat this damage. Although 
an abundance of information is available regarding the repair of nuclear DNA, DNA repair 
within mtDNA remains relatively unknown (Houtgraaf et al., 2006). Until recently mtDNA was 
believed to have no repair system at all due to the increased DNA mutations observed in 
mtDNA compared to nuclear DNA (Yakes and Van Houten, 1997, Mecocci et al., 1993). 
However this was because most of the mtDNA is coding and polycistronic, hence mutations 
have a higher chance of leading to a biochemical defect, and due to the high oxidative stress 
present within mitochondria, high levels of DNA damage were inevitable. Recent advances 
however have paved the way to better understand the repair mechanisms present in mtDNA 
(Alexeyev et al., 2013, Bowmaker et al., 2003). A list of proteins involved in mammalian mtDNA 
repair and their function in presented in table 1.1 
Figure 1.6 Models of replication for the mtDNA. In the top image, SDM starts replication at the OH and as the OL 
strand is revealed, replication of the lagging strand begins. The bottom image demonstrates the RITOLS model 
where the replication of both strand is initiated at the OH region, and the lagging start replicates using RNA 




Protein Gene Function Pathway Reference 
Oxoguanine 
glycosylase 
OGG1 DNA glycosylase BER (Hashiguchi et 
al., 2004, Cotter 
et al., 2004, 
Karahalil et al., 
2003) 
MYH glycosylase MUTYH DNA glycosylase BER (Cotter et al., 




UNG1 DNA glycosylase BER (Chatterjee and 
Singh, 2001, 





YB-1 Endonucleolytic activity 
– create double strand 
DNA breaks at site of 
mismatch 
MMR (de Souza-Pinto 
et al., 2009) 
Polymerase γ POLG Insert new base pairs at 
damaged sites 
All (Copeland and 
Longley, 2003, 





MTH1 Triphosphatase  - 
hydrolyse damaged 
dNTPs so it does not get 
incorporated into DNA 
Non-
specific 







APE1 Multifunctional – Repair 
of AP sites, Generate 
single strand breaks at 
site of damage, 3'-5' 
exoribonuclease activity 
BER/MMR (Tell et al., 2001) 
Endonuclease III-like 
protein 1 





1 and 2 
NEIL1, 
NEIL2 
DNA glycosylase BER (Mandal et al., 





PKNP DNA Nucleases BER (Mandal et al., 
2012, Tahbaz et 
al., 2011) 





DNA2 DNA Nucleases BER (Copeland and 
Longley, 2008, 
Zheng et al., 
2008) 
Nuclease EXOG EXOG endonuclease BER (Kalifa et al., 
2009) 








DUT1 Produces thymidine 
nucleotide precursors 
so uracil concentration 
decreases and does not 







DNA repair protein 
RAD51 homolog 1 
RAD51 Recombination of 
double stranded breaks 
Non-
specific 
(Sage et al., 
2010) 
Table 1.1 List of proteins associated with the DNA (and RNA) repair of mitochondrial DNA and their functions. BER 
refers to base excision repair and MMR to mismatched repair 
Since each type of DNA damage is different in terms of its chemical or physical properties, a 
different mechanism of repair is required for each type of damage. This includes nucleotide 
excision repair (NER), base excision repair (BER), mismatch repair (MMR) and recombination 
repair. The most reported type of repair in mitochondria is BER where the damaged base pair 
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is exchanged for an undamaged base pair, therefore BER is responsible for the repair of 
smaller modifications.  
Although BER happens in the nucleus as well as mitochondria, they can be differentiated by 
the fact that the proteins involved in the mitochondrial BER pathway are specific isoforms or 
splice variants from the nuclear versions of the same enzymes. In the BER pathway, a damaged 
DNA base is recognised and cleaved at the site of a glycolytic bond by DNA glycosylases such 
as OGG1, MUTYH or UNG1. This produces an abasic (AP) site. Endonucleases such as APE1 
then function to break the phosphodiester bonds and remove the damaged base pair. The 
repair activity of Polƴ functions to insert the correct base pair and the strand is ligated through 
the action of DNA ligase III (Bohr, 2002, Bohr et al., 2002) 
A number of DNA glycosylases associated with the BER pathway have been identified as 
localising to the mitochondria, these include OGG1, MUTYH and UNG1. OGG1 is involved in 
the initial stages of the BER pathway and is responsible for cleaving DNA at the damaged base. 
It has two splice variants; OGG1α and OGG1β. OGG1β is mitochondrial specific; however both 
contain an N-terminal targeting sequence for mitochondrial localisation (Nishioka et al., 1999, 
Takao et al., 1998). Other evidence suggests that OGG1β does not have glycosylase activity 
and OGG1α is responsible for this activity in both the nucleus and mitochondria (Hashiguchi 
et al., 2004). MUTYH is also a DNA glycosylase involved in the BER pathway. It recognises and 
cleaves adenine that is paired inappropriately. The isoform p57 of MUTYH localises to 
mitochondria (Ohtsubo et al., 2000). UNG1 also functions as a DNA glycosylase and localises 
to the mitochondria. It is responsible for removing uracil from DNA and in turn activating the 
BER pathway (Nilsen et al., 1997).  Following the activity of such DNA glycosylases, the 
remaining damaged site is processed by APE1 which is also identified as localising to the 
mitochondria (Tell et al., 2005). Following this, the correct base pair is inserted by catalytic 
subunit of polγ (Copeland and Longley, 2003). The DNA is then ligated back together by DNA 
ligase III which also contains mitochondrial encoded proteins (Muftuoglu et al., 2014). This 
process mostly explains short-patch BER which is the correction of a single base pair. A long-
patch BER also exists, which repairs up to 12 base pairs. Although not extensive, there is 
evidence of this pathway occurring in the mitochondria as well (Szczesny et al., 2008, Liu et 
al., 2008, Akbari et al., 2008).  
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The MMR pathway also has shown activity in the mitochondria (Mason et al., 2003, de Souza-
Pinto et al., 2009). However, unlike the proteins involved in nuclear MMR pathway such as the 
endonuclease EXO1, the mitochondria uses YB-1 a DNA binding protein which can bind to 
mismatched base pairs (de Souza-Pinto et al., 2009). This study also demonstrated that 
depletion of YB-1 leads to an increased level of mtDNA mutations as shown using a 
chloramphenicol-resistance selection assay. This selects specifically for cells with mutant 
mtDNA as chloramphenicol binds to ribosomal RNA and inhibits protein synthesis within the 
mitochondria. Mutated cells survived as ribosomal RNA genes would be mutated and hence 
not bound to.  
The mtDNA is double stranded and hence prone to double stranded breaks, this form of 
damage requires recombination repair. Although not a lot of information is available on 
recombination repair of double strand breaks in the mitochondria, a recombination protein; 
RAD51, has been identified as localising to the mitochondria. This protein is involved in repair 
of double strand break repair and it was noticed as accumulating following oxidative stress 
(Sage et al., 2010).   
TFAM, as mentioned before, has a role in the packaging of mtDNA by inducing a u-shaped 
bend in the mtDNA. Although this protects nucleotides from DNA damage, it also makes the 
DNA inaccessible for repair enzymes such as the ones involved in BER. Overexpression of 
TFAM has demonstrated excessive binding of TFAM with mtDNA in cultured cells (Maniura-
Weber et al., 2004). This can shield mtDNA from the activity of OGG1, APE1 and can also 
prevent incorporation of new bases by polγ (Canugovi et al., 2010). This study also 
demonstrated that inhibition of TFAM results in increased mtDNA repair as mtDNA was not 
‘hidden’ from the enzymes involved in repair and TFAM knockdown showed an increase in 
mtDNA mutations measured using quantitative-PCR.   
 MtDNA transcription and translation 
TFAM is a key protein involved in the transcription of mtDNA. Due to its involvement in the 
maintenance and packaging of mtDNA into nucleoids (Bogenhagen et al., 2008, Kaufman et 
al., 2007). TFAM initiates transcription by binding to sequences on the light and heavy strand 
promoter regionof mtDNA producing long transcripts coding for multiple proteins (Falkenberg 
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et al., 2007, Shi et al., 2012, Ngo et al., 2014, Ngo et al., 2011c). The sequences that TFAM 
binds to are present within the D-loop and are called L-strand promoter (LSP), Heavy strand 
promoter 1 and 2 (HSP1 and HSP2). LSP is used to transcribe the light chain and HSP1 and 
HSP2 for the heavy chain. HSP1 is responsible for transcribing short sequences of mRNA and 
HSP2 is responsible for transcribing the majority of the heavy strand (Montoya et al., 1983). 
This TFAM binding causes the mtDNA to alter its conformation allowing the transcription 
machinery to be recruited and initiate transcription (Ngo et al., 2011a, Rubio-Cosials et al., 
2011). This machinery includes the RNA polymerase POLMRT, which is responsible for the 
synthesis of the new molecule, and the two transcription factors mtTFB1 and mtTFB22 
(Falkenberg et al., 2002). The binding of these transcription factors initiates the transcription, 
and synthesis of the mRNA molecule then occurs simultaneously in both directions, matured 
by enzymes such as RNase P (Rossmanith and Karwan, 1998). This is particularly important 
due to the polycistronic nature of the mtDNA molecule. Termination of transcription is 
mediated by Mitochondrial Transcription Termination Factor (mTERF) (Yakubovskaya et al., 
2010). The transcript produced from the LSP also produces RNA primers that also play a role 
in replication of the mtDNA suggesting a link between translation and replication since both 
use the same template (Fernández-Silva et al., 2003, Chang and Clayton, 1985).  
Similar to nuclear mRNA translation, mitochondria also follows the steps of initiation, 
elongation and termination, however the mitochondria contain their own ribosomes for this 
purpose; the mitoribosomes. Initially the template mRNA strand is bound to the smaller 
subunit (28s) of the mitoribosome mediated by Mitochondrial Translational Initiation Factor 
3 (mtIF3) (Koc and Spremulli, 2002). Synthesis is initiated by the AUA or AUG codon on the 
template mRNA, which codes for formylmethionyl-tRNA, which is recruited by Mitochondrial 
Translational Initiation Factor 2 (mtIF2) (Bilbille et al., 2011). This formylated version of 
methionine is only used at initiation of translation.  
Following initiation, elongation occurs mediated by Tu Translation Elongation Factor, 
Mitochondrial (mtTUFM). This mediates aminoacylated tRNA binding and GTP hydrolysis at 
the Aminoacyl-tRNA binding site (A-site) of the ribosome. Mitochondrial translation 
elongation factor (mtEFT) binds to and mediates the recycling of TUFM by inducing the 
exchange of GDP to GTP, allowing it to bind more aminoacylated tRNAs (Emperador et al., 
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2017). The elongation continues when the amino acid at the site moves into the peptidyl-tRNA 
binding site (P site) and Exit site (E site). The movement of these tRNAs through these sites 
are mediated by mitochondrial translation elongation factor G1 (Takeuchi et al., 2010).  
The final step is termination. This is driven by recognition of the stop codons AGG, AGA, TAA 
or TAG at the A-site. Rather than an aminoacylated tRNA, this recruits Eukaryotic Translation 
Termination Factor 1 (ERF1), which mediates the release of the newly formed polypeptide 
chain from the mitoribosome (Janzen and Geballe, 2004, Guenet et al., 1999). The machinery 
is then recycled for the next mRNA template to be translated.  
1.6 MtDNA deletions 
Mitochondrial DNA can harbour a range of mutations including deletions (ΔmtDNA), point 
mutations and duplications. Mitochondrial DNA, due to its proximity to ROS,  and intron-less 
nature, could be susceptible damage (Brown et al., 1979). Adding to this is the reduced 
accuracy of Polƴ compared to DNA polymerases for the nuclear DNA (Kunkel and Loeb, 1981, 
Nissanka et al., 2018). MtDNA deletions caused by these can either remove a few base pairs 
or could be large scale effecting 1000s of basepairs (Damas et al., 2013). ΔmtDNA can be 
present as a single mtDNA deletion or as multiple mtDNA deletions within an individual cell. 
These can be transmitted through the germline, can arise sporadically over the life span of an 
individual, or as a result of mutations in mtDNA maintenance genes, e.g. POLG (Zeviani et al., 
1988, Schon et al., 2012, Shanske et al., 2002, DiMauro and Davidzon, 2005, Longley et al., 
2005, Hudson and Chinnery, 2006b, Naïmi et al., 2006). Deletions occurred in the germline or 
during the early stages of gestation and expanded to high levels as a result of genetic 
bottleneck. Since this deletion was present in germline, it may be present in every cell 
(Yamashita et al., 2008). The theory of genetic bottleneck suggests that, as a method of 
reducing replication of a damaged mtDNA molecule during oogenesis, only a small number of 
maternal mtDNA molecules undergo replication and amplify to high levels. This could then 
limit the probability of a damaged mtDNA molecule being passed on to the offspring 
(Marchington et al., 1998). However, if this is the case, if the maternal mtDNA molecules 
contain an mtDNA mutations such as deletion, this could then be amplified within the 
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offspring. In support of this theory was the data that suggested a lack of association between 
heteroplasmy levels between mothers, offsprings or siblings (Chinnery et al., 2004).  
ΔmtDNA can also be the result of mutations in the nuclear genes which are responsible for 
the maintenance of mtDNA, e.g. POLG (Longley et al., 2005, Hudson and Chinnery, 2006b, 
Naïmi et al., 2006). Mutations in this gene can result in an unstable polγ leading to errors in 
the mtDNA sequence causing an accumulation of deletions or depletion of mtDNA (Brandon 
et al., 2013, Hanisch et al., 2015).  Similar to this, variants in the mitochondrial helicase, twinkle 
(section 1.5.1) are also associated with an accumulation of ΔmtDNA and depletion (Tyynismaa 
et al., 2005, Spelbrink et al., 2001). These deletions would differ between each cell as the 
mtDNA defect was not present in germline. An accumulation of multiple ntDNA deletions can 
also occurs as a result of ageing. Many studies have demonstrated an age-related increase in 
mtDNA deletions within various tissues such as brain, heart and muscle (Bender et al., 2006a, 
Bua et al., 2006, Kraytsberg et al., 2006a, Zhang et al., 1992). The deleted mtDNA, along with 
wildtype mtDNA, undergoes replication which would increase the number of deleted mtDNA 
molecules within a cell through a process known as clonal expansion (section 1.6.3).  
A number of studies have demonstrated that the majority of mtDNA deletions lie within the 
major arc. One such deletion is the common 4977bp deletion. This is associated with ageing 
and a number of disease conditions such as Huntington’s disease and Parkinson’s disease 
(Horton et al., 1995, Ikebe et al., 1990, Taylor and Turnbull, 2005). This deletion removes 
4977bps between two flanking 13bp direct repeat sequences present at m.8470-8482 and 
m.13447-13459 which results in the loss of subunits from complex I, complex IV and complex 
V, and a number of tRNAs. A vast number of other mtDNA deletions have also been thought 
to occur as a result of direct repeat sequences (Samuels et al., 2004). This is because the direct 
repeat sequences are complementary to each other and can bind with each other leading to 
the deletion of the sequences between the repeats. Other deletions can occur due to indirect 
repeats, which are not identical repeats of each other, for example there may be a difference 
of one or two base pairs within a sequence, ACGTGCTAAC rather than ACTTGCTCAC. A small 
number of deletions also occur without any repeat sequences (Samuels et al., 2004). 
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Multiple ΔmtDNAs are particularly fascinating due to their proposed involvement in ageing 
and many age related diseases such as neurodegenerative diseases (including Parkinson’s 
disease) and sarcopenia (Krishnan et al., 2012, Aiken et al., 2002). An accumulation of 
ΔmtDNAs has been noticed in a number of tissues with ageing, which is particularly prominent 
with post-mitotic tissues such as brain and skeletal muscle (Bua et al., 2006, Bender et al., 
2006c, Kraytsberg et al., 2006b, Lee et al., 1994). Due to the fact that mtDNA does not 
containing any non-coding regions, deletions will often cause a biochemical defect. Therefore 
it is important to understand the mechanism which leads to the formation of ΔmtDNA, which 
still remains unclear. Two theories have been put forward to explain this phenomena; Errors 
in replication and inaccurate repair.  
 MtDNA deletion formation through replication 
In a previous study by our group, deletions from single substantia nigra neurons were analysed 
from PD patients, a ΔmtDNA disorder patient and aged matched individuals (Reeve et al., 
2008). The distribution of the breakpoints was analysed. The 5’ was set as being the region 
close to OH and 3’ being close to OL. The results show there was no difference in distribution 
of the deletions between the three groups. A total of 89 deletions was observed within these 
three groups. Out of this, 80% involved direct repeats with ~42% being perfect repeats and 
~38% being imperfect repeats. Only ~20% contained no direct repeats. With no differences in 
the types of deletion detected between the 3 groups, this suggested that the method of 
deletion formation is likely to be the same in the three groups. A further systematic review 
looking at human ΔmtDNA reported a total of 263 ΔmtDNA (Samuels et al., 2004). They 
discovered 90% of the sequences contained repeat sequences with 60% carrying perfect 
repeats and 30% imperfect repeats. This study (Samuels et al., 2004) also discovered that the 
mtDNA contains only 5 direct repeat sequences that have a length of 13bp’s or over. Out of 
these, the pairs with both the direct repeat sequences within either the major arc or within 
the minor arc have been associated with deletions in patients. One of these was the common 
4977bp deletion (Zhang et al., 2002, Moraes et al., 1991). This means that the deletion does 
not exclude the OL or the OH region, allowing the deleted molecule to replicate again. The 
remaining direct repeat sequences occur in either the major and minor arc and result in 
deletion of either the OL or the OH region and interestingly, they have never been associated 
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with a phenotype (Damas et al., 2013). This is because they eliminate one of the origins of 
replication hence replication of the deleted molecule cannot take place. However, deletions 
that remove OL have been discovered in post-mitotic tissues which opposes this theory 
(Baumer et al., 1994, Kajander et al., 2000, Rygiel et al., 2016). 
This (Samuels et al., 2004) study also found that the 3’ end of all deletions they analysed were 
located in close proximity to m.16070, with very few deletions described to have gone past 
this region. This could be due to the adjacent ‘termination-associated sequence’. These pieces 
of evidence suggest that mtDNA replication could be involved in ΔmtDNA formation. 
However, although minimal, there have been deletions reported that span this region 
suggesting that there are other mechanisms of deletion formation (Kajander et al., 2000, 
Samuels et al., 2004, Bodyak et al., 2001, Bua et al., 2006).  
A mechanism of deletion formation by mtDNA replication occurs as a result of slipped strand 
replication. This is because the light strand remains single stranded until the OL is exposed, 
during which repeat sequences can bind to each other, exposing the DNA in between (figure 
1.7). However, this assumes mtDNA replicates via SDM and as mentioned above, and there 
are other well supported theories of replication. A major argument against ΔmtDNA formation 
through replication is that when analysed, human colonic crypt stem cells, although actively 
replicating contain clonally expanding point mutations, and no ΔmtDNAs (Taylor et al., 2003b). 
This is also not due to natural selection against deletions, as these tissues have shown very 
low evidence of selection (Greaves et al., 2012). If replication was the factor leading to 
deletions, the colonic crypt stem cells should contain higher levels of ΔmtDNA compared to 
post-mitotic tissue such as skeletal muscle and brain in which mitochondrial turnover is much 
slower (Wang et al., 1997). Additionally the discovery of deletions that extend into the minor 
arc and remove OL (Rygiel et al., 2016) also suggests that replication alone cannot explain 




Figure 1.7 Slipped strand model of mtDNA deletion formation. 1) Initially the replication of heavy strand is 
initiated at OH, leaving the L-strand single stranded. 2) This allows complementary sequences on the light strand 
to bind to the region of the H-strand not being replicated. The DNA loop that is formed as a result of this mismatch 
is then degraded 3) this will result in two daughter molecule, one with the full 16kbp, and another with a deletion. 
Image taken with permission from (Reeve, 2007). 
 
Another method of deletion formation through replication is due to replication stalling 
(Wanrooij et al., 2004). This was explained using recombinant baculovirus to analyse the Polγ 
fidelity via the Y955C mutation. This mutation, within the active site of the polymerase 
domain, structurally altered the active site and could lead to replication stalling which can lead 
to double strand breaks (DSB). The paper explains that this mutation resulted in a decreased 
affinity for nucleotides (Ponamarev et al., 2002), therefore when the polymerase reaches a 
region that contains repetition of the same nucleotide, due to this low affinity and a depletion 
of this nucleotide in the vicinity, replication cannot continue, leading to stalling and further 
DSBs. This study also reported an increased number of repeating nucleotides at the 
breakpoints of deletions. Furthermore one of the genes associated with ΔmtDNA in human 
patients is the TWNK gene, which encodes for the previously mentioned twinkle helicase. A 
mutation in this gene resulted in an accumulation of replication intermediates and 
accumulation of ΔmtDNA in a transgenic cell line and a mouse model, suggesting that 
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replication was stalled. The paper suggested that mtDNA depletion, associated with TWNK 
mutations, is due to this replication stalling and this is the mechanism of ΔmtDNA formation 
in these cells (Goffart et al., 2008). 
Recently, copy-choice recombination has been put forward as the mechanism of deletion 
formation during mtDNA replication via SDM (Persson et al., 2019). This hypohthesis also 
suggests that during replication of the H-strand, the single stranded L-strand can bind to 
repeat sequences within itself forming a loop. When the L-strand is synthesised, the resulting 
loop is not replicated. This is similar to the previous replication stalling theory, however 
without the double strand breaks.  
 MtDNA deletion formation through repair 
Another possible method of ΔmtDNA formation is through repair. Although, repair pathways 
exist to correct mtDNA damage, these are not infallible. As mentioned before the BER pathway 
is the major repair pathway that has been observed in mitochondria. During repair via BER, 
intermediates containing single strand breaks are recognised and cleaved by DNA 
glycosylases, processed and correct base pairs are inserted before ligating it back to the 
original strand. However if BER is interrupted, these breaks can accumulate as seen in yeast 
(Ma et al., 2008). This can then disrupt other processes such as replication which could 
potentially lead to an accumulation of mtDNA mutations. However, this is more specific for 
point mutations as BER is involved in the removal of a single base pair. It could be suggested 
that we see an accumulation of ΔmtDNA (Bender et al., 2006a, Kraytsberg et al., 2006a) as 
repair mechanisms for these mutations are absent or not adequate.  
Another theory set forward by (Krishnan et al., 2008) is that deletion formation occurs through 
the repair of double strand breaks (DSB) (figure 1.8). They suggest that after a DSB is made, 
this is susceptible to 3’→5’ exonuclease activity which is generally involved in proofreading 
activity and removes mismatched base pairs. This would then leave the mtDNA single 
stranded at the site of the break, allowing the DNA to mis-anneal to a direct repeat sequence 
forming a ΔmtDNA. Examples of 3’→5’ exonucleases are POLG and RNA exonuclease 2, an 
oligoribonuclease, which localises to the mitochondria which could mediate this deletion 
formation (Nguyen et al., 2000, Hudson and Chinnery, 2006a). This hypothesis suggests that a 
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direct repeat is required for deletions to form, and while these are associated with the 
majority of mtDNA deletions, previously mentioned studies have identified breakpoints that 
do not correspond with a direct repeat (Reeve et al., 2008, Samuels et al., 2004). 
 
Figure 1.8 MtDNA deletion formation through repair of double strand breaks. 1) Initially mtDNA is damaged as a 
result of insult such as ROS. 2) This requires repair which could initiate a double strand break for repair. 3) The 
DNA undergoes degradation 4) this leaves single strands of DNA. 5) this allows repeat sequences present on the 
single strand to anneal due to homologous recombination, and any remaining single stranded DNA could be 
degraded. 6) which leaves a deleted mtDNA molecule. Image taken with permission from (Reeve, 2007). 
Another theory that could be suggested as to why there are more deletions in post-mitotic 
tissues than mitotic ones is that the nuclear genome has reduced transcription of mtDNA 
repair proteins. Due to this, these repair proteins would not be transcribed from the nuclear 
genome and thus would not be accessible for the mitochondria. Transcriptomic studies have 
demonstrated an age-related decrease in nuclear encoded mitochondrial proteins (Preston et 
al., 2008). This is also supported by a study (Imam et al., 2006) which demonstrated an age-
dependent decrease in various DNA glycosylases in five brain regions; caudate nucleus, frontal 
cortex, hippocampus, cerebellum and brain stem. This was done on mice aged 6 and 18 
months, mitochondrial as well as nuclear DNA glycosylases were identified. This is also 
supported by another study which demonstrated an age-dependent decrease of BER activity 
in the mitochondria in mice cerebral cortices (Chen et al., 2002). Since mtDNA is double 
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stranded and circular a further theory has suggested that the formation of DNA conformations 
such as a hairpin, cloverleaf or cruciform occur due to repeat sequences that are 
complementary with each other. These structures can also increase mtDNA vulnerability to 
deletions (Damas et al., 2012). This again points towards repair as a method of deletion 
formation since these structures are not described within any of the replication models. 
Since Polγ is also involved in repair pathways, the PolgAmut/mut mouse can be studied to 
understand repair as well. With inadequate repair, ΔmtDNA formation, especially in the case 
of Polγ mutations, is said to be due to ineffective proof reading activity of the polymerase 
resulting in incorporation of inaccurate nucleotides which are not correctly ‘proof read’. This 
could lead to accumulation of point mutations and which will then be cleaved and possibly 
lead to DSB, which can lead to ΔmtDNA  (Krishnan et al., 2008). However, a study using patient 
tissue containing the Polγ mutation Y955C showed that the levels of point mutation in the 
cytb encoding region did not differ significantly between patients and control individuals, 
suggesting that the accuracy in replication and or repair is not diminished (Wanrooij et al., 
2004). However other mechanism could have a different mechanism of action.  
 Clonal expansion of mtDNA deletions 
Clonal expansion of mtDNA mutations refers to the process by which ΔmtDNA or any other 
mutation might expand to high levels in a single cell. Once the deletion level crosses the 
threshold value, this leads to OXPHOS deficiency and mitochondrial dysfunction resulting in 
disease (Campbell et al., 2012, Fayet et al., 2002). There are three main theories for how 
mtDNA mutations clonally expands; survival of the smallest, survival of the slowest and 
random genetic drift. 
I) Survival of the smallest 
Survival of the smallest was the first theory to be suggested (Wallace, 1989, Wallace, 1992). 
This theory suggests that deleted mtDNA molecules, since they are smaller, replicate much 
faster allowing the deletion to accumulate. There has been evidence uncovered that both 
supports and disputes this theory. Initial support for this ‘survival of the smallest’ theory was 
put forth by an in vitro study on human fibroblasts containing both wildtype and a deleted 
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mtDNA molecule. They caused mtDNA depletion using ethidium bromide treatment, and 
when the mtDNA repopulated, there was an increase in ΔmtDNA within the cell lines that 
harboured them compared to the wildtype mtDNA molecules. This suggested that deleted 
mtDNA replenished their population significantly faster than full length, wild type mtDNA 
molecules (Moraes et al., 1999). This was replicated in another study which also demonstrated 
that deleted mtDNA accumulation (Diaz et al., 2002). They also used a cell line with point 
mutations and demonstrated that there was no increase of these mutations further 
suggesting a size advantage. One of the main criticisms for the original Moraes et al study was 
that the higher level of ΔmtDNA was due to the toxicity induced by ethidium bromide. 
However, the Diaz et al study also looked at normal conditions, which still showed a 
preferential accumulation of shorter mtDNA molecules. This study is also supported by 
another study that looked at iPSC cells reprogrammed from human fibroblasts (Russell et al., 
2018). This revealed that the level of a ΔmtDNA increased with sequential passage, which was 
not observed in cells harbouring point mutations. This has also been investigated in vivo using 
mice (Fukui and Moraes, 2008). These mice expressed a restriction endonuclease, which was 
targeted specifically to the mitochondria in adult neurons. This restriction enzyme has the 
ability to induce double strand breaks by cleaving the mtDNA that will be repaired by DNA 
repair machinery forming ΔmtDNAs (section 1.6.2). Furthermore, they demonstrated that 
larger deletions, accumulated faster in adult neurons, than smaller deletions.  
A major piece of evidence against this theory is that the accumulation of point mutations to 
high levels is also commonly seen. MtDNA molecules containing point mutations do not have 
the smaller size advantage yet they accumulate to high levels similar to those of ΔmtDNA 
particularly within mitotic tissues (Michikawa et al., 1999, Khaidakov et al., 2003, Trifunovic et 
al., 2004, Taylor et al., 2003a). A study of the colorectal epithelium demonstrated an 
accumulation of point mutations with ageing (Greaves et al., 2014). However, accumulation 
of ΔmtDNA with age, rather than point mutations is prominent in post-mitotic cells such as 
neurons; hence, survival of the smallest theory could still be the mechanism of ΔmtDNA 
accumulation in post-mitotic cells. In addition to this, there was a suggestion that faster 
replication is not advantageous for mtDNA, due to its long half-life (~6-31 days) compared to 
its short replication time (~1 hour) (Korr et al., 1998, Gross et al., 1969, Clayton, 1982). This 
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suggest that, even if replication occurs faster, there is no benefit since mtDNA molecules are 
present for a much longer time. Hence, replication time would not be the rate-limiting step in 
this process. 
II) Survival of the slowest 
The survival of the slowest theory takes into account mitochondria’s ability to produce ROS as 
a by-product of OXPHOS. This theory suggests that in mitochondria with ΔmtDNA, the OXPHOS 
system, due to decrease in normal function, has a reduction in the amount of ROS produced. 
This in turn prevents the mitochondria from being targeted for mitophagy, hence the ΔmtDNA 
is allowed to replicate and accumulate (De Grey, 1997). However, evidence against this theory 
suggests that in mitochondria with OXPHOS dysfunction and mtDNA mutations including 
ΔmtDNA, there is an increase in ROS production (Indo et al., 2007). Also in cytoplasmic hybrids 
(cybrid) cells containing the common deletion causing an OXPHOS defect, an increase in ROS 
within the mitochondria was noticed (Peng et al., 2006).  
III) Random drift 
Another theory of clonal expansion suggests that there is no selective mechanism for mtDNA 
replication and that accumulation of ΔmtDNA is random (Elson et al., 2001). This was 
supported by a mathematical model that was developed that predicted that up to 4% of post 
mitotic cells will be COX negative by the 8th decade of life, which was concurrent with 
histochemical data. However, in neurons, by the 8th decade of life, over 50% deletion 
heteroplasmy is observed (Bender et al., 2006c, Kraytsberg et al., 2006b). This theory also 
supports and provides an explanation for the accumulation of point mutations. However, this 
theory does not explain clonal expansion in patients with multiple ΔmtDNA due to nuclear 
mutations, as they tend to have a younger age of onset and higher levels of COX deficiency 
(Campbell et al., 2014, Lax et al., 2012, Cottrell et al., 2000).  
IV) Other possible theories 
Recently, another theory has suggested that clonal expansion of deletions occurs due to the 
connection between replication and transcription, where transcription of the L-strand 
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produces an mRNA that can initiate replication. This study used bioinformatics analysis of 
ΔmtDNA to suggest a negative feedback loop where transcription levels are controlled by the 
availability of certain proteins coded by the mtDNA. In the case of ΔmtDNA, when these 
proteins are not available, mtDNA transcription is still upregulated, which can also lead to an 
increase in replication of this molecule. The analysis discovered that the mtDNA coded genes; 
ND4, ND5 and ND6, functioned in this feedback loop. Although most mtDNA deletions do 
remove these genes, ΔmtDNA has also been observed as accumulating in cases where these 
candidate genes are not deleted (Damas et al., 2013). 
 MtDNA deletions in post-mitotic cells  
Although ΔmtDNA have been associated with diseases such as Kearns-Sayre syndrome (KSS), 
the age-dependent accumulation of ΔmtDNA was first reported in the early 90’s, particularly 
in post-mitotic tissues (Cortopassi and Arnheim, 1990, Cooper et al., 1992, Cortopassi et al., 
1992, Soong et al., 1992). Low levels of specific ΔmtDNA, previously described as being 
pathogenic in mitochondrial diseases, were discovered in tissue from heart and brain from 
aged individuals, however, these mutations were not observed in fetal heart and brain tissue 
suggesting they accumulate with age (Cortopassi and Arnheim, 1990). A fascinating factor 
uncovered was that the same tissue from different individuals contained more similar deletion 
loads than different tissues within the same individual (Cortopassi et al., 1992, Meissner et al., 
2006), suggesting that the same tissues accumulate ΔmtDNA in a similar fashion. In support 
of this, a study comparing mtDNA mutations in the colon of PolgAmut/mut mice and aged wild-
type individuals showed that the location of the genes effected were not significantly different 
between both cases (Baines et al., 2014). Alongside this, ΔmtDNA have also been associated 
with normal ageing, and age associated conditions such as Parkinson’s disease and muscle 
myopathies (Bender et al., 2006c, Cortopassi et al., 1992, Holt et al., 1988, Reeve et al., 2008). 
More evidence of ΔmtDNA association with ageing was established when a study comparing 
mtDNA mutations in PolgAmut/mut mice and aged wild-type individuals showed that although 
the location of the genes effected were not significantly different, there was a significant 
difference in the type of mutation as point mutations were noticed in both groups, but 
ΔmtDNA was present only in aged individuals (Baines et al., 2014). 
66 
 
 MtDNA deletions in neurons 
Of all the post-mitotic cells, neurons seem to be particularly susceptible to ΔmtDNA. A study 
compared the level of the ‘common’ deletion which cleaves 4977 bps and demonstrated the 
highest levels in the brain compare to muscle and heart (Meissner et al., 2008). They also 
mentioned that in older individuals, compared to adolescent individuals, the deletion load 
increased by 3 fold.  This increase in ΔmtDNA within neurons could be due to the complexity 
of these cells and their function, resulting in a high energy demand, thus increasing their 
dependence on mitochondria to produce this energy through OXPHOS activity. This high 
requirement for oxygen could also result in a higher level of oxidative stress, which has the 
potential to induce mtDNA damage. Damaged mtDNA can also result in mtDNA mutations and 
damaged OXPHOS function which results in a further increased in oxidative stress creating a 
vicious cycle of mtDNA damage and oxidative stress (Circu and Aw, 2010). 
Clonal expansion of ΔmtDNA in neurons was investigated in two studies looking at 
dopaminergic neurons (Bender et al., 2006c, Kraytsberg et al., 2006b). Bender et al laser-
microdissected individual neurons from the Substantia Nigra (SN) of PD patients and control 
(healthy aged) individuals and conducted long range PCR. They demonstrated that SN neurons 
from both groups contained multiple ΔmtDNA which had clonally expanded to high levels in 
both COX-deficient and COX-positive neurons. The presence of multiple deletions which were 
different in each neuron suggested that they were acquired, as an inherited mutation would 
produce the same ΔmtDNA species in all the cells studied from each patient. This age related 
increase in ΔmtDNA was also supported by Kraytsberg et al, further suggesting a role of clonal 
expansion. Both of these papers demonstrated a higher level of ΔmtDNA in COX-deficient 
neurons suggesting a link between the ΔmtDNA and mitochondrial dysfunction. Following 
this, a study by our group looked at the actual break points of these ΔmtDNA (Reeve et al., 
2008). They found that similar break points were observed within the ΔmtDNA in 3 groups: 
PD patients, ΔmtDNA disorder patients and age matched controls. This suggested that the 




ΔmtDNA, specifically the differences between brain regions is discussed in more detail in 
section 3.1 (chapter 3) 
 MtDNA deletions and neurological disease 
As mentioned previously, ΔmtDNA are associated with a number of age associated 
neurodegenerative conditions such as Parkinson’s disease, Huntington’s disease and 
Alzheimer’s disease (Aiken et al., 2002, Bender et al., 2006c, Krishnan et al., 2012). 
Mitochondrial diseases can also occur as a result of ΔmtDNA. Mitochondrial diseases are a set 
of conditions caused by inherited mutations (in both the nuclear and mitochondrial genomes) 
that lead to mitochondrial dysfunction. One such condition is progressive external 
ophthalmoplegia (PEO). This can be caused by an inherited mutation with the twinkle helicase 
protein or Polγ (section 1.5.1) that leads to the presence of multiple ΔmtDNA which 
accumulate within an individual (Spelbrink et al., 2001, Van Goethem et al., 2001). In these 
conditions, patients most commonly exhibit myopathies, however neuropathies have also 
been observed (Kiechl et al., 2004). Polγ mutations in humans are also associated with early 
onset Parkinsonism in a number of studies (Davidzon et al., 2006, di Poggio et al., 2013, 
Puschmann, 2013). A recent study conducted whole exome sequencing on a cohort of PD 
patients and identified variations within mtDNA maintenance genes such as POLG, POLRMT 
and OGG1 (Gaare et al., 2018). Single large scale deletions have also been associated with 
Kearns-Sayre syndrome (KSS), which is a neuromuscular disease, with neurological symptoms 
such as ataxia, cognitive decline and seizures (Khambatta et al., 2014). These studies suggest 
a direct association between ΔmtDNA and neuronal health and survival. 
 Why are SN neurons particularly prone to accumulating mtDNA deletions? 
A reason for the sensitivity of SN dopaminergic neurons to these ΔmtDNA could be due to 
high oxidative stress as a result of their function. SN neurons are one of the largest neurons 
within the brain, and are highly arborized with a total axonal length of 4.5m (Bolam and 
Pissadaki, 2012). They also have an increased rate of oxygen consumption and more axonal 
mitochondria compared to dopaminergic neurons from the ventral tegmental area (VTA) 
(Pacelli et al., 2015). Due to this size and complex arborization, there is an increase in 
dependence on the OXPHOS system and oxidative stress (Haddad and Nakamura, 2015, Pacelli 
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et al., 2015). Studies have demonstrated increased oxo-8-dG levels in the midbrain (containing 
SN) compared to other regions such as cerebellum (Cardozo-Pelaez et al., 2000). This oxidative 
stress is further exaggerated  by the metabolism of dopamine, which produces oxidative 
molecules such as dopaminergic quinines and H2O2 which can lead to oxidative stress if not 
properly degraded by glutathione peroxidase (Andersen, 2004). Hydroxide radicals and ions 
are produced from the Fenton reaction between H2O2 and iron, while ferritin, a protein that 
binds and stores iron, has been demonstrated to be decreased in the SN of PD patients 
suggesting an increase in cellular free iron levels to react with H2O2 (Dexter et al., 1991, James 
et al., 2015). In addition to this, neuromelanin, found within SN neurons, is also capable of 
binding iron. In PD and ageing, a decrease in neuromelanin levels is observed further elevating 
the levels of unbound iron (Mann and Yates, 1983, Kastner et al., 1992, Zucca et al., 2017). All 
of this suggests a toxic cycle between iron and dopamine within dopaminergic neurons adding 
to the high oxidative stress in these cells (Hare and Double, 2016).  Furthermore, SN neurons 
exhibit a high rate of lipid peroxidation and protein nitration (Dexter et al., 1989, Good et al., 
1998). Glutathione, one of the antioxidant enzymes within the mitochondria, is also reduced 
in the SN of PD patients further suggesting a link between the SN and increased oxidative 
stress (Bharath et al., 2002, Sofic et al., 1992). 
 MtDNA deletions in PolgAmut/mut transgenic mice 
Tables 3.1 presents mtDNA deletion levels detected in PolgAmut/mut transgenic mice. The mice 
used in this thesis were a gift from Dr Laura Greaves (Wellcome Centre for Mitochondrial 
Research), and have been described in detail in section 2.2.1. Briefly these mice demonstrate 
an accumulation of mtDNA deletions and point mutations alongside a premature ageing 
phenotype (Kujoth et al., 2005). In PolgAmut/mut mice, ΔmtDNA form due to error prone 
replication instigated by defective DNA polymerase γ. Since this is the only polymerase which 
functions in the mitochondria, any mutations within this gene can have a large effect (Bolden 
et al., 1977, Luoma et al., 2004). The D257A mutation within the mice used for this study, 
codes for a missense mutation that affects the proof reading domain of the catalytic subunit 
which alters the 3’-5’ exonuclease activity of the enzyme (Falkenberg et al., 2007). Normally 
this region is involved in identifying mismatched basepairs which are then repaired by 
exonuclease activity. Therefore the mutation results in mismatches being retained within the 
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genome. This mutation is also suggested to affect the ligation of the mtDNA following 
replication which will be discussed in detail later in this section (Macao et al., 2015).  
These PolgAmut/mut mice demonstrate the presence of multiple ΔmtDNA species, which 
increase with age, especially within the brain (refer to table 3.1). This renders it a good model 
to study ΔmtDNA, as in humans, patients with POLG mutations also lead to multiple deletions 
and often Parkinsonism (Bender et al., 2006b, Davidzon et al., 2006, Trifunov et al., 2018, Van 
Goethem et al., 2001). In patients with POLG mutations, the mtDNA deletions mtDNA 
molecules retain a circular structure, however, mtDNA deletions in PolgAmut/mut mice are 
understood to be linear. A suggested mechanism of deletion formation in PolgAmut/mut mice is 
through faulty ligation of the 5’- end (Macao et al., 2015). Studies have suggested that when 
replication of a single mtDNA strand is complete, 3’-5’ exonuclease activity is required to 
produce a nick that is ligated when replication of both strands end. However in PolgAmut/mut 
mice, the replication does not stop when it returns back to the origin of replication. Instead 
this is continued and due to this the remaining product cannot be ligated and it is left as a nick. 
When the next round of replication happens, this then produces a double strand break and a 
linear mtDNA molecule. It has also been suggested that the mutated version of Polγ does not 
require Twinkle to linearise the double stranded mtDNA, instead it can produce short 
fragments of mtDNA from the double strands (He et al., 2013, Farge et al., 2007). This will 
produce fragments observed as ΔmtDNA in a long range PCR experiment, however these 
might not be reflecting the accumulation of ΔmtDNA as these short fragments are linear and 
might prevent further replication due to disturbed origin of replication sites. Recent studies 
have demonstrated that these linear fragments are degraded quickly, even within 4 hours 
(Peeva et al., 2018, Nissanka et al., 2018), which could explain the association of POLG 
mutations and mtDNA depletion syndromes (Naviaux and Nguyen, 2004, Van Goethem et al., 
2001, Mehta et al., 2011) and could be further evidence that these ΔmtDNA are in fact linear. 
However, this depletion can also be caused by inefficient polymerase gamma. Alongside this, 
PolgAmut/mut mice demonstrate premature ageing phenotype Therefore, in this study, 





1.7 Significance of this thesis 
Although the field studying ΔmtDNA has seen much progress over the years, the mechanism 
of mtDNA formation and accumulation to high levels remain uncertain. One of the mechanism 
that have been theorised to lead to ΔmtDNA is mtDNA replication (section 1.6.1). This thesis 
aims to shed light on mtDNA replication, with particular emphasis on neurons due to the high 
levels of ΔmtDNA observed here. This would be beneficial in establishing the impact of mtDNA 
replication in mtDNA deletion formation. Therefore, the aims of this thesis were as follows; 
1. To study mtDNA replication in various brain regions to correlate with the different 
levels of ΔmtDNA observed in these regions 
2. To develop a model to study mtDNA replication in vitro within various cell lines 














Chapter 2 : Materials and Methods 
2.1 Equipment, software, reagents and consumables 
 Equipment  
Equipment Supplier 
ABI Step-one Plus Real Time PCR system 
Applied Biosystems 
ABI veriti-96 well Thermo Cycler 
Applied Biosystems 
AMT CCD camera (for TEM) Deban 
Antigen Retrieval Unit 2100 Retriever 
Autoclave Prior Clave 
Autoclave Astell 
Axioimager M1 microscope Carl Zeiss 
Bench-top Centrifuge 3-15 Sigma 
Biorad Chemidoc Biorad 
Corning LSE Vortex mixer Sigma Aldrich 
Electrophoresis power supply Cleaver scientific 
Eppendorf Thermomixer Eppendorf 
Horizontal Agarose Gel Electrophoresis Systems Amersham 
Laminar flow hood Jencons-PLS 
Microtome Microm 
Nanodrop ND-1000 Spectrophotometer Labtech International 
Nikon A1R point scanning confocal microscope  Nikon 
Pipette 1000-10μL (Gilson)  StarLab  
Pipette boy Integra 
PURELAB flex Elga 
Rotatest shaker R100 Luckham 
Serial block face scanning electron microscope Zeiss Sigma 
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Stereology microscope Olympus BX51 
Sterilizing oven Laboratory Thermal Equipment Ltd. 
Transmission Electron Microscope Philips CM100 
UV hood Bioair 
Vortex genie 2 Scientific Industries 
Table 2.1 List of equipment used in this thesis 
 Software 
Software  Supplier 
3view 
Gatan 
A1R scanning confocal system 
Nikon 




Digital Micrograph v2.31.734.0 
Gatan 
ImageJ 
Public domain, NIH 








NIS-Elements Viewer v4.2 Nikon 
Prism v7.0 Graph pad 
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Table 2.2 List of softwares used in this thesis 
 Reagents and consumables  
Reagents/Consumables   Supplier 
“Mr Frosty” Freezing container Thermo Scientific 
0.2ml Thin-Walled PCR Tubes Thermo Scientific 
0.5ml PCR Tubes Thermo Scientific 
1.5ml Eppendorf Tubes Thermo Scientific 
1kb DNA ladder Promega 
2ml Eppendorf tubes Thermo Scientific 
5-Chloro-2-deoxyuridine thymidine (CldU)  Sigma-Aldrich  
5-Iodo-2-deoxyuridine (IdU)  Sigma-Aldrich  
60mm dishes Fisher Scientific  
6-well/12-well plates Greiner Bio-One  
96-well plate Semi-Skirted with Raised Rim Starlabs 
Agarose Biolin 
Aphidicolin   Bertin Pharma 
Avidin/biotin blocking kit  Vector Laboratories  
B27 supplement GIBCO 
bisBenzimide Hoechst 33258 Sigma Aldrich 
Brain Derived Neurotrophic factor (BDNF) R & D systems 
Cellometer Auto T4 Nexcelom  
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Cellometer disposable counting chambers Nexcelom 
Concentrated HCl Sigma-Aldrich 
Coverslips (22mm and 13mm) VWR International 
Cryostor CS2 Freeze Media Biolife solutions 
Nunc Cryotube Sigma-Aldrich 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
DNA Away  Thermo Fisher  
DNA extraction Kit Qiagen 
Doxycycline  Stemcell technologies 
DPX BDH 
Dulbecco’s Modified Eagle Medium (DMEM) GIBCO 
Dulbecco’s Modified Eagle Medium/F-12 media GIBCO 
Dulbecco’s Phosphate buffered saline (DPBS) GIBCO 
Eosin CellPath 
Ethanol  Fisher Scientific  
Fetal Bovine Serum (FBS) GIBCO 
Filter pipette tips  Tip One 
Formalin solution, neutral buffered, 10%  Sigma-Aldrich 
Geneticin (G418) Sigma Aldrich 
Glial-cell derived neurotropic factor (GDNF) R & D systems 
Gloves Ultrasense 
GoTaq® Long PCR Master Mix Promega 
Haemotoxylin  TCS Biosciences Ltd.  
Histoclear  National Diagnostics  
Human Epidermal Growth Factor (hEGF) GIBCO 
Human Fibroblast Growth Factor (hFGF) 
GIBCO 
Human Neurotrophin-3 (hNT3) R & D systems 
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Hydrochloric acid 37%  VWR 
Laminin Sigma Aldrich 
L-Glutamine GIBCO 
Matrigel  Millipore 
MitoTracker Green FM Thermo Fisher 
mTeSR1 media 
Stem cell technologies 
N2 supplement GIBCO 
Nomal goat serum (NGS) Abcam 
Normal donkey serum (NDS) Abcam 
Normal goat serum  Sigma-Aldrich  
Nutristem  Biological industries 
Parafilm Pechiney plastic packaging 
Paraformaldehyde solution 4% in PBS Santa-Cruz Biotechnology  
PBS tablets  Sigma-Aldrich  
PCR Primers – long range Eurofins 
Pencillin/Streptomycin  GIBCO 
Poly-D-Lysine (PDL) Sigma Aldrich 
ProLong® Gold Antifade Mountant Life Technologies 
Proteinase K solution Fisher Scientific 
Real Time PCR primers  Applied biosystems  
Rock inhibitor (Y-2763-ROCKi) Millipore 
Scalpels  Swann Morton  
Sodium Pyruvate GIBCO 
Sterilin™ 7ml Polystyrene Bijou Containers Thermo Scientific 
Superfrost plus glass microscope slides Thermo Scientific 
SYBR safe DNA gel stain Invitrogen  
T75cm2 vented flasks Corning  
TAE buffer Sigma-Aldrich  
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Tamara labelled probes (ND1, ND4, Dloop) Applied biosystems 
Taqman mastermix  Applied Biosystems 
Tetramethylrhodamine, Methyl Ester, Perchlorate 
(TMRM) 
Thermo Fisher 
Tissue cassettes CellPath 
Tris-acetate EDTA buffer Sigma-Aldrich 
Tri-sodium citrate dihydrate VWR 
Trizma base  Sigma-Aldrich 
Trypan Blue GIBCO 
Trypl-E Express GIBCO 
Tween®-20  Sigma-Aldrich 
Uridine Sigma Aldrich 
X-VIVO media Corning 
Table 2.3 List of reagents and consumables used in this thesis 
 Antibodies 
Primary Antibodies Isotype Supplier 
Anti-CaMKIIα antibody (6G9) Mouse IgG1 Santa Cruz 
Anti-DAT antibody Rat polyclonal abcam 
Anti-DNA antibody, double stranded, clone BV16-
13 
Mouse IgG2a Merck Millipore 
Anti-Grp75 antibody Rabbit 
polyclonal 
Abcam 





Anti-mtTFA antibody Mouse IgG2b Abcam 
Anti-NDUFB8 antibody IgG1 Abcam 
Anti-Tyrosine Hydroxylase antibody Rabbit 
polyclonal 
Sigma 
Anti-VDAC1 / Porin antibody [20B12AF2] 
(ab14734) 
Mouse IgG2b Abcam 
CldU (Bromodeoxyuridine/BrdU Antibody (BU1/75 
(ICR1)) 
Rat IgG2a BD Biosciences 
IdU (Purified Mouse Anti-BrdU) Mouse IgG1 Novus biologicals 
MitoTracker Red CMXRos n/a Thermofisher 
Monoclonal anti b-tubulin  Mouse IgG2b Sigma-Aldrich 
PicoGreen n/a Thermofisher 
Smi-31 Mouse IgG1 Cambridge 
Bioscience 
Tom20 antibody  Mouse IgG2a Santa Cruz 
Tom20 antibody (FL-145): sc-11415 Rabbit 
polyclonal 
Santa Cruz 
Twinkle antibody Rabbit 
polyclonal 
Protein Tech 







COX-EM fixative  
 
2% Glutaraldehyde  
0.1M Sorrenson's buffer (pH7.4)  
 
Differentiation media 100ml Neurobasal media 
2ml B27 supplement 
1ml N2 supplement 
1ml Pencilin/Streptomycin 
(50μg/ml) 
1ml Sodium Pyruvate (1mM) 
0.2ml Uridine (50mg/ml) 
10ng/ml Brain Derived 
Neurotrophic factor (BDNF) 
10ng/ml Glial-cell derived 
neurotropic factor (GDNF) 
10ng/ml Human Neurotrophin-3 
(hNT3) 
DNA electrophoresis gel buffer  
 
100ml 10x Tris-acetate EDTA buffer  
 900ml Nanopure water 
DNA electrophoresis running buffer  
100ml 10x Tris-acetate EDTA buffer  
900ml Nanopure water 
Single cell lysis buffer 
250μl 1% Tween 20  
50μl 0.5M TrisHCl pH8.5  
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195μl dH2O  
5μl proteinase K 
MTeSR media 400ml mTesR base Medium 
100ml MTesR supplement 
5ml Pencilin/Streptomycin 
(50μg/ml)   
5ml Sodium Pyruvate (1mM) 
1ml Uridine (50μg/ml) 
NutriStem Media 500ml Nutristem hPSC XF Medium 
5ml Pencilin/Streptomycin 
(50μg/ml) 
5ml Sodium Pyruvate (1mM) 
1ml Uridine (50μg/ml) 
Phosphate Buffered Saline (PBS)  
 
1 tablet in 100ml dH2O  
 
Proliferation media 100ml  
Dulbecco’s Modified Eagle Medium 
(DMEM)/F12 media 
2ml B27 supplement 
1ml N2 supplement 
1ml Pencilin/Streptomycin  
1ml L-gutamine 
 
(filter through at this point, then 
add the following) 
 




10ng/ml  Human Fibroblast Growth 
Factor (hFGF) 
Tris-Buffered Saline (TBS, pH 7.4)  
1.2g Trizma Base  
17g NaCl  
2L dH2O 
Concentrated HCl  
 
Tris-Buffered Saline, Tween 20 (TBST, pH 7.4)  
1.2g Trizma Base  
17g NaCl  
2L dH2O 
Concentrated HCl  
2ml Tween  
 
 
TEM fixative (pH 7)  
 
2% Glutaraldehyde  
0.1 M Sodium Cacodylate 
Tri-sodium citrate antigen retrieval buffer 
(pH 6.0) 
2.9g tri-sodium citrate dehydrate 
(10mM) 
1L dH2O 
0.5ml tween  
Luxol fast blue solution 




10% acetic acid 
Cresyl fast violet solution 
0.2g Cresyl fast violet 
100ml distilled water 
Acetate buffer solution 
13.5ml Acetic acid  
23.5g Sodium acetate 
2000ml distilled water 
0.1% cresyl fast violet in 1% acetic acid 
50ml Cresyl fast violet solution 
500ml Acetate buffer solution 
500ml Distilled water 
Table 2.5 List solutions and their contents used in this thesis 
2.2 Mouse brain tissue methods 
 PolgAmut/mut mitochondrial mutator mice 
The PolgAmut/mut mouse, originally produced by (Trifunovic et al., 2004), were a generous gift 
from Dr Laura Greaves (Wellcome centre for mitochondrial research, Newcastle University). 
These mice had a knock-in missense mutation which resulted an alanine to aspartate (D257A) 
conversion effecting the proof reading activity to produce a defective PolγA. These mice have 
an accelerated ageing phenotype resulting in a reduced life span. They also have observational 
phenotypes such as alopecia, weight loss, kyphosis, and many age related conditions such as 
anaemia and osteoporosis. They also have molecular age related changes such as increased 
mtDNA point mutations and deletions.  
A total of 17 mice were used for this study. Prior to culling, they were housed in the 
Comparative Biology Centre (CBC) at Newcastle University. These mice were housed 
individually and kept in a constant temperature of 25oC with a 12 hour light/dark cycle. These 
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mice were cared for by Carla Bradshaw (Technican, Wellcome centre for mitochondrial 
research, Newcastle University). More details about the mice and their age are provided in 
the chapter (section 3.3.1) 
 Thymidine analogue labelling of mouse tissue 
The mice were labelled with 5-Chloro-2-deoxyuridine thymidine (CldU, Sigma Aldrich) and 5-
Iodo-2-deoxyuridine (IdU, Sigma Aldrich) by Dr Craig Stamp and Carla Bradshaw (Wellcome 
centre for mitochondrial research, Newcastle University). Thymidine analogues are 
incorporated into the cell during DNA replication and hence identify any replicating DNA. The 
timing and concentration of CldU and IdU labelling was developed and optimised for the mice 
with the help of Dr Craig Stamp who used this method to label replicating stem cells within 
colonic crypts (Stamp, 2016). CldU is made up in PBS at a concentration of 5mg/ml. The 
powder dissolves into the solution with vortexing. The pH is adjusted to 7.4 and the solution 
is passed through 22µm sterile filter and stored at 4oC until use.  
 IdU is also made up at 5mg/ml, however solubilisation requires further steps as the solubility 
in PBS is at 2mg/ml. Hence IdU is left in a 55oC water bath for 8 hours, following this, 100 ul of 
2M NaOH is added into solution dropwise until it is completely dissolved. This requires 
adjusting the pH back to 7.4 using 10M HCl. The volume of NaOH and HCl are also recorded to 
ensure a final concentration of 5mg/ml. This solution is passed through a 22µm sterile filter 
and stored at 55oC on the day of injection as it precipitates out of solution.  
The mice are injected via the intra-peritonal cavity at a dose of 50mg/kg. The injection 
schedule is present in table 2.6. Briefly these mice were injected with 50mg/kg of CldU twice 
a day for 4 days at 10:00 hours and 18:00 hours. On day 4, they were injected with CldU as 
normal at 10 am, however at 6pm; they were injected with 50mg/kg of IdU and sacrificed after 
a further 14-16 hours. Therefore all the mitochondrial DNA which had replicated in the 





 Day 1 Day 2 Day 3 Day 4 Day 5 
Action 1 
Injection: 
CldU – 50 
mg/kg 
Injection: 
CldU – 50 
mg/kg 
Injection: 
CldU – 50 
mg/kg 
Injection: 






10:00 10:00 10:00 10:00 8:00-10:00 
Action 2 
Injection: 
CldU – 50 
mg/kg 
Injection: 
CldU – 50 
mg/kg 
Injection: 
CldU – 50 
mg/kg 
Injection: 





18:00 18:00 18:00 18:00 - 
Table 2.6 Thymidine analogue labelling schedule 
 Harvesting the mouse brain 
Mice were sacrificed by cervical neck dislocation and the brains were harvested as quickly as 
possible. The brain was cut down the midline in an anterior to posterior direction. One half 
was mounted in OCT and moved to -80oC immediately. This was intended to be used for 
molecular analysis. The other half was added to a cassette and left overnight in a 10% formalin 
solution, neutral buffered (Sigma Aldrich). This was then transferred into 70% ethanol and 
fixed in paraffin wax by Newcastle Brain Tissue Resource (NBTR, Newcastle University). This 
half was used for histological staining and immunohistochemistry. 
 Haematoxylin and Eosin staining 
Mouse brain tissue was cut sagittally at 5μm using a microtome (Bright Instruments, 0TF5000) 
and stored at 37OC overnight and then at room temperature until use. For anatomical 
confirmation to identify different regions of the brain, every 5th section cut from the brains 
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was stained histologically using Haematoxylin and Eosin or Cresyl Fast Violet/Luxol Fast Blue 
staining. 
Haematoxylin is used to stain the nuclei as it stains for acidic substances such as RNA and DNA 
giving it a blue colour. Following this, the section is stained with Eosin which stains for basic 
substances such as cells, organelles and proteins in pink.  
Briefly, paraffin-fixed tissue sections were heated to 65oC for 20 minutes to melt the paraffin 
wax, and were then subjected to rehydration through histoclear and a graded ethanol series 
(100% x2, 95%, 70%) to distilled water. The slides were submerged in haematoxylin for 1 
minute and then run under normal tap water until the water ran clear to ensure removal of 
excess staining. Following this, they were submerged in eosin for 30 seconds and washed in 
tap water again. The slides were then dehydrated through an ethanol series (70%, 95% and 
100% x2), washed in histoclear and mounted under coverslip glass with DPX. 
 Cresyl Fast Violet/Luxol Fast Blue staining 
The 5μm sections mentioned above were also stained with Cresyl Fast Violet (CFV) and Luxol 
Fast Blue staining (LFB) for further anatomical confirmation.  The sections were heated and 
rehydrated according to the protocol metioned in the previous section in order to melt the 
paraffin wax. Following this, the sections were rinsed in 95% ethanol and left in luxol fast blue 
solution overnight at room temperature (this can also be done at 60oC for 3 hours). The 
stained sections were then washed in 95% ethanol and then in distilled water. The stain was 
then differentiated in lithium carbonate solution for 10-30 seconds, which also removes 
excess LFB staining. The differentiation was then continued in 70% ethanol. At this point, the 
grey and white matter are clearly distinguishable and the nuclei will be decolourised. If this is 
not the case, the differentiation is repeated with lithium carbonate solution and 70% ethanol. 
When the staining has reached optimal colour, the sections were stained in 0.1% cresyl fast 
violet in 1% acetic acid for 10-15 minutes, washed in distilled water and dehydrated using an 
ethanol series (70%, 95% and 100% x2) and finally washed in histoclear. Following this they 
were mounted under coverslip glass with DPX. Following this protocol, the myelin will be 
stained in blue with variation in the staining intensity, and the nuclei and nissl substances will 
stain in purple. Images are available in chapter 3  
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then differentiated in lithium carbonate solution for 10-30 seconds, which also removes 
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not the case, the differentiation is repeated with lithium carbonate solution and 70% ethanol. 
When the staining has reached optimal colour, the sections were stained in 0.1% cresyl fast 
violet in 1% acetic acid for 10-15 minutes, washed in distilled water and dehydrated using an 
ethanol series (70%, 95% and 100% x2) and finally washed in histoclear. Following this they 
were mounted under coverslip glass with DPX. Following this protocol, the myelin will be 
stained in blue with variation in the staining intensity, and the nuclei and nissl substances will 
stain in purple. Images are available in chapter 3. 
 Immunofluorescent labelling of mouse brain tissue 
Immunohistochemistry was performed using a method modified from previous protocols 
(Grünewald et al., 2014). Briefly, paraffin-fixed tissue sections were left at 37oC and 
rehydrated through histoclear and ethanol and washed with distilled water as mentioned for 
the H&E staining in section 2.2.4. Antigen retrieval was then performed for 40 minutes at 
pressure and at a high temperature in 10mM sodium citrate buffer with 0.05% Tween-20 
(pH6). Antigen retrieval was extended with emersion in 1.5M HCl for another 40 minutes. The 
sections were rinsed with distilled water and incubated in 10% normal donkey serum and 
normal goat serum (NGS/NDS, Sigma). A combination of both was used since the secondary 
antibodies used were produced from both these species. The incubation lasts 1 hour and acts 
to block any non-specific targets which could react with the host species of the secondary 
antibody. The sections were also incubated with avidin and biotin respectively for 15 minutes 
each. Sections were subjected to primary antibodies Tom20 (Santa Cruz), CIdU (BD 
Biosciences) and IdU (Novusbio) (table 2.7) over night at 4oC, following by incubation with 
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fluorescently conjugated secondary antibodies (Life Technologies) and biotin for 2 hours at 
room temperature. Following this, streptavidin-546 was added for 2 hours, and then Hoechst 
(Life Technologies) for 20 minutes. The section were mounted in ProLong Gold (Invitrogen). 
Sections were also washed with TBST between each step and stored in -20OC until imaged. 

















1:200 - - 488 
CldU Rat 
IgG2a 












1:200 Biotin-546 1:100 546 
Table 2.7 Antibodies used for Immunofluorescence of mouse brain tissue, along with their species, isotype and 
dilution. For suppliers, refer to materials section 2.1.4. 
 Analysis of thymidine analogue labelling 
Purkinje cells from the cerebellum, dopaminergic neurons from substantia nigra, pyramidal 
cells from the frontal cortex (layers 3 or 4) and CA1/CA2 regions of hippocampus were 
analysed to keep variability between different neurons in the same region to a minimum. 
Identification of specific neurons within these regions are mentioned in the chapter (section 
3.3.3). The images were analysed using IMARIS (Bitplane) by creating a mitochondrial 
surface based on the Tom20 staining (figure 2 . 1). Initially the volume, area, intensity and 
number of voxels were the parameters analysed. These surfaces were masked on to the IdU 
and CldU channels to identify incorporation into the mtDNA. This was done individually for 
each cell.  All of these channels were background corrected using the intensity values from 
a no primary control. Surfaces were created for both IdU and CldU. Once the surfaces are 
produced, IMARIS measures the surfaces and produces values for various parameters. The 
total sum of all of these values for an individual cell is calculated and expressed as a 
percentage of the total sum of values of the Tom20 channel of that cell. This provided a 
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percentage per cell of total mitochondria that have incorporated IdU and/or CldU into their 
mtDNA.  
 
2.3 Mammalian Cell culture 
 HeLa cells 
HeLa cells were cultured in a T75 vented flasks in Dulbecco’s Modified Eagle Medium (DMEM) 
media with the addition of 10% FBS, 2 mM L-glutamine, 1 mM Sodium Pyruvate, 50μg/ml 
uridine and 50μg/ml penicillin/streptomycin. The cells were placed in incubator at 37oC and 
with 5% CO2 until they reached a confluency of 70% at which point they were passaged.  
 HeLa cell passaging and freezing down 
The media from the HeLa cells was aspirated and the cells washed with Phosphate buffered 
saline (PBS) to remove dead cells and any excess media. Following this, 5ml of Trypl-E Express 
was added to the cells to disassociate the cells from the growing surface of the T75 flask.  The 
Figure 2.1 IdU and CldU channel surfaces created from masked mitochondrial surface based on Tom20 staining 
within individual cells. Scale bar represents 3µm. 
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flask was then returned to the incubator at 37oC and 5% CO2 for 3 minutes. The activity of 
Trypl-E Express was then quenched using 3ml of fresh media containing fetal bovine serum 
(FBS). This is because Trypl-E Express is a serine protease which allows it to break the matrix 
that adheres the cells to the flask and FBS contains serine protease inhibitors which inhibit 
Trypl-E Express from further activity which could lead to apoptosis of the cell. The cell and 
media suspension was then moved into a universal and centrifuged at 1200RPM for 4 minutes. 
The supernatant was then removed and the cells were re-suspended in 1ml of media. The cells 
were seeded into a new T75 flask at a total seeding density of 1x106 per dish. 
Cells were frozen down using freezing media containing FBS and 10% Dimethyl Sulfoxide 
(DMSO). A volume of 1ml of media containing 1x106 cells were added to each cryotube to be 
frozen down. The cryotubes were then placed in a Mr Frosty Freezing container overnight in -
80oC to freeze the cells in stages protecting their viability. Following this, the cryotubes are 
moved into a liquid nitrogen dewar for long term storage. 
 Induced pluripotent stem cells 
All the cell lines used were a kind gift from Dr Oliver Russell (Wellcome centre for 
mitochondrial research, Newcastle University). Fibroblasts were obtained from a patient with 
Pearson’s syndrome who had an mtDNA deletion of around 6kb (nt7777:nt13794). These were 
reprogrammed into induced Pluripotent Stem Cells (iPSC) according to the protocol using a 
sendai vector containing the  reprogramming factors c-Myc, Sox2, Klf4 and Oct4 (Fusaki et al., 
2009). These cells were used in a previously published paper (Russell et al., 2018). The 
reprogramming produced clones with varying levels of heteroplasmy. For this study, a high 
heteroplasmy clone (~40% mtDNA deletion) and a low heteroplasmy clone (>10% deletion) 
were used. The control cell line used was Human Dermal fibroblasts, adult (HDFa) which were 
reprogrammed according to the same protocol. Since these cells had no mDNA mutations, 
they acted as controls.  
 The stem cells were cultured in matrigel coated dishes at a seeding density of 1.7x104 per 
cm2. The high and low heteroplasmy cell lines were cultured in Nutristem media (see 
materials; solutions) with additional Rho-associated Kinase inhibitor (Rock inhibitor,  10μM) 
to aid the survival of cells as it blocks apoptosis and Geneticin (G418, 0.1 mg/ml) for antibiotic 
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selection for cells containing the construct. Nutristem media was required for the survival of 
the clones (Russell et al., 2018). HDFa cells were grown in mTeSR1 media (see materials; 
solutions) with additional Rock inhibitor (10μM) and Geneticin (G418, 0.1mg/ml). In both 
cases, media was replaced after 24 hours removing Rock inhibitor allowing cells to proliferate. 
 Matrigel Preparations 
Matrigel is a gelatinous substance that provides a matrix-like structure for the stem cells to 
adhere to within a plastic dishes. Originally developed from a mouse sarcoma, it mimics the 
environment found within tissues and provides the stem cells with the support usually 
required from a feeder cell layer such as extracellular matrix proteins and growth factors. 
Matrigel is prepared in aliquots, as per the manufacturer’s instructions. This is different for 
each batch and the volume required for each batch is mentioned on the manufacturer’s 
instruction for that batch. This is aliquoted out accordingly and stored at -80oC.  
Before use, the 60mm dishes/6-well/12-well plates to be coated are placed in the freezer at -
20oC over night to pre-chill in order for the matrigel to not set too quickly. On the day of 
coating, the matrigel aliquot is placed in ice alongside X-VIVO media (8ml per aliquot of 
matrigel). The matrigel is thawed on ice using cold X-VIVO media and added to appropriate 
dishes. A 60mm dish requires 3ml, a 6-well plate requires 1.5ml and a 12-well plate requires 
1ml. The dishes are left at -4oC overnight for it to polymerase and produce a gel like substance 
to which the cells can adhere to. Before use, the matrigel dishes are checked under a light 
microscopy for properly formed matrix structure and any contaminations. These are then 
washed out with PBS before adding fresh media.  
 Freezing down and defrosting cells 
The cells were initially collected using a centrifuge at 1200 RPM for 5 minutes. The supernatant 
is discarded and the cells suspended in Cryostor CS2 Freezing Media. This is moved into a 
cryotube with 1x106 cells placed in each cryotube and placed in a Mr Frosty Freezing container 
overnight in -80oC before being moved into a liquid nitrogen dewar.  
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The stem cells were defrosted by addition of 1 ml of nutristem media until thawed. This was 
transferred into a 20 ml universal flask and centrifuged as mentioned above. The supernatant 
is aspirated and the cell pellet is re-suspended in another 1ml of fresh nutristem media. This 
is then added into a 60 mm matrigel dish as mentioned above and left in incubator at 37oC 
and 5% C02. Each cryotube contains 1x106 cells and when defrosting, all of this is added to the 
dish as a number of cells are lost while defrosting.  
 Cell culture 
Briefly, once the cells have reached 70% confluency, they were passaged and added to a 12 
well plate on 13mm coverslips (VWR International). The seeding density was 150,000 cells per 
well for HeLa cells and 250,000 cells per well for the iPSCs. The coverslips were etched using 
2M HCl (Sigma-Aldrich) for 6 hours on a magnetic stirrer, followed by 3 washes with distilled 
water before baking in the oven overnight. The coverslips were added to the 12 well plates 
using sterile tweezers and coated with PDL (0.01ng) (Sigma-Aldrich) and laminin (0.02ng) 
(Sigma-Aldrich) to allow cells to adhere. PDL and laminin were only used for HeLa cells; the 
iPSCs required matrigel (Millipore) coating.  
 iPSC Cell Counting and passaging 
Similar to the passage of HeLa cells (section 2.3.2), iPSC cells were washed with PBS and 1ml 
of Trypl-E Express was added to the 60mm dish containing the cells, and left in the incubator 
for 3 minutes. The cells were gently pipetted up and down to disassociate the cells from 
matrigel before adding 1ml of fresh Nutristem media to block Trypl-E Express. The cells were 
centrifuged (1200RPM for 5 minutes) and the cell pellet was re-suspended in 1ml of fresh 
Nutristem media with Rock inhibitor and G418. The cells were then counted by adding 10μl of 
re-suspended pellet to 10μl of trypan blue to get a 1:1 ratio. Trypan blue is used to measure 
cell viability as live cells are not permeable to the dye. This was placed on to a cellometer 
disposable counting chamber and counted using the Cellometer Auto T4. The cells were 
transferred to a matrigel coated 60mm dishes at a seeding density of 5x105 per dish. Following 
24hours, the media was replaced without rock inhibitor as described earlier. The cells are 
allowed to grow until 70% confluent which happened roughly after another 48 hours. 
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 Differentiating iPSC stem cells into neurons 
Neurons were generated using the transcription factor Neurogenin2 (ngn2) from human 
fibroblasts. Ngn2 is a transcription factor expressed in neural progenitor cells that allows 
differentiation into neuronal cells. The original fibroblasts mentioned in section 2.2.3 also 
contained an e-piggyBac vector with the neuronal specific transcription ngn2, transformed by 
Novartis following a published protocol (Zhang et al., 2013). This was under the control of a 
TET-ON system hence doxycycline was used to initiate transcription of ngn2.  
Following passage, for proliferation, 2x106 cells were seeded into 60mm matrigel coated 
dishes with Proliferation media (see materials; solutions) with additional Rock inhibitor (0.1 
mg/ml) and doxycycline (1 μg/ml). Doxycycline is an antibiotic which acts to induce activation 
of ngn2 gene expression through the tetracycline controlled tet-on system. After 24 hours, 
the media was replaced without rock inhibitor as described earlier. The cells were allowed to 
proliferate for 72 hours after seeding into dishes.  
After 72 hours, the cells were passaged as described (section 2.3.4) and seeded into 12-well 
plates containing 1ml of differentiation media (see materials; solutions). These wells contain 
13mm round etched glass coverslips coated with Poly-D-Lysine (PDL) and laminin (see next 
section 2.3.8). A half media change was performed every 2 days and this involved removing 
0.5ml of the media from the well and adding fresh 0.5ml of differentiation media. The cells 
were allowed to mature for 7 days prior to experimentation at which stage they became post-
mitotic and active cell division is completely halted.   
 Preparing coverslips and PDL/Laminin coating 
The neurons were grown on 13mm coverslips in 12-well plates. The purpose of this was to 
allow removal of the glass coverslips for experiments to stain the cells using 
immunofluorescence. The coverslips were initially etched in 1M HCl and left on a shaker for 1 
hour. The purpose of etching is to smoothen the surface of the coverslips for the cells to grow 
on. The coverslips are then washed in distilled water to remove all HCl and put in the oven for 
4 hours.  
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The coverslips were added to the 12-well plates using sterile tweezers. 0.01ng/ml of PDL was 
prepared in Dulbecco's Phosphate-Buffered Saline (DPBS) and 1ml was added to each well. 
This was incubated at room temperature for 1 hour which aids the cells in adhering to the 
surface of the coverslips and wells due to their polyatomic properties. Following three washes 
with DPBS, 0.02ng/ml, Laminin was prepared in DPBS and 1ml was added to each well. This 
was left for a minimum of 30 minutes or until use at room temperature. Laminin is a protein 
found within the extracellular matrix and aids with adhesion of cells to surface as well as with 
normal cell responses such as differentiation, evading apoptosis and proliferation (Esco et al., 
2001). Before use the wells and coverslips were washed again with DPBS.  
 MtDNA extraction and cell lysis 
DNA needed to be extracted from the cells in order to check the level of heteroplasmy in the 
cells to maintain consistency. Cells were centrifuged at 1200 RPM for 5 minutes and the 
supernatant discarded. PBS was added to the pellet to wash. This was then centrifuged again 
and PBS aspirated out. The cell pellets were flash frozen by dipping in liquid nitrogen before 
moving into -80oC for storage until used.  
Single cell lysis buffer (500µl; see solutions section in 2.1.5) was added to the cell pellet and 
the mixture was moved into 5 PCR tubes with 100μl in each tube. The lysis mix was then 
vortexed and placed in an ABI Gene Amp 9700 Thermal cycler. Cell lysis was performed by 
subjecting the samples to 2 cycles at 56oC for 60 minutes, 1 cycle at 95oC for 10 minutes and 
finally cooled to 4oC until required. 
Real-time PCR assay 
Since the heteroplasmy in iPSC cells can vary with passage number, the heteroplasmy was 
confirmed with each passage utilising an established real time PCR assay (He et al., 2002). This 
technique analyses the levels of MTND1 and MTND4. The deletion within this cell line (base 
pairs nt7777:nt13794) removes ND4 however ND1 remains intact within the mtDNA. 
Therefore by comparing the levels of MTND4 to MTND1 will give an estimate of the level of 
deletion in the cells. 
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Briefly, this uses the 7D1-B2M plasmid to calculate the heteroplasmy levels. This plasmid 
contains single copies of MTND1, MTND4, the D-Loop region and B2M, hence this is used as a 
control to which the cell lines are compared to. B2M is also commonly used to analyse the 
copy number as this is a nuclear house-keeping gene and would reveal the total number of 
cells. This can be compared with the MTND1 which represents each mtDNA molecule.  
Theoretically since this plasmid contains single copies of MTND1 and MTND4, this would 
contain no deletion when the levels of each are quantified. A standard curve is produced from 
serial dilutions of this plasmid with each dilution analysed in triplicate alongside cell samples. 
From this, a trend line is produced and assessed for efficiency and a gradient of ‘-3.36’ has the 
highest efficiency. The heteroplasmy levels in the cell samples are calculated using this 
gradient.  
The reagents required for the master mix are presented in table 2.8. A volume of 15μl of 
master mix is added to each well of a 96-well plate. Following this, 5μl of sample DNA is added 
to each well except the no template control, to which 5μl of autoclaved H20 is added. As 
mentioned, all samples are run in triplicate. The plates are sealed, vortexed to mix all the 
reagents with the sample DNA and centrifuged. Real time PCR was conducted using an ABI 
Step-one Plus Real Time PCR system with the following conditions; 1 cycle at 50OC for 2 min, 
1 cycle of 95 OC for 10 minutes, 40 cycles of 95 OC for 15 secs and 60 OC for 1 minute. 
Reagents Volume (µl) Final concentration Manufacturer 
Taqman Universal PCR mastermix 10 1X Applied Biosystems 
MTND1 forward primer 0.6 10µM Eurofins MWG 
MTND1 reverse primer 0.6 10µM Eurofins MWG 
MTND4 forward primer 0.6 10µM Eurofins MWG 
MTND4 reverse primer 0.6 10µM Eurofins MWG 
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MTND1 probe VIC 0.4 5µM Life Technologies 
MTND4 probe FAM 0.4 5µM Life Technologies 
Autoclaved dH20 1.8 -  
Sample DNA 5 -  
Table 2.8 Reagents and DNA used for each sample to run the real time PCR. The manufacturers are also listed. 
 Preparation of IdU and CldU 
All the methodology with preparing CldU and IdU in solution, and details of the cell lines used 
are all provided in section 2.3 
CldU and IdU were purchased as powders (Sigma Aldrich). CldU has good solubility in distilled 
water and a stock solution of 1 mg/ml was prepared. IdU was more difficult to get into 
solution. The solubility for the powder was 2 mg/ml. A stock of 1 mg/ml was prepared in 
distilled water and left at 55°C in a water bath overnight. If the powder had not dissolved the 
following day, the solution was left in the water bath and vortexed at intervals of 20 minutes 
until all particles had completely dissolved. Other steps, which have been previously shown to 
facilitate dissolution, included the addition of 100 µl of 2 M NaOH (drop wise) until dissolved 
and balanced to pH 7, however this was not required for this study. 
 Cell fixation and Immunofluorescent labelling of Cells 
All the cell lines used were treated the same for fixation and immunofluorescent labelling. 
Prior to staining, the cells were washed using PBS to remove dead cells and excess media. 
Following this, 4% paraformaldehyde at 4oC was added to the cells at a volume of per each 
well in a 12-well plate. This was left to incubate at 37oC for 20 minutes. Usually this can be left 
at room temperature, however since the remaining wells contained cultured cells, the plate 
was moved into the incubator to protect the viability of these cells. Following this, the cells 




Before staining, the PBS was aspirated. The coverslips were removed from the wells using 
tweezers and placed on a parafilm sheet. This has an hydrophobic surface, hence any liquids 
added to the coverslips will remain on the coverslip. Using DPBS, 3 washes were performed 
after each step. Antigen retrieval was performed using 1M HCl for 30 minutes. Since all the 
secondary antibodies in this case are raised in goat, the coverslips are blocked with 10% 
normal goat serum (NGS) for 1 hour. The primary antibodies were prepared in TBS and 10% 
NGS. A list of all the primary and secondary antibodies used for immunofluorescence in cells 
are mentioned in table 2.9. Incubations with the antibodies were performed overnight at 4oC. 
The following day, secondary antibodies were prepared again in TBS and 10% NGS, and 
incubated with the cells for 1 hour at room temperature. The sections were then labelled with 
Hoechst at 2.5μg/ml for 20 minutes before the coverslips were fixed with Prolong gold on to 
a glass slide and stored in -20OC until imaged. The coverslips were then imaged on the Nikon 





















1:100 Goat anti mouse 









Mouse IgG2b 1:200 Goat anti mouse 





Table 2.9 Antibodies used for Immunofluorescence of HeLa cells/iPSC stem cells/Differentiated Neurons, along 






Analysis of the cells following immunolabelling with IdU was conducted in a similar manner to 
analysis carried out on mouse brain tissue in section 2.2.6. Briefly, IMARIS (Bitplane) was used 
to create surfaces based on the mitochondrial marker (tom20) and was done individually for 
each cell. This was then masked on to the IdU channel and a surface was created based on 
presence of IdU staining limited to the area of mitochondrial marker in the cell. This would 
identify the levels of IdU within the mitochondria for each cell. All of these channels were 
















Chapter 3 : Understanding the possible link between mtDNA replication and 
mtDNA deletion load in the mouse brain 
3.1 Introduction 
 Variations in mtDNA deletion load between neuronal subtypes 
Neurons are particularly susceptible to ΔmtDNA (section 1.6.5).  An increase in COX-deficiency 
with ageing is observed particularly in comparison to other post-mitotic cells such as muscle 
(Cottrell et al., 2001, Kraytsberg et al., 2006b). A study compared levels of the ‘common’ 
4977bp deletion in different tissues and demonstrated the highest levels in the basal ganglia 
of the brain with a value of 2.9% which decreased to 0.00019% in muscle, with even lower 
levels detected in heart (Meissner et al., 2008). This study also found that in older individuals, 
compared to adolescent individuals, the deletion level increased by 3 fold.  A suggested reason 
for the higher level of ΔmtDNA within neurons could be due to their complexity and function 
resulting in a high-energy demand, thereby increasing their dependence on mitochondria to 
produce ATP through OXPHOS activity. This high requirement for oxygen within neurons could 
also result in a higher level of oxidative stress, which has the potential to induce mtDNA 
damage. Damaged mtDNA could result in OXPHOS function decline which again adds to the 
increased oxidative stress creating a vicious cycle of mtDNA damage and oxidative stress (Circu 
and Aw, 2010, Linnane et al., 1989). 
Even though neurons generally contain the highest ΔmtDNA level, variations between 
neuronal regions have been observed. Table 3.1 and 3.2 presents a literature review of studies 
that have assessed the levels of ΔmtDNA in different brain regions and the changes that occur 
in age and disease models. Although variations exist, the level of ΔmtDNA is generally the 
highest in the SN and the lowest in the cerebellum. This differential level of ΔmtDNA could 
possibly be due to variations in mitochondrial enzyme activity based on specific cellular 
requirements, mitochondrial membrane potential and PGC-1α expression all suggesting a 
varied dependence on the OXPHOS system (Pickrell et al., 2011). These variations could also 
potentially be the result of variation in mtDNA turnover, replication or repair, as they have 
been suggested to be involved in ΔmtDNA formation.  
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Although many previous investigations used homogenate tissue, studies at a single neuron 
level have also demonstrated similar results, with the SN presenting the highest level of 
ΔmtDNA when compared to the putamen and the frontal cortex (Bender et al., 2008) or cortex 
and cerebellum (Dölle et al., 2016). The ΔmtDNA load within the SN, compared to other 
regions, is further elevated with ageing and Parkinson’s disease (Bender et al., 2006c, 
Kraytsberg et al., 2006b). These two studies also discovered that the total number of deleted 
mtDNA molecules can exceed more than 50% of total mtDNA within SN neurons, and 
suggested these could be causative of respiratory chain deficiency, possibly effecting neuronal 






















Three specific ΔmtDNA 
with deletion sizes of 
3726bp, 3867bp and 
4236 were only 
noticed in aged mice. 




















































































Deletion not quantified – band 
intensity highest in hippocampus, 
followed by cortex and lowest in 
cerebellum.  
Deletions also increased with age in WT 
















Data obtained for this thesis and 





























































50% 70% 15% 
PolgAwt/mut 4% 6% 2% 
Table 3.1 Brief literature review of the levels of ΔmtDNA observed within different brain regions in mice. The 
studies presented include various genotypes including wildtype (WT) and PolgAmut/mut mice. Many of these studies 
also looked at the levels of deletion at various ages, hence the ages of the mice are presented in the ‘Age’ column. 
The regions and deletions column presents the specific regions examined and the levels of ΔmtDNA observed 
within these regions. In some cases this column is divided by genotype and or age as indicated. The final column 
describes the method of deletion analysis. This was important to highlight as some techniques are more sensitive 


































SN 0.0030 0.46 
Putamen  0.0010 0.19 
Thalamus 0.0008 0.0085 
Cerebellum 0.0001 0.0013 
(Corral-
Debrinsk




















































































































































































This is a 
visual 
estimate 
SN 32% 40% 
Cortex 15% 15% 
Cerebellum 13% 13% 
Table 3.2 Brief literature review of the levels of ΔmtDNA observed within different brain regions in humans. The 
column indicated as ‘condition’ presents the cases used such as healthy ageing (highlighted in grey) or Parkinson’s 
disease. Many of these studies also looked at the levels of deletion at varying ages (the ages of the individuals 
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are presented in the ‘Age’ column). The regions and deletions column presents the specific regions looked at and 
the levels of ΔmtDNA observed within these regions. The values are a ratio based on the control or percentages 
as stated. In some cases this column is divided by controls and patients or with age. The final column describes 
the method of deletion analysis. This was important to highlight as some techniques are more sensitive than 
others, and could explain any variations in the data 
 Thymidine analogue 
Thymidine is one of the pyrimidine base pairs of DNA. Analogues of thymidine have been used 
to label and study nuclear DNA replication for many years (Taylor et al., 1957, Hendee et al., 
1963), and it is one of the most commonly used techniques to do this (Van Laar et al., 2018). 
This technique has also been adapted to specifically study mitochondrial DNA (mtDNA) 
replication (Van Laar et al., 2018, Phillips et al., 2017). There are a number of analogues that 
are structurally similar to thymidine (figure 4.1); however, the methyl group on the fifth 
position of the pyrimidine ring is replaced in each case. Initial studies used radiolabelled 
isotopes such as tritium (H3) to label thymidine, which was detected using autoradiography 
(Taylor et al., 1957). Later on, other analogues were developed based on the same model. One 
of the first employed was 5-bromo-2'-deoxyuridine (BrdU), followed by 5-chloro-2'-
deoxyuridine (CldU), 5-Iodo-2′-deoxyuridine (IdU) and more recently 5-Ethynyl-2'-
deoxyuridine (EdU) (Davis and Clayton, 1996, Lentz et al., 2010, Phillips et al., 2017). A further 
benefit of using a thymidine analogue to study DNA replication is that since uracil, rather than 
thymidine is used by RNA, RNA will not be labelled thus reducing false positive incorporation. 
These analogues can be incorporated into the genome during replication substituting in for 
thymidine. Since these bases are halogenated in replacement for the methyl group, they can 
then be detected using specific antibodies (figure 3.1), targeted to each thymidine analogue. 
These primary antibodies were initially developed by immunising mice with these analogues, 
isolating the spleen from these animals and obtaining hybrid clones which were tested using 
ELISA assays for specificity to the thymidine analogues (Gratzner, 1982). These primary 
antibodies are a specific isotype that can be recognized by a secondary counterpart labelled 
with a fluorophore, which can be visualised using a specific wavelength where the 
fluorescence of the secondary antibody can then be observed with a microscope. This method 
has been used in many instances (Van Laar et al., 2018, Harris et al., 2018, Phillips et al., 2017, 
Davis and Clayton, 1996, Flory Jr and Vinograd, 1973), including in-vivo work on human cancer 
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patients (Eriksson et al., 1998). These patients received BrdU as part of their treatment, as 
high concentrations of BrdU can increase cell susceptibility to ionizing radiation making it 
beneficial when used in combination with chemotherapy or radiation treatment (Levkoff et 
al., 2008, Djordjevic and Szybalski, 1960, Prados et al., 2004). After post-mortem, their brains 
were used to investigate and identify adult neurogenesis in the dentate gyrus which had been 

















Figure 3.1 Thymidine analogues used for labelling DNA replication. Tritium thymidine uses autoradiography for 
detection. 5-bromo-2'-deoxyuridine (BrdU), 5-chloro-2'-deoxyuridine (CldU), 5-Iodo-2′-deoxyuridine (IdU) use 
antibodies that bind to the specific group. 5-Ethynyl-2'-deoxyuridine (EdU) utilises click chemistry where a 




One of the limitations of this method is that these analogues can be incorporated during all 
processes involving DNA synthesis, including DNA repair (Taupin, 2007). Another limitation to 
take into consideration is that the thymidine analogue also fails to label around half of dividing 
cells for unknown reasons (Kee et al., 2002). This could be due to a low concentration of the 
analogue which can partially be avoided by increasing the concentration; however these 
analogues can be toxic at high doses (Sekerková et al., 2004). This is because the thymidine 
analogue can be interpreted as a large level of DNA damage in the cell by various repair 
pathways (repair pathways of the mtDNA discussed in section 1.5.2). 
Although the specific mechanism of toxicity by thymidine analogues remains unclear, a large 
amount of data is available on the toxicity caused by other thymidine analogues, such as 
azidothymidine (AZT) and stavudine (d4T) which are used in antiretroviral treatments of 
HIV/AIDS patients. These thymidine analogues exhibit a dose and time-dependent increase in 
mitochondrial dysfunction (including impaired membrane potential), mtDNA damage, ROS 
and autophagy (Kline et al., 2009, Stankov et al., 2013). For analogues such as AZT, the 3’ ‘OH’ 
group is replaced by an ammonia group hence when this is incorporated into the DNA during 
synthesis, the chain extension is terminated due to the lack of an ‘OH’ group. This then inhibits 
the DNA polymerase and leads to mtDNA depletion (Scruggs and Naylor, 2008). Due to this 
reason, these analogues not used to study DNA replication. 
 Significance of this study 
As mentioned in the introduction the formation of ΔmtDNA could be linked to mtDNA 
replication. Therefore, to further understand the impact of replication on deletion formation, 
it is important to discern its characteristics, specifically the level of replication in different 
neuronal populations. This may then also shed light on the reasons why different regions of 
the brain show varied levels of deletions, in both mice and humans (Perier et al., 2013, Dölle 
et al., 2016, Gu et al., 2002). This difference could prove beneficial in understanding the 
involvement of replication in deletion formation by looking at associations between the levels 
of replication and corresponding levels of ΔmtDNA within these regions. The primary objective 
of this study was to measure replication levels to see whether alterations in this process could 
be linked to the accumulation of the mtDNA deletions observed with age and disease. This 
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will be useful to develop hypotheses that may support or oppose current deletion formation 
theories. The mtDNA replication levels were also deduced in wildtype and PolgAmut/mut mice 
to shed further light on how this correlates with defective replication or ageing. To deduce 
replication levels thymidine analogue labelling was used.  
3.2 Aim and objectives 
 Aims 
The aim of this chapter was to assess mtDNA replication levels in different regions of the 
mouse brain. 
 Objectives  
The following objectives were fulfilled in this study; 
• To compare mtDNA replication levels between different brain regions 
• To compare mtDNA replication levels in neurons between young and aged mice 
• To compare mtDNA replication levels in neurons between WT and PolgAmut/mut 
mutator mice 
• To compare the levels of mtDNA replication and ΔmtDNA in various neuronal types 
 
3.3 Methods 
 Double thymidine analogue labelling in vivo 
The methods utilised for this study are detailed extensively in section 2.2.2. Briefly, these mice 
were injected with 50mg/kg of CldU twice a day for 4 days at 10am and 6pm. On day 4, 
they were injected with CldU as normal at 10am, however at 6pm; they were injected with 
50mg/kg of IdU and sacrificed after 14-16 hours (Table 2.6). Using this approach mtDNA 
which had replicated in the past 4.5 days would be labelled with CldU and the last 15 hours 
with IdU. The time-frame was optimised for another study, and as positive staining was 
observed, this was continued (Stamp, 2016). Details of the mice used in this study are 









F Wild type 3.9 
3.7 
F Wild type 3.9 
F Wild type 3.9 
F Wild type 3.2 
POLG Young 
F PolgAmut/mut 4 
3.3 
F PolgAmut/mut 2.4 
F PolgAmut/mut 3.3 
F PolgAmut/mut 3.4 
WT Aged 
F Wild type 12.6 
11.4 
F Wild type 12.6 
F Wild type 10.9 
F Wild type 10.1 
F Wild type 10.9 
POLG Aged 
F PolgAmut/mut 11 
10.9 
F PolgAmut/mut 10.1 
F PolgAmut/mut 12.1 
F PolgAmut/mut 10.3 
Table 3.3 Mice used in this study. The table presents the gender, genotype and the ages of the mice used. The 
mean age for each group is also calculated. The highlighted grey cells represent littermates in each group. 
 Immunohistochemistry to identify CldU/IdU labelling 
Details of all antibodies used in this chapter are provided in section 2.1.4. Serial sections were 
stained with anti-BrdU (to detect CldU), anti-IdU (discussed in section 3.4.1) and Tom20 
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antibodies to calculate the levels of replication in these brain regions. For analysis, four regions 
of the brain were selected, and within these, specific neurons were chosen. This was 
conducted to reduce variability between different neurons of the same region. Purkinje cells 
from the cerebellum, pyramidal cells from the cortex (layer 3/4) and hippocampus, and 
dopaminergic neurons from the SN were selected. Selection of these cell types was due to 
their abundance in these regions. The neurons per images were selected at random. These 
regions were chosen based on the differential levels of ΔmtDNA and the literature available 
on ΔmtDNA of these regions (see table 3.1 and 3.2).  
 Immunohistochemistry to identify specific cells 
Immunohistochemistry was performed according to section 2.2.5. Initially the sections were 
stained using Tom20 as a mitochondrial marker, alongside CamKII which is a marker for 
pyramidal cells (hippocampus and cortex) and tyrosine hydroxylase (TH), a marker for 
dopaminergic neurons (SN). These neurons were chosen specifically due to the amount of 
literature available on them and their specificity within a region. Although the neurons of the 
cerebellum and hippocampus are easily identified, these neuronal markers were required to 
correctly identify the neurons of the SN and pyramidal cortical neurons. These markers were 
applied to sections to confirm the presence of the regions of interest, serial sections were then 
used for further CldU/IdU detection. 
 Microscopy and analysis 
Images were initially obtained using the Axioimager M1 (Zeiss). Wide field fluorescent imaging 
did not provide adequate resolution to allow in depth study of CldU/IdU incorporation into 
mitochondria, therefore the Nikon A1R confocal system was used. To further analyse the 
images, various parameters were trialled in IMARIS and Image J (Fiji) (appendix 8.4). All of the 
parameters produced similar results which suggested the same pattern of thymidine analogue 
incorporation between the different groups. Therefore, based on the manufacturer’s 
suggestion and the 2D nature of the images, ‘number of voxels’ was the parameter analysed 
using IMARIS (Bitplane) for all images. The thymidine analogue staining was expressed as a 
percentage of the total mitochondrial mass values in order to compensate for the differential 
cell sizes.  
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 Statistical analysis 
All statistical analysis are detailed in the appropriate sections with the results in order to 
explain the graphs. Briefly, due to variations between the mice, as confirmed by Kolmogorov-
Smirnov testing (p<0.05), one way-ANOVA was used to compare the different groups. Since 
the data is not normally distributed, quantile normalisation was used to account for the 
variation between the two replicates allowing them to be comparable (more details in 
appendix 8.6). The p-values obtained were then corrected using the ‘false discovery rate’ 
method. The statistical comparisons and normalisations were conducted by Dr Conor Lawless 
(Wellcome Centre for Mitochondrial Research).   
3.4 Results 
 Optimisation 
I) identifying an appropriate mitochondrial marker 
Selection of an appropriate mitochondrial marker was crucial due to the nature of the 
experimental design. A mitochondrial marker was needed to normalise the levels and account 
for variation in cell size, to in order to more accurately assess replication levels. The different 
mitochondrial markers tried were Glucose-regulated protein 75 (GRP75) (Abcam), Voltage-
dependent anion channel 1 (VDAC1) (Abcam), translocase of outer membrane (Tom20) (both 
Polγclonal rabbit and monoclonal mouse IgG2a) (Santa-Cruz). An anti-DNA (Merck Millipore) 
was also used to specificially mark the mtDNA. Neuronal markers were also used. All the 
mitochondrial antibodies and neuronal antibodies used are listed in table 3.4 which explains 
















anti-GRP75 Rabbit anti-SMI-31 IgG1 anti-BrdU Rat 
anti-VDAC IgG2b anti-MAP2 Rabbit anti-IdU IgG1 
anti-Tom20 (P) Rabbit anti-CamkII IgG1 
  
anti-Tom20 (M) IgG2a anti-TH Rabbit 
  
anti-DNA IgG2a 
    
Table 3.4 Mitochondrial, neuronal and mtDNA replication antibodies used. This table presents all the antibodies 
and the subtypes used which explains the antibody cocktails trialled for this study. All suppliers are listed in section 
2.14 
The ideal mitochondrial marker would label all the mitochondria within the cell, have high 
specificity for mitochondria, produce punctate staining allowing the differentiation of 
individual mitochondria and have a low background allowing the use of low exposure values 
while imaging. The initial mitochondrial marker tried was VDAC1 alongside MAP2 (figure 3.2). 
MAP2 is a neuronal cytoskeleton specific marker that labels the microtubule assembly 
proteins (Shafit-Zagardo and Kalcheva, 1998). VDAC is protein that forms a channel through 
the outer mitochondrial membrane which allows small hydrophilic metabolites to pass 
through and the opening and closing of this channel is dependent on membrane potential 
(Shoshan-Barmatz et al., 2010, Yu et al., 1995). Staining for GRP75, in conjunction with SMI-
31 was also trialled (figure 3.3). SMI-31 is a neuronal marker which stains for neurofilaments 
which contribute to the cytoskeleton of the neurons along with microtubules. GRP75 is a heat-
shock precursor protein which mainly localises to the inner mitochondrial membrane. Low 
levels of this protein can also be found in the endoplasmic reticulum and cytoplasmic vesicles 
(Honrath et al., 2017, Pilzer and Fishelson, 2005). This protein has a role in the biogenesis of 
iron-sulphur clusters, protein translocation within mitochondria and general maintenance of 
the mitochondria (Ahmad et al., 2011, Shan and Cortopassi, 2016). 
Both GRP75 and VDAC1 showed positive staining. VDAC1 did not give the same intensity of 
positively stained mitochondria as other markers. In terms of the GRP75, it was present mainly 
within the cell bodies with a low background. However, GRP75 has been suggested to localise 
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to ER and plasma membrane, hence this could skew the analysis. Following this, two Tom20 
IgG subtypes were trialled and stained (figures 3.4 and 3.5). Tom20 is part of the TIM/TOM 
complex which is involved in translocation of proteins into the mitochondria. Tom20, as the 
name suggest is present within the outer membrane. This is an excellent marker due to its 
specificity. Of the two subtypes tried, the polyclonal rabbit performed better as the staining 
was more punctate.  
Figure 3.6 presents the anti-DNA antibody. This was done to identify a mtDNA specific marker 
which would make the analysis more accurate. However, as seen in the figure, the mtDNA was 
not stained appropriately, due to large levels on non-specific staining. In addition to this, the 
nuclear DNA was also stained which would add additional steps to the analysis.   



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































II) Identifying specific neuronal populations 
Another crucial factor was accurately identifying neuronal populations of interest within the 
selected brain regions. This study investigated the cerebellum, cortex, hippocampus and SN, 
and the major cell types in these regions are Purkinje cells, pyramidal cells (cortex and 
hippocampus) and dopaminergic cells, respectively. Based on their morphology and the 
organisation of the cerebellum, Purkinje cells could be easily and accurately identified. This is 
because they exist as large distinct cells within the border between the molecular and granule 
layers within the cerebellum (Gharravi, 2016). When labelled with Tom20 the Purkinje cells 
are clearly visible between the molecular and granular layer (Figure 3.7).  However the 
pyramidal cells and dopaminergic cells required further labelling due to fewer architectural 
landmarks making them less easily identifiable, hence CamKII and TH were used. 
CamKII is a kinase enzyme that functions to phosphorylate serine and threonine within a 
protein, is regulated by calcium and is involved in neurotransmitter release (He et al., 2000). 
CamKII is particularly abundant in the pyramidal cells of the hippocampus since it is involved 
in hippocampal long term potentiation which strengthens synaptic activity, important for 
learning and memory (Lisman et al., 2012, Wang et al., 2013). This has been used previously 
to target specifically the pyramidal cells of the hippocampus, and since pyramidal cells are 
present in the cortex, this can also be used to identify this region (Ding et al., 2013). However 
studies have also found that this marker is expressed in other non-pyramidal cells, but at lower 
levels (Jones et al., 1994, Tighilet et al., 1998). Hence, this is not a pyramidal cell specific 
marker per se, however due to its abundance in pyramidal cells; this can be used to label them 
in conjunction with anatomical landmarks.  
In this study, CamKII was optimised for mouse brain tissue at dilution of 1:25 and 1:50 was 
tried based on the manufacturers’ guidelines and previous experiments conducted on human 
brain in our research group (Lax, unpublished) (Figure 3.8). 1:50 dilution was chosen for all 
future work because both dilutions presented similar levels of staining which co-localised with 
Tom20. Figure 3.9 presents CamkII staining within the cerebellum, hippocampus and cortex. 
The cerebellum was used as a negative control since there are no pyramidal cells within this 
region. The images were background corrected using a no primary control and the positively 
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stained cerebellar section. It is important to highlight that not all cortical cells were positive 
for CamkII (Figure 3.9B). This is because there are other subtypes of neurons present within 
this area. This is another reason why structurally identifying the cells types is important. 
Hippocampal pyramidal cells were also robustly detected using this approach (Figure 3.9C).  
To label dopaminergic neurons of the SN region, a TH antibody was used. This was previously 
optimised in our research group by Dr Amy Reeve and used at a dilution of 1 in 100. This 
antibody targets the tyrosine hydroxylase enzyme which converts the precursor tyrosine into 
dopamine, therefore, this is specific to dopaminergic neurons (Daubner et al., 2011). Since the 
anti-TH antibody has a polyclonal rabbit isotype, the monoclonal Tom20 (isotype IgG2a) was 
used to label the mitochondria.  
The anti-TH antibody targets the tyrosine hydroxylase enzyme which converts the precursor 
tyrosine into dopamine, therefore, this is specific to dopaminergic neurons (Daubner et al., 
2011). Since the anti-TH antibody has a polyclonal rabbit isotype, the monoclonal Tom20 
(isotype IgG2a) was used to label the mitochondria. The TH population could be identified 
even at a low magnification using this approach (Figure 3.10A). Figure 3.10B presents positive 
staining within the dopaminergic neurons and Figure 3.10C presents the hippocampus, which 
was used as a negative control for this antibody and presents without any positive TH staining. 
In some sections, two sets of TH positive cells were observed. This is due to the presence of 
dopaminergic neurons in SN and the nearby ventral tegmental area (Margolis et al., 2006). In 
these cases, a mouse brain atlas was used to identify the correct population. This antibody 
had been previously optimised by Dr. Amy Reeve (Wellcome Centre for Mitochondrial 
Research) and was used at a dilution of 1:100. 
The TH population could be identified at a low magnification using this approach (Figure 
3.10A). Figure 3.10B presents positive staining within the dopaminergic neurons and Figure 
3.10C presents the hippocampus, which was used as a negative control for the antibody and 
presents without any positive TH staining. In some sections, two sets of TH positive cells were 
observed. This is due to the presence of dopaminergic neurons in SN and the nearby ventral 
tegmental area (Margolis et al., 2006). In these cases, a mouse brain atlas was used to identify 
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III) CldU/IdU staining of mice brain 
Following all the optimisation and validation, immunohistochemistry was conducted on all the 
mice from the four groups. Specific neurons were identified as described in 3.3.3 and 
sequential sections were histologically stained to confirm the specific regions and neurons. A 
















































































































































































































































































































































































 Data obtained 
I) MtDNA replication  
Since various tissues, ages and genotypes of mice were used in this study, table 3.4 clarifies 
the subsequent abbreviations used for each tissue and mouse. The average level of CldU and 
IdU incorporation, as a percentage ‘number of voxels’ of the Tom20, is presented in table 3.5 
alongside the standard deviation of the data. The values are the total number of voxels of the 
CldU and IdU relative to the total number of voxels of the tom20 channel. The average values, 
for all the neurons studied, are discussed relative to age, tissue type and genotype in the 
forthcoming section.  




SN Substantia nigra 
WY wildtype young 




PO PolgAmut/mut aged 








Age/Genotype Region % CldU SD % ldU SD 
WY CER 31.05 17.68 8.90 10.17 
WY SN 11.27 8.26 7.85 11.43 
WY COR 20.42 14.24 2.04 3.86 
WY HIP 21.88 16.38 1.79 2.91 
PY CER 15.21 10.00 6.17 6.66 
PY SN 6.67 6.72 1.92 3.05 
PY COR 11.36 6.76 2.20 2.59 
PY HIP 8.55 4.21 0.20 0.43 
WO CER 18.99 16.37 7.33 7.70 
WO SN 10.63 8.23 3.75 5.42 
WO COR 7.43 10.24 1.78 3.30 
WO HIP 5.32 4.97 0.88 1.22 
PO CER 10.67 10.66 5.69 9.31 
PO SN 5.58 5.96 3.98 10.39 
PO COR 8.25 9.96 2.66 4.01 
PO HIP 1.94 1.85 3.71 4.41 
Table 3.6 Average level of thymidine analogue incorporation into the mtDNA. For each neuron, a total of CldU 
and IdU was calculated as a percentage of the tom20. The average of this is present in this table. Definitions of 
abbreviations can be found in table 3.5. 
As mentioned previously, CldU had been injected into these mice for 4 consecutive days and 
IdU had been injected into the mice ~15 hours prior to sacrifice. Therefore, CldU will label 
mtDNA which had replicated within the last 4 days and IdU, within the past 15 hours. Using 
both IdU and CldU would shed light on how mtDNA replication patterns change between the 
two time frames 
II) MtDNA replication levels – variation between neuronal subtypes 
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When comparing the CldU incorporation between the neuronal subtypes, a significant 
difference (p<0.05) was observed between all regions except between the cortex and 
hippocampus of young wildtype mice (Figure 3.12A). CldU incorporation was highest in the 
cerebellum, followed by the cortex and hippocampus, with the lowest level in SN. This pattern 
was also observed in young PolgAmut/mut mice (Figure 3.12B). For the wildtype aged mice 
(Figure 3.12C), the highest level of CldU incorporation was also within the cerebellum, 
however this was followed by the SN and then the cortex, with the lowest levels of 
incorporation in the hippocampus. For the aged PolgAmut/mut mice, all the regions, except the 
cerebellum and cortex, were significantly different from each other (figure 3.12D). The pattern 
of CldU incorporation levels remained the same as for young PolgAmut/mut mice, except the 
hippocampus which, like the wildtype aged animals, showed the lowest levels of 
incorporation. 
IdU incorporation was highest in the cerebellum of young wildtype mice (figure 3.13), 
however, there was no significant difference between the cerebellum and SN. There was also 
no significant difference between the cortex and the hippocampus as with the CldU, however 
the cerebellum and SN both showed significantly increased levels of IdU incorporation 
compared to cortex and hippocampus. The young PolgAmut/mut mice and the aged wildtype 
mice both presented with the same pattern of incorporation and significant differences 
between all the regions as the young wildtype mice (figure 3.13 B and C). Data from the aged 
PolgAmut/mut mice shows the same pattern however none of the areas show significant 









Figure 3.12 Regional variations in incorporation of CldU into mitochondria in mouse neurons – the abbreviations 
used in this graph are explained in table 3.5. The list of mice is present in table 3.3. Image A presents young 
wildtype mice, image B presents young PolgAmut/mut mice, image C presents aged wildtype mice and image D 
presents PolgAmut/mut mice. The error bars represent the +/-SD. n=4 mice per region. * indicates p < 0.05, ** 











Figure 3.13 Regional variations in incorporation of ldU into mitochondria in mouse neurons –the abbreviations 
used in this graph are explained in table 3.5. The mice list is present in table 3.3. Image A presents young wildtype 
mice, image B presents young PolgAmut/mut mice, image C presents aged wildtype mice and image D presents 
PolgAmut/mut mice. The error bars represent the +/-SD. n=4 mice per region. * indicates p < 0.05, ** indicates p < 





II) MtDNA replication levels– Effect of ageing 
The variations in CldU and IdU levels with ageing were also quantified. Figure 3.14 presents 
the variations in CldU incorporation in each brain region with ageing. All the brain regions, 
except the SN, in both genotypes, demonstrated a significant decrease (p<0.05) in CldU 
incorporation with age. The SN exhibited a low level of mtDNA replication, which remained 
similar with ageing.   
The majority of brain regions did not show a significant effect of ageing on IdU incorporation 
(figure 3.15). However, PolgAmut/mut and wildtype mice hippocampal neurons and wildtype SN 











































Figure 3.14 Variation with ageing in incorporation of CldU into mitochondria in mice neurons – the abbreviations 
used in this graph are explained in table 3.5. The list of mice is present in table 3.3. Image A presents wildtype 
mice and image B presents PolgAmut/mut mice. The error bars represent the +/-SD.  n=4 mice per region. * indicates 










Figure 3.15 Variation with ageing in incorporation of ldU into mitochondria in mice neurons – the abbreviations 
used in this graph are explained in table 3.5. The list of mice is presented in table 3.3. Image A presents wildtype 
mice and image B presents PolgAmut/mut mice. The error bars represent the +/-SD.  n=4 mice per region. * indicates 







III) MtDNA replication – variation with disease  
One of the aims of this study was to understand how mtDNA replication is altered in a model 
with defective replication. To study this, PolgAmut/mut mice were compared to the wildtype 
mice cohort. For CldU incorporation (Figure 3.16), compared to wildtype mice, there was a 
significant decrease (p<0.05) in incorporation observed in all brain regions in the PolgAmut/mut 
mice, suggesting a decrease in mtDNA replication levels. In the case of IdU (Figure 3.17), a 
similar decrease in observed in the PolgAmut/mut mice compared to the wildtype, however this 













Figure 3.16 Variation with wildtype and PolgAmut/mut model in incorporation of CldU into mitochondria in mice 
neurons – The abbreviations used in this graph are explained in table 3.5. The list of mice is present in table 3.3. 
Image A presents young mice and image B presents aged mice. The error bars represent the +/-SD.   n=4 mice per 










Figure 3.17 Variation with wildtype and PolgAmut/mut model in incorporation of CldU into mitochondria in mice 
neurons – the abbreviations used in this graph are explained in table 3.5. The list of mice is present in table 3.3. . 
Image A presents young mice and image B presents aged mice. The error bars represent the +/-SD.  n=4 mice per 




 MtDNA replication correlation analysis to previous literature 
I)  Correlation to mtDNA deletion level 
One of the aims of this study was to identify how the level of mtDNA replication correlates 
with the level of ΔmtDNA observed. In this study, this was also vital since a number of regions 
commonly associated with high ΔmtDNA demonstrated lower mtDNA replication levels. To 
identify, whether a correlation exists, it was important to investigate the relationship between 
CldU and IdU incorporation and ΔmtDNA.  
Even though deletion level in the mice from this study has not been investigated, a large 
number of studies within the literature have investigated this (table 3.7). One of these studies, 
Perier et al, investigated the percentage of ΔmtDNA and copy number in different brain 
regions and similar to this study, also used wild type and PolgAmut/mut mice (Perier et al., 2013). 
The brain regions investigated in the study by Perier et al were cerebellum, cortex, 
hippocampus, striatum and midbrain. Although they did not look specifically at the SN, this 
region is present within the midbrain and should provide a representative measure of deletion 
within the SN, however it will be effected by other neuronal subtypes present in the midbrain. 
Alongside this, this thesis analysed single cells, while the Perier et al.  study was conducted on 
homogenate tissue. However, all other parameters were consistent between the two studies. 
ΔmtDNA levels were measured using quantitative real-time PCR, and expressed as a 
percentage of the total mtDNA content. Details of the ΔmtDNA data from this study were 
kindly provided by Dr Celine Perier (Vall d’Hebron Institute of Research, Spain). The average 
percentage of ΔmtDNA and copy number per brain region per mouse, for both wild type and 
PolgAmut/mut animals were provided, however, comparative data between young and aged 
mice were not available. The average deletion levels are presented in table 3.6. As the raw 
values were not obtained, significant differences cannot be identified, however the original 
paper mentions significant differences (p<0.01) observed between different tissue types and 











11.67 21.17 66.83 




17.67 17.39 26.17 




19.83 22.83 57.17 




13.33 24.00 28.33 










Table 3.7 ΔmtDNAs in various brain regions. The difference in genotype is also highlighted in the table. The age 
of these mice range from 9-12 months. The deletions were calculated using quantitative real-time PCR and was 
expressed as a percentage of total mtDNA copy number. SD represents the standard deviation.  
 
To determine whether an association between mtDNA replication levels (based on thymidine 
analogue incorporation) and ΔmtDNA levels exists, correlation analysis was conducted by Dr 
Conor Lawless (Wellcome Centre for Mitochondrial Research). For each tissue common to 
both datasets (assuming SN is represented by the midbrain), one replicate each was randomly 
selected from both the replication dataset and from the deletion dataset. By repeating this 
procedure 10,000 times, a distribution representing the uncertainty about the correlation was 
built, allowing comparison between the datasets. A Pearson's correlation coefficient was 
conducted to test for correlation between replication datasets and deletion datasets in these 
tissues (figure 3.18). To test if the observed correlations are significantly different from zero, 
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the 5th and 95th percentile range (vertical blue dashed lines) was calculated and checked to 
observe if this range included zero (vertical red dashed line). The spread of data (black line) 
demonstrates that in both the IdU and CldU a significant difference from zero could not be 
demonstrated, and therefore, there was no correlation between mtDNA replication and 











































































































































































II) MtDNA replication and correlation with mtDNA copy number.  
As mentioned in the previous section, mtDNA copy number was also measured in the study 
by Perier et al. This is vital as an increase in mtDNA replication could lead to an increase in 
mtDNA copy number, and this has been suggested as a mechanism of protection against 
ΔmtDNA (Dölle et al., 2016). Therefore testing was performed to identify any association 
between mtDNA copy number and mtDNA replication level. Details of mtDNA copy number 
from their previously published study were kindly provided by Dr Celine Perier (Vall d’Hebron 
Institute of Research, Spain) and is presented in table 3.8 (Perier et al., 2013). To understand 
the relationship between mtDNA replication and copy number, correlation analysis, as 
mentioned in the previous section was performed. There was no significant correlation 






















9.92 8.70 19.33 




9.53 10.17 13.49 




6.72 7.37 19.48 




1.58 1.78 2.24 










Table 3.8 MtDNA copy number in various brain regions. The difference in genotype is also highlighted in the table. 




















































































































































































 Variability between individual mice 
Although the statistical testing identified significant differences between the groups, the 
variability between mice requires consideration. This is particularly important certain regions 
of the mice were not obtained due to technical difficulties. Alongside this, the numbers of 
neurons identified from each mice and region were also variable. The total number of regions 
and number of neurons in each region analysed is presented in table 3.9. In addition, as with 
humans, there are variations in other factors such as mtDNA deletions in individual mice which 
might also require consideration. Therefore, to further study this, individual mice were 
compared and presented in figure 3.20. 
Even when comparing different regions within individual mice, the cerebellum still displayed 
the highest levels of CldU and IdU incorporation in most mice and SN generally produced the 
lowest incorporation. This is in further support of the results obtained. There are variation in 
some cases for examples young 3 in graph 3.10A and young 4 in graph 3.10B demonstrated a 
higher value for cortex and hippocampus than the cerebellum, however this is not common, 






WY CER 4 163 
WY SN 2 106 
WY COR 4 186 
WY HIP 3 146 
PY CER 4 166 
PY SN 4 83 
PY COR 2 95 
PY HIP 1 60 
WO CER 4 169 
WO SN 3 117 
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WO COR 4 145 
WO HIP 4 151 
PO CER 4 89 
PO SN 3 90 
PO COR 4 138 
PO HIP 1 49 




























































































































































 Mitophagy levels between cerebellum and SN 
Variations were observed between IdU (15 hours) and CldU (5 days) incorporation, and a 
suggested mechanism for these differences could be an increase in mtDNA degradation or 
transport of mitochondria to distal regions between the time points. MtDNA degradation 
could occur due to an increase in mitophagy, hence if a certain region has increased basel level 
of mitopgahy, this would effect the thymidine analogue levels observed in this regions. 
Therefore, to understand any effect mitophagy could be having in this regions,  the levels of 
mitophagy in the cerebellum and the SN were used. For this, tissue from a mouse model 
allowing measurement of basal mitophagy was kindly donated by Dr Ian Ganley (University of 
Dundee) (McWilliams et al., 2016). Degradation of mitochondria via mitophagy would also 
lead to degradation of mtDNA therefore this could be studied relative to mitophagy. Briefly, 
these mice contain a construct comprising of both GFP and mCherry tags with the 
mitochondrial targeting sequence of FIS1, allowing expression to be targeted to the OMM of 
the mitochondria. Under normal circumstances both GFP and mCherry are expressed and 
therefore fluoresce. When a mitochondrion undergoes mitophagy, it is taken into a lysosome 
which contains an acidic environment that quenches the GFP, however the mCherry remains 
unaffected. Therefore, in the event of a mitophagic event, the only mitochondrial fluorescent 
signal comes from the mCherry tag. Therefore, this allows quantification of the levels of 
mitophagy within individual cells, based on the number of mCherry (red) puncta. These images 
were analysed using Colombus (PerkinElmer) by Dr Amy Reeve (Wellcome Centre for 
Mitochondrial Research). This analysis pathway detected the neuronal marker for each brain 
region, giving a measurement of neuronal area and then detected the bright mCherry spots 
specifically within this area for each neuron. The number of mCherry spots per unit area was 
then calculated, with each spot representing a mitochondria within a lysosome. As this was a 
preliminary study, only wildtype mice were used and images from a total of three mice were 
used for the SN and four for the cerebellum. These regions were chosen due to the variations 
observed within them in terms of mtDNA replication levels. The Purkinje cells from the 
cerebellum were identified by calbindin staining and SN dopaminergic neurons were stained 

























































































































































































































































































































































































Comparison of the two regions (figure 3.22) produced a significant difference (p<0.001) when 
compared via Mann-Whitney test as the data sets did not show a normal distribution 
(Kolmogorov-Smirnov test). A mean of 0.04 (SE +/- 0.002) mCherry puncta per cell was 
observed in the cerebellum, and higher levels of 0.06 (SE +/- 0.001) were observed in the SN. 
This suggests that there may be a significant upregulation of basal mitophagy in the SN 
compared to the cerebellum. However, this is a preliminary study, and further investigation, 
especially including the other brain regions, is required.  
 
Figure 3.22 Mitophagy levels from the MitoQC mice – This graph presents the number of mCherry puncta in 
individual cells from the Purkinje neurons in the cerebellum and dopaminergic neurons from the SN. n=4 mice for 




The key outcomes from this chapter are as follows; 
• MtDNA replication in individual cells from different regions of the brain was 
successfully identified, showing significant differences (p<0.05) in CldU and IdU 
incorporation between individual neuronal subtypes from the different brain regions. 
• There were significant differences (p<0.05) between individual neuronal populations 
between the young and aged group. 
• There were significant differences (p<0.05) between individual neuronal populations 
between wildtype and PolgAmut/mut mice. 
• Individual dopaminergic neurons from the SN show a significant increase (p<0.05) in 
the level of mitophagy compared to cerebellar Purkinje cells.  
 Differentiating between mtDNA repair and replication 
One of the criticisms of using thymidine analogue labelling to study replication is the 
simultaneous incorporation of this analogue during repair. Theoretically, repair and 
replication, both involve incorporation of nucleotides and thus positive puncta could 
represent incorporation through repair. However as mentioned in section 1.5.2, the most 
common type of repair observed in mtDNA is BER. This, or other types of repair such as double 
strand break repair, involve a smaller length of mtDNA compared to replication which 
presents the opportunity to incorporate CldU and IdU into the full 16.5kbp of the 
mitochondrial genome. This is also suggested by other studies that have used BrdU for mtDNA 
replication labelling (Davis and Clayton, 1996, Van Laar et al., 2018). Therefore, CldU and IdU 
incorporated by replication would give higher signal intensity than repair within each 
mitochondrial surface, due to the presence of multiple thymidine analogues. Alongside this, 
the thymidine analogues will compete with endogenous thymidine, hence the proportion of 
opportunities for thymidine analogue incorporation is further decreased for both replication 
and repair. In addition to this, even though the nuclei in post-mitotic neurons do not divide, 
there will be DNA repair happening to a greater level in the nuclear genome than within the 
mitochondria, attributable to the size of nuclear genome and the various pathways of repair 
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available for the nuclear DNA as highlighted in section 1.8 (Magnusson et al., 2003, Alexeyev 
et al., 2013). Due to this, if thymidine analogue via repair is incorporated into the DNA, this 
should also be co-localised with the nuclear marker; Hoechst. However, as presented in Figure 
3.9, in all the regions stained, IdU or CldU is not co-localised with Hoechst. 
The intensity of each mitochondrial surface was measured in this study (appendix 8.5), as 
CldU/IdU incorporation via repair would have significantly lower intensity than replication. As 
2 mitochondrial surfaces were noticed as having a significantly lower intensity than the other 
surfaces, this could potentially be identifying repair. This was also identified in 2 PolgAmut/mut 
mice. This may be due to the mutation in the proof reading domain of Polγ, leading to incorrect 
nucleotide incorporation, and therefore, repair is likely to be occurring at a higher level than 
in wildtype mice (Ponamarev et al., 2002, Trifunovic et al., 2004, Wanrooij et al., 2004). 
However, the low signal intensities of thymidine analogues thought to be due to repair could 
be non-specific signal. Either way due to the low frequency this would not affect the data, 
however the analysis was modified to remove these values. 
 Is there variation in mtDNA replication levels between neuronal subtypes? 
As mentioned in Table 3.1 and 3.2, previous literature has demonstrated varying levels of 
ΔmtDNA within the four neuronal subtypes investigated in this thesis. One of the methods 
through which these deletions are thought to form is replication. This can be due to the 
‘slipped-strand’ model or replication stalling (Section 1.1). Due to this suggested involvement 
of mtDNA replication in ΔmtDNA formation, and the differential levels of ΔmtDNA observed 
with different brain regions, the levels of mtDNA replication within four brain regions were 
investigated (SN, cortex, cerebellum and hippocampus). With ageing and in the PolgAmut/mut 
mouse model, the level of these ΔmtDNA are elevated, hence these were investigated to study 
how mtDNA replication is altered in ageing and in a disease model with an accelerated ageing 
phenotype. 
First of all, when comparing the different regions of the brain there was a similar pattern of 
CldU incorporation in the young wildtype and PolgAmut/mut groups. The highest level of 
incorporation was observed in the Purkinje cells of the cerebellum, followed by the pyramidal 
cells of the cortex, pyramidal cells in the hippocampus and finally the lowest level in the 
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dopaminergic neurons of the SN. In some cases, a difference between cortex and 
hippocampus was not observed, this could be because although the regions are different, the 
neuronal subtype is pyramidal cells in both cases and hence they could be behaving in a similar 
manner. Where ΔmtDNA are concerned, the lowest levels are generally detected within the 
cerebellum and the highest levels within the SN, suggesting that a higher level of mtDNA 
replication could possibly correlates negatively with higher level of ΔmtDNA.  
In the case of IdU, this pattern was mirrored, except in the SN. The cerebellum still presented 
the highest levels of IdU incorporation, however SN was the second highest. This suggests that 
time could have an impact on replication levels observed, and perhaps another process could 
be affecting the recently replicated mitochondria in the SN. This could be increased 
mitochondria transport, since SN neurons have long processes, mitochondria would be at high 
demand in distant regions of the cell and could have been transported there. Since the whole 
cell (including neurites) were not considered here, this could have an effect. Another process 
could be an increase in mitochondrial degradation through mitophagy, which was detected 
here as an increase in mCherry puncta per cell in the SN. However this requires further work 
to confirm.  
 Is there variation in mtDNA replication with ageing and in replication defective 
model? 
With ageing, both wildtype and PolgAmut/mut mice demonstrated a decrease in CldU and IdU 
incorporation (although this only reached significance (p<0.05) in 8 out 16 cases). This 
suggests that mtDNA replication declines with ageing, however, ΔmtDNA levels increase with 
ageing. This again suggests that a higher level of mtDNA replication does not lead to a higher 
level of ΔmtDNA. This data also suggests a possible negative relationship between the two 
factors, however this needs to be confirmed. Interestingly, no significant decrease in 
incorporation was seen in the SN. This again suggests, as in the previous section, another 
process that could be involved, especially due to the high ΔmtDNA levels observed in this 
region of humans.  
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 Correlative analysis of ΔmtDNA and copy number with mtDNA replication level 
As part of a collaborative study, previously published data (Perier et al., 2013) was obtained 
and correlated to the mtDNA replication levels observed in this study. This was done to 
identify any relationship between the levels of mtDNA replication and ΔmtDNA deletions. The 
Perier et al study was chosen as they used young and aged, wildtype and PolgAmut/mut mutant  
mice. They also investigated various brain regions including cerebellum, cortex, hippocampus, 
striatum and midbrain. Although they did not look specifically at the SN, this region is present 
within the midbrain and should provide a representative measure of deletion within the SN. 
The average values were obtained and correlation analysis was conducted by Dr. Conor 
Lawless (Wellcome Centre for Mitochondrial Research).  
The results obtained demonstrated no correlation between mtDNA replication and ΔmtDNA 
deletion levels within various brain regions, genotypes or in ageing. These data suggest that 
mtDNA replication may not have an impact on ΔmtDNA levels. However, this portion of the 
project does have a number of caveats. The Perrier et al study demonstrated the ΔmtDNA 
levels in homogenate tissue. Since different neuronal populations and glial cells are present 
within homogenate tissue samples, it could be suggested that the presence of other cells could 
affect the averages. Alongside this, an average of ΔmtDNA levels, rather than the raw values 
were used for each mouse. The statistical model was created by randomly associating 
ΔmtDNA and copy number with levels of mtDNA replication, therefore, the low number of 
values available could skew the data. Alongside ΔmtDNA levels, the Perrier et al study also 
provided the mtDNA copy number in these mice which also did not demonstrate a correlation 
with the mtDNA replication data. This is interesting as an increase in mtDNA replication could 
lead to an increase in mtDNA copy number. However, the copy number could also be affected 
by other processes such as mitophagy. In spite of these limitations, the data from this study 
suggests that mtDNA replication might not be the sole mechanism for deletion formation. 
 Other mechanisms which may lead to mtDNA deletion formation 
If mtDNA replication is not causative of ΔmtDNA, another suggested mechanism is mtDNA 
repair (explained in section 1.6). The replication levels could be downregulated as the 
template strand of mtDNA is undergoing repair due to mtDNA damage. This is supported by 
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the general decrease in mtDNA replication in regions with the highest levels of ΔmtDNA, for 
example the SN. MtDNA repair activity could be increased, due to the high levels of  ΔmtDNA 
levels in this region, potentially leading to the decrease in mtDNA replication. Previous 
literature has demonstrated that with age and disease, an increase in ROS production and 
mtDNA damage is observed. Studies in human skeletal muscle have demonstrated an age 
associated increase in DNA oxidisation using 8-Oxo-2'-deoxyguanosine (8-oxo-dG) (Short et 
al., 2005). An accumulation of 8-oxo-dG  with ageing has also been observed in the cortex and 
cerebellum in humans (Hamilton et al., 2001). It might be suggested that, due to this age 
associated increase in mtDNA damage, the mitochondria is prioritising repair of an mtDNA 
molecule rather than replication of a damaged mtDNA molecule. This is also supported by a 
study that measured 8-oxo-dG glycosylase activity and demonstrated an age related increase 
in the activity of this enzyme on mouse liver mtDNA (de Souza-Pinto et al., 2001). This was 
significantly higher than the activity of this enzyme on the nuclear genome. However, this 
study, and others, also observed the activities of Uracil DNA glycosylase and endonuclease G 
both of which remains unchanged or decreased in ageing and AD disease model (Gredilla et 
al., 2010, Imam et al., 2006, Soltys et al., 2019). Therefore, this requires further experiments 
to validate.  
Current literature has not studied mtDNA repair in different brain regions extensively, 
however a study has reported an age related decrease in DNA glycosylase activity in the 
mtDNA, but not in the nuclear DNA (Imam et al., 2006). They also demonstrated that this 
activity did not change with different brain regions suggesting that there is no difference in 
DNA repair between brain regions. Another study compared DNA glycosylase activities 
between hippocampus and cortex and observed lower levels in the hippocampus (Gredilla et 
al., 2010).  Although this demonstrated difference between brain regions, based on this 
‘repair’ theory, the data from this study demonstrates lower levels of mtDNA replication in 
the hippocampus than the cortex, and therefore is in opposition. However, these studies used 
homogenate cells and as SN was not studied. Alongside this, a recent paper demonstrated 
that a decrease in DNA glycosylase activity in AD patients was associated with a reduced 
mtDNA copy number, however there was no association with mtDNA mutations (Soltys et al., 
2019). Therefore, maybe the theory requires modification to propose that a decrease in 
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mtDNA replication is associated with reduced mtDNA repair activity, and other mechanisms, 
such as mtDNA transcription increase to compensate for the biochemical defect. However, 
this requires further investigation as mentioned in the future work. 
Alongside this, if ΔmtDNA formation is via replication stalling, it could be suggested that 
thymidine analogues could still be incorporated even though replication is stalled. With the 
analysis, this will be identified as a positively replicated mtDNA molecule even though 
replication in not complete to stalling. Therefore this is one of the limitations of this technique.  
 Mechanisms that could affect the level of mtDNA replication observed 
I) MtDNA copy number 
One of the mechanisms suggested in previous literature of coping with ΔmtDNA, is 
compensation via increased mtDNA copy number (Dölle et al., 2016). This might be beneficial 
since although it increases ΔmtDNA, the wildtype mtDNA will also increase and therefore any 
biochemical defect is compensated for by ‘biochemical threshold effect’ (Rossignol et al., 
2003). This was also demonstrated in the case of a point mutation, whereby an abundance of 
wildtype mtDNA results in minimal COX deficiency and hence mitochondrial dysfunction, 
further suggesting that wildtype copy number is an important compensatory factor for mtDNA 
mutations (Durham et al., 2007). Increased copy number could potentially have an effect on 
mtDNA replication as this is required for synthesis of new mtDNA molecules, however this is 
not the sole mechanism that may affect mtDNA copy number.   
When comparing the mtDNA replication levels detected in this study to copy number data, 
previous literature that used quantitative real-time PCR assay to determine mtDNA copy 
number in various regions of the mouse brain determined that SN neurons contained the 
highest level of mtDNA copy number (Fuke et al., 2011a). This study also highlighted that the 
lowest level of mtDNA copy number was present within the cerebellum. This suggests that an 
increase in mtDNA copy number is not associated with mtDNA replication, however as 
mentioned previously, this could be due to other processes such as mtDNA degradation or 
mitophagy. The mtDNA copy number recorded in other studies also demonstrates no 
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association with the differential mtDNA replication levels observed with this study (Dölle et 
al., 2016, Fuke et al., 2011a, Perier et al., 2013, Blokhin et al., 2008, Diaz et al., 2002). 
The literature is inconsistent regarding mtDNA copy number changes with ageing. Most 
studies have demonstrated an age-related decrease or no change on skeletal muscle, which 
similar to the brain, consists of post mitotic cells (Welle et al., 2003, Miller et al., 2003, 
Barazzoni et al., 2000, Frahm et al., 2005). However studies have also presented an increase 
in mtDNA copy number in the skeletal muscle (Barrientos et al., 1997, Pesce et al., 2001). As 
mentioned before, this could be due to the methodology employed and using homogenate 
tissue instead of specific cell types or a possible effect of the species used. However, in 
individual neurons dissected from the cerebellum, cortex and SN, generally an age-related 
increase in mtDNA copy number was observed, however, this was not compared within the 
study (Dölle et al., 2016). They, and others, also investigated the effect of a disease model on 
mtDNA copy number, finding a lower level of mtDNA copy number in PD patients (Dölle et al., 
2016, Pyle et al., 2015). This decrease in copy number was also observed in single neurons and 
glial cells from Multiple sclerosis (MS) patients (Blokhin et al., 2008). Therefore, although 
homogenate data is inconsistent, data from individual neurons demonstrates an age-related 
and disease-specific decrease in copy number which is in concurrent with the reduced mtDNA 
replication changes observed in these case for this study, though not demonstrating an 
association with the ΔmtDNA level observed. 
II) MtDNA transcription 
An increase in mtDNA mutations could also lead to mitochondrial dysfunction and biochemical 
defects (Stewart and Chinnery, 2015), due to this, there could be an increased requirement 
for mtDNA transcription to compensate for the biochemical defect. In situations such as these, 
a ‘replication-transcription’ switch has been suggested (Agaronyan et al., 2015). This is 
because both replication and transcription use the same mtDNA molecule as a template, 
therefore an increase in transcription could result in a decrease of mtDNA replication. 
Evidence against this comes from the observation that an increase in oxidative damage with 
age, leads not only to a decrease in mtDNA abundance but also a decrease in mRNA transcripts 
for COX3 and COX4 in the same individuals (Short et al., 2005). This suggests that transcription 
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is also down-regulated with an increase in mtDNA damage in these individuals. This is 
particularly relevant to the SN due to the high oxidative stress observed (section 3.1.3) which 
could result in the higher levels of mtDNA damage and decreased mtDNA replication observed 
via analogue incorporation.   
III) MtDNA transport 
Transport of mitochondria can also influence the mtDNA replication observed as recently 
replicated mtDNA molecules could be transported to other regions of the neurons not present 
within the focal plane, and hence the overall mtDNA replication levels could be effected. This 
could be particularly important in the SN, as between the IdU and CldU data, there are 
variations in the pattern of mtDNA replication (figure 3.20 and 3.21). This variation in mtDNA 
replication in SN was also observed with ageing, where all regions demonstrated a significant 
difference, however the SN displayed similar levels between young and aged (figure 3.22 and 
3.13). This suggests that mtDNA replication could be increased in SN, but newly replicated 
mtDNA molecules are transported to distal regions at a faster rate and are hence, not available 
for interpretation. These variations are particularly interesting due to high mtDNA levels 
observed in this region, as these could lead to an increased demand for ATP in various regions 
of the neuron, hence transport could be increased to compensate for this demand. To further 
understand this process, the localisation of CldU and IdU incorporated molecules was also 
investigated (chapter 5).  
IV) Mitophagy 
The difference in the pattern of mtDNA replication in SN between the IdU (15 hours) and the 
CldU (5 days), and with ageing, could also suggest a variation in mitophagy. To model mtDNA 
degradation in this study, mitoQC mice were analysed (McWilliams et al., 2016). Preliminary 
data showed that SN neurons demonstrate higher levels of basal mitophagy compared to 
Purkinje neurons. Along with the previous finding of lower replication levels compared to 
Purkinje neurons, it could be suggested that in the SN, due to an increase in mitophagy, 
mtDNA are being degraded, and as a result mtDNA replication levels in the SN appear 
decreased, when measured using CldU incorporation compared to IdU. This could potentially 
suggest that mtDNA replication is high within the SN (as observed with the IdU data), but due 
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to increased mtDNA degradation over time, they appear to contain lower mtDNA replication. 
However, even with the IdU labelling, the cerebellum demonstrated higher IdU incorporation 
than the SN, therefore the mtDNA replication level is highest within the cerebellum at both 
times. Alongside this, it is important to consider that mtDNA molecules have been suggested 
to have a half-life of 6-31 days, which is particularly high in post-mitotic cells which fall into 
the longer values of the 6-31 range (Clayton, 1982, Gross and Rabinowitz, 1969, Korr et al., 
1998). Recently analysis via stochastic computational models have suggested that the half-life 
is even higher (more than 31 days), when taking into account the levels of mtDNA mutation 
levels observed (Poovathingal et al., 2012). These suggest that the time point between the IdU 
and CldU is not sufficient to observe mtDNA degradation. Therefore, this would require 
further work.  
  Future work 
Half of each brain from the mouse in this study was separated and frozen for molecular 
analysis. These can be used to laser-microdissect individual cells from different regions of the 
brain and analyse the level of total ΔmtDNA and copy number using quantitative real-time 
PCR Taqman assay (He et al., 2002, Russell et al., 2018). This would provide a better 
comparison of these parameters as this will be in individual cells, and also specifically 
correlated with CldU and IdU incorporation levels 
As mtDNA replication is suggested to be not associated with ΔmtDNA from previous literature 
analysed in this study (figure 3.21), mtDNA repair needs to be analysed within different brain 
regions. Repair can be investigated in these tissues by transcriptomic or proteomic analysis to 
study the expression levels of various proteins involved in the repair pathway (table 1.1). The 
levels of these protein activity could also be vital to measure. This can be done by measuring 
mtDNA damage such as 8-oxo-dG in various regions of the brain. Transgenic mice with 
knockout of mtDNA repair genes such as OGG1 could also be utilised for this purpose 
(Yuzefovych et al., 2016). 
A bigger sample set for the MitoQC mice including an ageing cohort would provide a more 
developed picture of how this process is effected in these tissue regions and ageing. This is 
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particularly important as this study observed a difference in mitophagy levels between the 
cerebellum and the SN.  
Mitophagy, specifically in the mice brains used for this study, can be investigated. Protein 
expression could be measured by targeting for the lysosome markers such as anti-LC3II, anti-
LAMP2A or anti-parkin. This, co-localised to a mitochondrial marker, could identify specific 
changes in the levels of mitophagy 
Since it has been suggested that mtDNA has a half-life of 31 days, a longer time frame of 
labelling might produce results that are more representative. Since this has not been studied 
in vivo, this would require optimisation. Alongside this, previous literature has suggested that 
mtDNA replication only take ~75 minutes, hence this time frame is appropriate to study 
mtDNA replication.  
Since transcription has been suggested to be one mechanism effecting the level of mtDNA 
replication, this required investigation. This could be done using transcriptomic studies to 
deduce the mRNA expression of various OXPHOS subunits in various tissues and deducing how 
this is altered in ageing.  
 Final conclusion 
MtDNA replication as studied using thymidine analogue labelling shows significant differences 
between brain regions, with ageing and in the PolgAmut/mut mice. Although variations were 
present, mtDNA replication generally demonstrated a decrease in regions associated with the 
highest levels of ΔmtDNA, suggesting that higher levels of mtDNA replication do not in fact 
correlate with high levels of ΔmtDNA. This was also demonstrated using data obtained from a 
previous study measuring ΔmtDNA in various regions of wildtype and PolgAmut/mut mice. 
However, this could be due to the limitations as discussed. Alongside this, other factors such 
as mtDNA repair, transcription and mitophagy could also affect the overall process and would 
require further investigations.  
Although no association between the mtDNA replication and mtDNA was observed, there 
were some reoccurring patterns that are important to consider.  
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Generally in regions with an increase in ΔmtDNA (such as SN compared to cerebellum, young 
mice compared to aged mice and wildtype compared to PolgAmut/mut mouse), a decrease in 
CldU incorporation, and therefore mtDNA replication was observed. A number of alternative 
mechanisms have been suggested for this such as mtDNA repair, transcription, mtDNA 
turnover and transport into distal regions. These require further investigations.  
As double thymidine analogue labelling was used, this allowed investigations of how mtDNA 
replication changed between two time points. This study demonstrated that there were 
difference in the pattern of mtDNA replication levels as notice with the CldU (4 days) and with 
IdU (~15 hours) particularly in the SN. SN was also differently effected with ageing compared 
to the other regions. Alongside this, quantification of mitophagy discovered increased levels 
within the SN neurons compared to cerebellum. All of these suggest a combination of effects 














Chapter 4:  Optimising thymidine analogue labelling as a tool to assess the 
site of mtDNA replication in actively dividing cell lines 
4.1 Introduction 
 Thymidine analogues to study mtDNA replication 
Thymidine analogue labelling was a milestone in helping to understand the characteristics of 
mtDNA turnover. This technique was used initially on mitochondrial fractions in vivo to 
confirm that mtDNA does in fact replicate by incorporating nucleotides, similar to nuclear DNA 
(Karol and Simpson, 1968, Parsons and Simpson, 1967). BrdU was also used to initially 
determine that mtDNA replicates via a semi-conservative mechanism (Gross and Rabinowitz, 
1969). Another study utilised buoyant density experiments to separate BrdU labelled 
mitochondria, which demonstrated the production of two species, one which represented 
unlabelled mtDNA (roughly 41.9mg/ml) and one which represented heavily labelled mtDNA 
(roughly 95.3 mg/ml). They also noticed a number of intermediate hybrids representing lightly 
labelled mtDNA. They thus concluded that mtDNA can be replicated multiple times or not at 
all at a specific time point (Flory Jr and Vinograd, 1973).  
The time taken for mtDNA replication was studied using tritium thymidine and BrdU in a pulse 
chase manner (chase periods between 1.5-22h) on immortalised mouse cell lines  
(Bogenhagen and Clayton, 1977). They found incorporation of both analogues within the same 
mtDNA molecule at the shorter periods and concluded that mtDNA replication was ‘quick’ as 
mtDNA were labelled with both analogues after the first few chase time points. They also 
demonstrated that mtDNA replication occurs independently of the cell cycle since a constant 
fraction of mtDNA was labelled after each time point (Bogenhagen and Clayton, 1977). More 
recently, Davis and Clayton demonstrated BrdU incorporation into mtDNA in HeLa cells within 
2 hours of adding the analogue (Davis and Clayton, 1996). This early incorporation of BrdU 
was due to thymidine-Kinase II (TK2) knock out, an enzyme responsible for thymidine 
synthesis specifically for the mitochondria (Johansson and Karlsson, 1997). They also agreed 
with the previous study that that mtDNA replication occurs independently of the nuclear 
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genome, since enucleated cells also showed BrdU incorporation into the mitochondria (Davis 
and Clayton, 1996).  
Further experiments using post-mitotic myoblasts demonstrate that mtDNA replication did  
occur in post-mitotic cells, however this was suggested to be happening at a lower level as it 
took 16 hours to identify BrdU positive mtDNA in these cells, compared to 0.5-6 hours in HeLa 
cells (Magnusson et al., 2003). This was repeated by another study using embryonic chicken 
peripheral neurons (Amiri and Hollenbeck, 2008). They discovered that mtDNA replication 
occurred in both the cell body and axon of neurons. However, unlike (Magnusson et al., 2003), 
they noticed BrdU staining within the mtDNA from 3 hours. This was suggested to be due to 
more sensitive and robust techniques, such as an additional antigen retrieval step and HCl 
treatments to denature the mtDNA. A further study compared the level of BrdU incorporation 
(to investigate mitochondrial biogenesis) into mtDNA of primary neurons from wild type and 
amyloid beta precursor protein (AβPP) transgenic mice at two time points (4 and 20hours) 
(Calkins and Reddy, 2011). Their study demonstrated increased BrdU incorporation from 4 to 
20 hours and interestingly the comparatively higher level of BrdU labelling occurred in the 
AβPP transgenic mice and when mitochondrial damage was induced in neurons with H2O2 and 
rotenone. This led them to conclude that the increase in BrdU labelling, and therefore 
mitochondrial biogenesis, was a compensatory mechanism in response to damage (Calkins 
and Reddy, 2011).   
The studies mentioned in this section all used BrdU as a thymidine analogue; however, my 
study aimed to conduct pulse chase labelling to identify the turnover of mtDNA, hence double 
thymidine analogue labelling with CldU and IdU was used. BrdU antibodies have a lot of cross 
reactivity with CldU or IdU, because CldU and IdU are obtained from antiserum of rodents 
injected with BrdU. Hence, BrdU could never be used in conjunction with these analogues 
(Bianco et al., 2012, Asano et al., 2015). However, there is no cross reactivity between CldU 
and IdU, and both of these have been used in conjunction with each other in a number of 
studies (Tuttle et al., 2010, Schorl and Sedivy, 2007, Bulgar et al., 2013, Hirota et al., 2016). To 
further ensure a lack of cross reactivity between CldU and IdU in this study, the secondary 
antibodies were selected based on an additional purification step where they are subjected 
to a matrix containing potentially cross-reactive species that would bind any cross-reactive 
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antibodies. BrdU could be used in conjunction with EdU however, this would require two 
staining protocols using antibodies and a click reaction with fluorescence conjugated azide 
that could be detrimental to cell viability and multiple wash steps could affect the cell’s 
adherence to the coverslips. Some studies have also highlighted cross reactivity between the 
BrdU antibody and EdU (Liboska et al., 2012).  
Methods of thymidine analogue labelling have been used for many years, but more sensitive 
methodology development papers have been published very recently suggesting a need for 
better labelling techniques (Harris et al., 2018, Phillips et al., 2017). Combined with this, 
although many studies have used thymidine analogues to investigate mtDNA replication, none 
have attempted to quantify the site of mtDNA replication and the effect of mtDNA mutation 
on this.  
This study aimed to optimise thymidine analogue labelling of cultured cells, including 
reprogrammed iPSCs and neurons with mtDNA deletions. This method will allow the site of 
mtDNA replication to be identified, as discussed in chapter 5. Initially optimisation will be 
conducted on HeLa cells. Although not post-mitotic, this would be a good model to use due to 
their quick doubling time and robustness. Since HeLa cells were used to optimise a method 
that can be modified for the iPSCs and neurons, this can be justified.  
 
4.2 Aim and objectives 
 Aim 
The aim of this chapter was to develop and optimise a method to label and visualise mtDNA 
replication and to use this to assess mtDNA replication levels in cells containing mtDNA 
deletions. This could be used to further shed light on deletion formation in various cell lines. 
 Objectives  
The following objectives were fulfilled in this study; 
• To develop a method of thymidine analogue labelling in HeLa cells 
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• To apply this method to reprogrammed iPSCs and differentiated neurons with mtDNA 
deletions 
4.3 Methods 
 CldU/IdU labelling 
Preparation of CldU and IdU working stocks is described in section 2.3.12. The cells were then 
subjected to IdU and CldU labelling (concentrations as optimised and mentioned in results 
(Section 4.4.2). After the initial addition of IdU and/or CldU, the cells were stored in an 
incubator at 37oC with 5% CO2 allowing further growth and replication. The cells were fixed at 
various time points following the addition of the thymidine analogue labels. Cells were fixed 
using 4% paraformaldehyde (Santa-Cruz Biotechnology) for 20 minutes before washing with 
DPBS. Cells were immunofluorescently labelled as per the protocol described in section 2.3.6 
to visualise the incorporated thymidine analogues. Anti-CldU (Novus biological) was produced 
using chemical BrdU as an immunogen. This antibody has a high affinity for CldU and no cross 
reactivity with thymidine or IdU according to the manufacture’s protocol. Anti-IdU (BD 
Biosciences) was produced by using IdU as an immunogen, and therefore is not cross-reactive 
to CldU. Mitochondrial markers were also optimised along with their concentrations, details 
of this can be found in section 4.3.1. Images were acquired using a Zeiss axioimager M1 and 
Zen 2011 or Nikon confocal microscope and NIS elements at 40x magnification. The analysis 
of individual neurons and quantification of IdU levels are explained in detail in section 2.3.7.  
4.4 Results 
 Method optimisation – Mitochondrial markers  
Tom20, VDAC and anti-DNA antibodies have been previously discussed in section 3.4.2 as they 
were also optimised for use in the tissue study. Images of Tom20 and TFAM staining are 
presented in figure 4.1 and 4.2 respectively. TFAM has role in mtDNA maintenance, 
replication, transcription and packaging into the nucleoids, all of which is discussed in detail 
in chapter 1 (section 1.5). TFAM is found in abundance within nucleoids (Bogenhagen et al., 
2008, Kaufman et al., 2007). Due to this location within nucleoids, it was selected as an 
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appropriate marker to normalise the thymidine analogue labels. Tom20 has also been 
described previously (section 3.4.2) and is a subunit within the TIM/TOM complex on the outer 
membrane of mitochondria and is involved in transport of proteins into the mitochondria.  
For tom20, dilutions from 1 in 200 to 1 in 1000 were tried based on manufacturer’s instruction 
and previous tissue study (section 3.4). 1 in 400 was identified as the optimal dilution and was 
carried forward and presented in all further figures. The tom20 staining (figure 4.1 and 4.2) 
was reliable with punctate staining around the nucleus, similar to that seen within tissue. For 
TFAM, dilutions of 1 in 100 and 1 in 200 were tried and the images from 1 in 100 are presented 
in figure 4.2. This antibody was punctate but the staining was not uniformly present within 
the cell co-localising with tom20 suggesting that a number of mitochondrion were not 
labelled. This could be an issue with the antibody, and only one type of TFAM antibody was 
used. A lower dilution might have also provided an increased region of positive staining, but 
could have also increased background staining. A reassuring factor is that most of the TFAM 

























Figure 4.1 Optimisation of mitochondrial marker staining. This image displays staining with TOM20 with Hoechst 
staining nuclear DNA as observed in HeLa cells. The scale bar represents 20µM. The images were obtained at 40x 




The anti-DNA antibody (Merck Millipore) binds to double stranded DNA (dsDNA) with a very 
low affinity for single stranded DNA (ssDNA). It was initially produced using synthetic base 
pairs and calf thymus DNA as antigens (Ballard and Voss, 1985). This study also mentioned 
how the affinity for ssDNA was minimised by purifying using an ssDNA binding agarose, 
however according to the manufacturer’s guidelines, there is still a 28% reactivity with ssDNA, 
making it less specific as it can also bind to mRNA within the cytoplasm. PicoGreen is a 
Figure 4.2 Optimisation of mitochondrial marker staining. This image displays staining of the mitochondria with 
tom20 and TFAM in iPSC stem cells.  The Hoechst stains the nucleus. The scale bar represents 10µM. The images 
were obtained at 40x magnification using Nikon A1R confocal microscope and zoomed in to clearly visualise 
TFAM. Hoechst was imaged at 405nm, tom20 in 488nm and TFAM in 647nm. 
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fluorescent synthetic dye which is capable of binding to nucleic acids resulting in an increased 
fluorescent signal (Haugland et al., 1995). When compared to Hoechst, PicoGreen bound with 
same sensitivity to all the nucleic acids and is 400 fold more sensitive (Singer et al., 1997). This 
study also demonstrated that PicoGreen could detect small concentrations of DNA as little as 
25pg/ml. It has also been used to label mtDNA in previously reported studies (Ashley et al., 
2005, Ashley and Poulton, 2009, Tyynismaa et al., 2004).  
The anti-DNA antibody (figure 4.3) and PicoGreen (figure 4.4) show similar nuclear staining as 
they both stain the same substrate. However, the PicoGreen did not produce any staining co-
localised with the mitochondrial marker. The PicoGreen concentration was already optimised 
at 3µl of stock per ml (Ashley et al., 2005). The anti-DNA antibody was trialled at 1 in 100 and 
1 in 200 dilutions. This was lower than previous studies as this was commonly used to detect 
nuclear DNA, and this study required mtDNA staining (Henault et al., 2012). 
The anti-DNA antibody staining is saturated within the nucleus as the exposure time was set 
based upon the positive identification of any mtDNA signal which resulted in the nuclear DNA 
fluorescent signal often being more intense. One of the obvious problems with the two 
methods of detection was the nuclear labelling. The method of analysis developed at this point 
required a specific mitochondrial marker, and the nuclear staining could have effected that. 
However, this could have been overcome by setting a threshold and subtracting the nuclear 
staining based on the Hoechst staining. Alongside this, the nuclear staining was too saturated, 
especially for PicoGreen, which could result in a scattered light around the nucleus that might 









Figure 4.3 Optimisation of mitochondrial marker staining. This image displays staining of the nuclear and mtDNA with anti-DNA 
antibody in HeLa cells. Hoechst stains nucleus. The scale bar represents 10 µM. The images were obtained at 40x magnification 

















































































































































































































The next markers trialled were Twinkle and VDAC (figure 4.5). Twinkle is a mitochondrial 
helicase causing the mtDNA to unwind for replication (Korhonen et al., 2003). Although the 
protein has been identified as localising to the mitochondrial matrix and nucleoids, in this 
study, this marker appeared more nuclear, with limited punctate staining within the 
mitochondria (Spelbrink et al., 2001, Korhonen et al., 2004). Therefore, this was not 
considered an appropriate marker. The nuclear staining could be because the TWNK gene that 
codes for this protein in encoded in the nuclear genome, hence translated, and transcribed in 
the nuclear region before being transported to the mitochondria. The nuclear staining is 
present in abundance therefore this could also be due to any bleed through occurring from 
the other channels. However, a reassuring factor was that in areas within the cytoplasm that 
had positive staining for Twinkle, these foci co-localised nicely with the IdU suggesting that 
IdU was being incorporated into the mtDNA and that the staining was positive, as highlighted 
in the figure 4.5.  
VDAC is also encoded by the nuclear genome however, it is specifically localised to the 
mitochondria. It is present on the outer mitochondrial membrane as is involved in the 
transport of proteins and other metabolites (section 1.2) (Shoshan-Barmatz et al., 2010). Two 
dilutions of this antibody were used; 1 in 200 and 1 in 500 were trialled based on previous 
work in our lab (Ahmed et al., 2017, Rocha et al., 2015).  VDAC, similar to the in vivo staining 
(figure 4.1), produced very faint staining without any specific punctate foci. This antibody was 
also imaged in the 647 wavelength at which the laser-blocking filter in the Nikon A1R confocal 
system is not as efficient hence, some reflection is possible and since it is a higher wavelength, 
the theoretical resolution is also decreased according to the manufacturer. Alongside this, 
since the antibody has successfully stained mitochondria previously in our lab, the problem 
might lie with the protocol (Ahmed et al., 2017, Rocha et al., 2015). However, these studies 
were in vivo and this might require optimisation in vitro. Tom20 produced punctate staining 
therefore VDAC was not further optimised.   
NDUFB8 (figure 4.6) was also considered as a mitochondrial marker. NDUFB8 is a subunit of 
NADH dehydrogenase (complex I), present within the inner mitochondrial membrane. This 
antibody has been previously used in our lab at a dilution of 1 in 100 (Ahmed et al., 2017, 
Rocha et al., 2015). NDUFB8 was a good marker since the staining was punctate and was visibly 
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specific. However, tom20 was still preferred due to a lower dilution and exposure time. The 
lower exposure time could be beneficial in reducing photo bleaching.  
Mitotracker (figure 4.7) was the final mitochondrial marker trialled. This is a dye that is added 
to live cells, is taken up by mitochondria as a function of their membrane potential where it 
then accumulates. The concentration used was 50nM which was previously used for live cell 
imaging (Buckman et al., 2001, Dickinson and Chang, 2008). Mito tracker Red CMXRos was 
used specifically since the dye is stable upon fixation of cells.  The Mito tracker stain was weak 
resulting in the requirement for a high exposure time. The staining also looks very perinuclear. 
There could abundance of mitochondria in the perinuclear region due to the presence of a 
number of nuclear factors required for mitochondrial functions, which could lead to the 
abundant staining in this area (Geisler et al., 2010, Psarra and Sekeris, 2008, Leigh-Brown et 
al., 2010). However this was not observed when other mitochondrial markers were utilised, 
hence could be false positive or nonspecific. Alongside this, staining was not punctate and was 
not considered further.  
Since Tom20 showed punctate staining which was specific and accurately detected 




















































































































































































































































































Figure 4.6 Optimisation of mitochondrial marker staining. This image shows NDUFB8 staining alongside CIdU staining 
in iPSC stem cells. Scale bar represents 10 µM. The images were obtained at 40x magnification using Zeiss microscope. 




Tom20 was selected due to uniform and punctate staining within cells (figure 4.1 and 4.2).  
 Thymidine analogue concentration optimisation  
Previously, the combination of CldU and IdU for labelling has been used in vivo but their use 
in vitro is a very recent development where these analogues have been utilised to study the 
formation of the ‘common’ 4977bp mtDNA deletion (Phillips et al., 2017). However, the use 
of these analogues in the specific cell lines included in this study is novel. Due to this, further 
optimisation was required.  
Initially, the concentration of the thymidine analogues used was based on previous in vivo 
experiments in this thesis (section 2.2.2) and previous literature that used BrdU labelling in 
vitro to study both nuclear and mitochondrial replication (Amiri and Hollenbeck, 2008, Calkins 
and Reddy, 2011, Davis and Clayton, 1996, Dimitrova and Gilbert, 1999, Magnusson et al., 
Figure 4.7 Optimisation of mitochondrial marker staining. This image shows Mitotracker staining alongside CIdU 
staining in iPSC stem cells. Scale bar represents 20 µM. The images were obtained at 40x magnification using Zeiss 
microscope. Hoechst was imaged at 405nm, Mitotracker in 546nm and CIdU in 647nm 
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2003). All of these previous studies used 10-30µM to detect mtDNA replication. A 
concentration of 15µM was used initially for the optimisation of this study. This equates to 
5.311µg/ml of IdU based on its molecular weight (354.10g/mol) and 3.94µg/ml of CIdU 
(molecular weight 262.65g/mol). Both thymidine analogues were added to the cells for 2-48 
hours at time points 2-3 hours apart. Initially this lead to a high level of cell death in the HeLa 
cells, which was the most robust cell line used in this study (further details in appendix 8.1). 
Due to this, the concentration of the thymidine analogues required further optimisation. A 
concentration range from 3-60µg/ml was tested for each thymidine analogue however, a large 
amount of cell death (morphologically identified in figure 4.8) was observed with IdU labelling 
even at 3µg/ml (figure 4.9), and hence the concentration was reduced further to trial a range 
between 1-6µg/ml. The cells were labelled for 24 or 48 hours. Although the cell death was 
quantified, this was not representative of the images as many dead cells are removed during 





CldU and IdU labelling at various concentrations is presented in figure 4.9 and 4.10. The 
parameters analysed to identify optimum concentration were total number of cells and total 
number of cells with mtDNA incorporation of thymidine analogue (figure 4.11). In figure 4.9, 
the IdU labelling in HeLa cells is displayed at various concentrations. This shows that both 
nuclear DNA and mtDNA signal was faint at 2µg/ml, though the highest level of mitochondrial 
IdU signal was noticed at 2.5µg/ml. At high concentrations such as 6µg/ml, the majority of the 
IdU was incorporated into the nuclear genome. The higher concentrations were expected to 
have a higher level of mtDNA incorporation of the analogues since more analogue was 
available for incorporation; however, this was not the case. This could be because at higher 
Figure 4.8 IdU staining of HeLa cells. Cell death was observed in most of the images with the treatment. The 
images above were taken of cells following dosing with IdU at a concentration of 2.5µg/ml. The white arrows 
highlight dead cells. These cells are identified based on their morphology and increased saturation compared to 
dividing cells due to perinuclear clustering as a response to damage. They also have a condensed nuclei and cell 
body and as a result, they appear round in shape at a much smaller size than a surviving cell highlighted by the 
yellow arrow. Actively dividing cells are identified via the incorporation the IdU into the nucleus. Scale bar is 50 
µM. The images were obtained at 20x magnification using the Zeiss microscope. Hoechst was imaged at 405nm, 
Tom20 at 488nm and IdU at 546nm. 
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concentrations, despite an increased level of thymidine analogue incorporation into mtDNA, 
these concentrations had caused an increase in cell death (figure 4.8). The nuclear 
incorporation of CldU remained similar at all the concentrations trialled, however noticeable 
differences were observed in the number of cells incorporating CldU that co-localised with 
Tom20 (figure 4.10). An increase in the number of cells with mitochondrial incorporation was 






















































































































































































































































































































































































































































































































































The effect of IdU and CldU concentration on thymidine analogues incorporation into the 
mitochondria for 24 and 48 hours is shown in figure 4.11. Graphs A and C in the figure 
represent the total cell count for IdU and CldU labelled HeLa cells. This was based on the total 
number of individual Hoechst stained nuclei in each image, as it includes all nuclei, this also 
accounts for the dead cells. The total number of labelled cells were higher in the IdU labelled 
group compared to the CldU. For the IdU labelled cells, there was a decrease in cell count 
after 48 hours incubation compared to a 24 hour incubation period. All the 24 hour 
concentrations were compared to the untreated control as the untreated was also fixed after 
24 hours. For the CldU labelled cells, even the low concentrations had an effect on cell survival 
suggesting that the toxicity was high and maybe a lower concentration might be required. 
However, this would compromise the mtDNA incorporation of the thymidine analogue.  
Figures 4.11B and 4.11D present the total number of cells at each concentration and time 
point that showed positive mitochondrial thymidine analogue staining which co-localised 
with the mitochondrial marker (Tom20, quantified using Image J (Fiji)). This did not include 
the dead cells due to difficulties in identifying nuclear or mitochondrial incorporated analogue 
as morphologically the cells appear condensed and hence were difficult to distinguish. 
For CldU the maximum incorporation of the analogue, occurred at 3µg/ml and for the IdU, 
the maximum incorporation was equal at both 2.5µg/ml and 6µg/ml. For the CldU, the time 
points of 24 and 48 hours produced similar number of cells with incorporation into the 
mitochondria, except for the lower concentrations of 3µg/ml and 6µg/ml. There is an increase 
in mitochondrial incorporation of CldU at 48 hours because the CldU was available in the 
media for a longer time. This increase is not imitated at higher concentrations potentially due 
to toxicity as demonstrated by the decreased total number of cells. Similarly, at higher 
concentrations the level of IdU incorporation was much lower following 48 hours incubation 
compared to 24. Correspondingly, the total number of cells is also lower compared to 24hours 
suggesting a toxic effect over a longer incubation period. At concentrations lower than 
2.5µg/ml, there were no cells showing positive staining for IdU within the mitochondria 




Figure 4.11 Optimisation of CldU and IdU labelling in HeLa cells. Images A and B presents the total cell count per 
image for CldU and IdU respectively. Images C and D presents the total number of cells that incorporated each 
of the label into the mitochondria (co-localised with mitochondrial marker; Tom20). N=10 images for each 
thymidine analogue label. Significant differences were determined between the untreated cells and those cells 
incubated with CldU and IdU, * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001 obtained 
using one way-ANOVA.. As the untreated cells were fixed after 24 hours, the data from 48 
 
The optimal concentration was chosen as the concentration at which there was the highest 
amount of mtDNA incorporation of the analogue with maximum total number of cells 
(suggesting cell viability) compared to the untreated cells. For CldU labelling, an optimal 
concentration of 6µg/ml was chosen due to the increased mitochondrial incorporation and 
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without compromising the total number of cells. For IdU 2.5µg/ml was chosen for similar 
reasons. Since visualisation of the staining needed high resolution imaging to be able to 
distinguish mitochondrial structure and analogue incorporation, confocal microscopy was 
used for all future imaging (figures 4.12).  
 Dual thymidine analogue toxicity  
After optimising the concentration of thymidine analogues, HeLa cells were labelled with IdU 
(pulse) for 24 hours followed by CldU for a variety of times ranging from 1-48 hours (chase) 
(figure 4.12). The combination of CldU and IdU labelling produced punctate staining at 40x 
magnification that co-localised with Tom20. A noticeable factor was that the level of cell 
death was still high. This was particularly visible when the thymidine analogues were 
incubated with cells for a longer time (figure 4.12B). Compared to row A, the cells appear to 
have a more condensed nucleus and cell body, with saturated staining suggesting high levels 
of cell death which was quantified (figure 4.13). Due to this, for all future analysis a single 
thymidine analogue label was used to minimise toxicity and cell death. IdU was chosen as the 
thymidine analogue to carry forward. This was because it showed a higher level of 
incorporation into the mtDNA compared to CldU (figure 4.12 and 4.13). The lower levels of 
CldU incorporation into mtDNA could be because of the toxicity. As seen in figure 4.11, the 
total cell count is increased in IdU labelled cells in comparison to CldU. Therefore, in the CldU 
experiments, the cells that have incorporated CldU could have detached from the surface, 
decreasing the total number of cells with CldU labelled mtDNA. This further favoured the use 




























Figure 4.12 Images of CldU and IdU labelled HeLa cells obtained with confocal imaging. In image A the IdU was 
added and left for 24 hours, the cells were washed and CldU was added and left for 1 hour. In Image B, the 
same process as before, but the CldU was left for 24 hours. Dead cells are highlighted in image B with white 
arrows. Scale bar represents 10 µM. The images were obtained at 40x magnification using Nikon A1R confocal 






 Reduction of IdU nuclear staining  
Following optimisation of the working concentration, IdU was added and the cells were fixed 
at various time points from 0.25-8 hours. One of the main issues of this experiment was the 
abundance of thymidine analogue incorporation into the nucleus (figure 4.11, 4.12 and 4.13). 
Since the nuclear DNA is much larger, when it is actively replicating, the majority of the IdU 
will be incorporated here limiting the IdU available for mtDNA, and increasing the 
concentration is not a viable option due to toxicity. Therefore, to halt nuclear genome 
Figure 4.13 Graphical representation of the percentage of cells with nuclear and mitochondrial incorporation of 
thymidine analogues. The y axis represents the percentage of the total cells within an image that have 
incorporate the analogue in to the nuclear genome and the mtDNA, calculated from the total number of cells 
based on the Hoechst foci. The cells were labelled with IdU and left for 24 hours, the cells were washed and CldU 
was added and left for 24 hours. The differences are not statistically significant.  N =73 cells. 
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replication, aphidicolin (Sigma) was used. This is an antibiotic, isolated from Nigrospora 
sphaerica, that has been used in previous studies that utilised thymidine analogue labelling 
(Rodriguez-Acebes et al., 2018, Speit et al., 2016). Aphidicolin blocks nuclear DNA replication 
and repair, by inhibiting eukaryotic nuclear DNA polymerases of the B-family; Polα, Polδ, Polε 
and Polζ (Hanaoka et al., 1979). This is achieved by causing conformational changes to their 
active site by rotating the template guanine, which then blocks cytosine base pairs from 
binding (Baranovskiy et al., 2014). Aphidicolin does not inhibit mtDNA polymerase γ (Polγ), 
therefore although nuclear DNA replication is halted, mtDNA replication can continue. This 
inhibition of nuclear incorporation of thymidine analogues, allows their incorporation into 
mtDNA to be more easily visualised.  
Based on previous literature, a stock of aphidicolin was made up in DMSO and used at a final 
concentration of 7µg/ml (Davis and Clayton, 1996). This study also found complete arrest of 
nuclear DNA replication occurred within 1-2 hours, therefore aphidicolin was added 3 hours 
prior to IdU labelling in this study, and was left in the media for the duration of the experiment 
until the cells were fixed (figure 4.14). In the cells untreated with aphidicolin, the majority of 
the IdU has been incorporate into the nucleus with a scarce amount of incorporation to the 
mtDNA. With aphidicolin treatment, there was no nuclear staining at all and an increased 
amount of IdU was incorporated into the mtDNA. Therefore, this step was added to the 
protocol. Following this, the cells were stained with IdU and fixed at 1 hour intervals until 48 
































































































































































































































































































 Thymidine analogue labelling in iPSCs and derived neurons 
Thymidine analogue labelling was also trialled on iPSCs and neurons reprogrammed from 
patient fibroblasts (Russell et al., 2018). This is because the overall aim of this thesis was to 
study mtDNA replication and how it is related to the high levels of mtDNA deletion that are 
detected in some neuronal populations with advancing age. During reprogramming into 
iPSCs, clones with varying levels of heteroplasmy were produced. This allowed the use of 
isogenic cell lines with varying levels of mtDNA deletion load. In this study, the cell line with 
high deletion (~40% deletion load) was used as a disease model and compared to a low 
deletion cell line (>10% deletion load) which acted as an isogenic control. These iPSCs were 
also differentiated into neurons to provide a model to investigate the correlation between 
mtDNA replication location and mtDNA deletion load within neurons in an in vitro setting.  
The differentiation of the stem cells into neurons is described in section 2.3.7. A seeding 
density of 3x105 was optimised for the stem cells and 5x105 for the neurons per well. This was 
based on the cell viability within the time taken for this experiment. This seeding density is 
higher than the HeLa cells since iPSCs have a longer doubling time of 44 hours compared to 
24.67 hours for HeLa cells (Boisvert et al., 2011, Takahashi et al., 2007). Both the stem cells 
and the neurons could potentially be more sensitive to thymidine analogue toxicity compared 
to the HeLa cells. This is because HeLa cells are able to tolerate mechanical disruption more 
and are also more adherent to the growing surface; hence, a higher seeding density was used 
to compensate for this. After labelling, IdU was successfully incorporated into the mtDNA of 
iPSCs (figure 4.15) and neurons (figure 4.16). The cells were fixed at intervals of 2 hour for 20 
hours, and cell viability was noticed as being reduced at longer time points of incubation with 
the analogue. Figure 4.15 has cell lines from two different time points (8 and 10 hours), as 
















































































































































































































































Figure 4.16 IdU labelled neurons. The image presents the set of cells with a high and low deletion load at labelling 
time 8 of hours. The images were obtained at 40x magnification using Zeiss microscope. Hoechst was in 
wavelength 405, mitochondria are stained for with Tom20 and imaged at 488 and IdU was imaged at wavelength 




The key outcomes from this chapter are as follows; 
• A model to label mtDNA replication in vitro and suitable analysis method for 
quantification of results were successfully optimised 
• iPSCs and neurons were successfully labelled with IdU, which is novel 
 Thymidine analogue labelling methodology 
The aim of this study was to develop a methodology to label mtDNA replication in vitro, which 
was successfully developed in the HeLa cells and carried forward to iPSCs and neurons. This 
was beneficial to deduce the location of mtDNA replication as reported in chapter 5.  
One of the limitations of the technique is that the thymidine analogue competes with 
endogenous thymidine. TK2 is responsible for thymidine synthesis for mtDNA and knock out 
of this gene has been used in previous studies to halt thymidine production and ensure that 
endogenous thymidine is not available for mtDNA replication, ensuring complete 
incorporation of the thymidine analogues (Davis and Clayton, 1996). However, in this study, 
since this methodology was developed for use in various cell lines, genetic TK2 ablation was 
not feasible. Alongside this, TK2 mutations in humans have led to mitochondrial disease and 
mtDNA depletion, therefore this could affect the reliability of the result (Saada et al., 2001). 
Another option would be to use siRNA knockdown for TK2 which would give similar results to 
genetic knockout, however it is not as reliable either.  
Another limitation is the use of single analogue. Initially a double thymidine analogue labelling 
with a pulse chase method was used, however due to reduced low cell viability, an individual 
analogue was used. A pulse chase method would have been beneficial in normalising any 
variation between cell lines or the different passages used to create a baseline of mtDNA 
replication. A methodology for mtDNA labelling with ldU and CldU  in vitro was developed 
recently and the name ‘mito-SMARD’ (single-molecule analysis of replicating DNA ) was coined 
(Phillips et al., 2017), however this requires further downstream processes and is not feasible 
for single cell. The combination of analogues in this study could have been optimised again 
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following addition of aphidicolin. In this case, a lower concentration of CldU and IdU could 
have been used and the combination of both of these might not have been toxic for the cells. 
This is a consideration for future work. 
In addition, the thymidine analogue and the antibodies used could be additional limiting 
factors. In terms of the thymidine analogue chosen, the initial reason for using CldU and IdU 
instead of BrdU was because of its cross reactivity with the other analogues in terms of the 
antibodies, due to the structural similarities in the thymidine analogues. Another reasoning 
for the use of these specific analogues was because they were used in the in vivo study of this 
thesis (chapter 3); hence, this would offer continuity, allowing comparison between the 
projects. BrdU and EdU could also have been used in conjunction with each other, however 
this requires a more elaborate methodology as one analogues relies on antibodies for 
visualisation and the other on fluorescence conjugated azide (Liboska et al., 2012). However, 
since single thymidine analogue labelling was used, other analogues could have been trialled. 
EdU could have been optimised for visualising mtDNA replication as this protocol does not 
require the use of harsh chemicals and temperature for antigen retrieval (Haines et al., 2010a, 
Lentz et al., 2010). However, the HeLa cells in this study remained unaffected by the harsh 
chemicals, such as HCl, and the temperature used, further supporting the use of this analogue.  
 IdU incorporation into iPSCs and neurons 
The use of a thymidine analogues on iPSCs and neurons reprogrammed from a patient 
fibroblast was novel. Previous studies that have looked at mtDNA replication in neurons in 
vitro have used primary cultured neurons from animals (Magnusson et al., 2003, Haines et al., 
2010b, Calkins and Reddy, 2011).  
As high cell death was also observed in the iPSCs and neurons, the methodology could be 
improved. Since the concentration was optimised in HeLa, they could potentially tolerate the 
mechanical disruption more, and are more adherent to the surface compared to the iPSCs and 
neurons. Hence, the concentration of the IdU used might need to be further optimised for the 
iPSCs and neurons. This is one of the steps for future work. All the previous studies in vitro 
that have used thymidine analogues have used HeLa cells or primary cell cultures and for a 
shorter length of labelling time (Amiri and Hollenbeck, 2008, Bogenhagen and Clayton, 1977, 
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Calkins and Reddy, 2011, Davis and Clayton, 1996, Magnusson et al., 2003, Phillips et al., 
2017). Therefore, in these cases, the thymidine analogue might be tolerated due to this. 
Another limitation is the longer doubling time of the iPSCs compared to HeLa cells (Boisvert 
et al., 2011, Takahashi et al., 2007). Even during culture, HeLa cells would reach 70% 
confluency by 2 days whereas iPSCs take about 4 days. This longer doubling time could indicate 
that the mtDNA turnover is happening slower and hence the time point studies might also 
require further optimisation. Alongside this, differentiated neurons are not dividing; hence, 
this turnover could be even slower in neurons. This is supported by in vivo data that studied 
the half-life of mtDNA in various tissues of rat using isotope thymidine (Gross et al., 1969). It 
was discovered that mtDNA has a half-life of 31 days within the brain compared to 6.7 days in 
the heart and 9.4 days in the liver. This is also supported by an in vitro study looking at an 
undifferentiated embryonic carcinoma cell line (Wang et al., 1997). They demonstrated that 
ethidium bromide at concentrations that induced damage in the undifferentiated cells, could 
not damage the neuronal cells differentiated from the same cell line. They concluded that this 
is due to the slow turnover rate of mtDNA in neurons, which results in the ethidium bromide 
not being incorporated into the mtDNA. Such evidence suggests that the technique is still 
sensitive but the timing needs optimisation.  
 Future work 
The methods described in this chapter were carried forward to successfully label mtDNA 
replication and to examine the mtDNA replication levels and loci in multiple cell lines, however 
there are still ways in which this method could be improved. A few examples are listed below. 
• Signal enhancers such as biotin and streptavidin, tyramine signal amplification or 
Image-It FX could be used to enhance the weak mtDNA signals. This could also result 
in using a reduced concentration of IdU that might increase the cell viability in iPSCs. 
• Use digitonin prior to fixing cells. This is a detergent that solubilises the cell membrane 
as it binds to cholesterol and other β-hydroxysterols which are present in the plasma 
membrane, hence any non-specific incorporation into the cytoplasm will be removed 
with this was step (Smale, 2009). 
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• Optimise combined concentration of CldU and IdU after addition of aphidicolin. 
• Optimisation of IdU concentration on iPSCs and neurons. 
• To further test the methodology, cells with knock out Polγ could be used to observe if 
thymidine analogue is incorporated. Since is Polγ involved in both replication and 
repair, it should block total thymidine analogue incorporation.  
• TK2 knock out HeLa cells could be used to identify if the pattern of labelling is similar.  
• The cells could also be labelled with a different thymidine analogue such as BrdU or 
EdU to confirm the pattern of mtDNA labelling.  
 Final conclusion 
Although the methodology has been developed to study mtDNA replication in vitro, this 
requires further improvements as suggested in the above sections. Use of this methodology 
on iPSCs and neurons were novel. The staining technique optimised here was used in 













Chapter 5:  Chapter 5: Investigating the localisation of mtDNA replication in 
neurons: Implications for mtDNA deletion formation and accumulation. 
5.1 Introduction 
 Is there a preferential location for mtDNA replication in neurons?  
While studies observing mtDNA replication have shown this process can occur in axons, the 
majority of mtDNA replication has been suggested to occur within the cell body (Amadoro et 
al., 2014, Amiri and Hollenbeck, 2008, Calkins and Reddy, 2011). Since the metabolic needs of 
the neuron are not uniform (Wong-Riley, 1989), mtDNA replication occurs in the perinuclear 
region of the cell, with mitochondria then transported into various regions, as and when 
required (Davis and Clayton, 1996, Chang and Reynolds, 2006). Initially studies on HeLa cells 
showed increased mtDNA replication in the perinuclear region using BrdU staining, which with 
time became present within the cytoplasm (Davis and Clayton, 1996), suggesting that mtDNA 
is replicated near the nucleus, and mitochondria containing these mtDNA molecules are then 
transported to peripheral regions. Studies have also visualised mtDNA replication in the axons 
of cultured primary neurons, however, this occurred at lower levels compared to the cell body 
(Amiri and Hollenbeck, 2008, Lentz et al., 2010, Calkins and Reddy, 2011). In fact 32.92% of 
cell body mitochondria showed BrdU incorporation, compared to only 0.22% of neuritic 
mitochondria (Calkins and Reddy, 2011). This perinuclear hotspot for replication is further 
supported by the fact that mtDNA replication depends on a number of proteins transcribed 
from the nucleus such as twinkle and Polγ (Young and Copeland, 2016). This is particularly 
important for neurons due to axon and dendrite length being a limiting factor for the 
interaction of nuclear encoded factors with distal mitochondria. Although studies have 
observed thymidine analogue labelling 2 hours after enucleation. Incorporation was possible 
since a full complement of nuclear encoded proteins would remain, as mRNA or protein 
turnover would take longer than 2 hours (Blomstrand and Hamberger, 1969, Koenig, 1958, 
Enríquez et al., 1996). Furthermore, PolyB has been found to be uniformly distributed within 
the cell body and neurites of differentiated SHSY-5Y cells (Magnusson et al., 2003). However, 
studies in SA15q-3 cells containing duplication of chromosome 15 (which encodes the catalytic 
subunit of Polγ) found that, despite an increase in Polγ protein expression, there was no 
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difference in mtDNA abundance. This demonstrated that the expression of Polγ is not 
associated with mtDNA abundance and suggests that it is not the rate-limiting factor in mtDNA 
replication (Schultz et al., 1998). This study also noted an abundance of mtSSB in the 
perinuclear region, supporting this as the location of mtDNA replication. MtSSB binds to the 
single strand template DNA during replication (section 1.5.1). Given the uniform localisation 
of PolγB (Magnusson et al., 2003) it could also be suggested that mtDNA replication may occur 
at multiple sites in the cell, although this does not oppose the cell body as a primary loci for 
mtDNA replication. However, PolγB is also required for the repair of mtDNA (section 1.5.1), 
hence the uniform localisation may reflect the repair of mtDNA in distal neurites and axons 
(Graziewicz et al., 2006). Studies have also shown the presence of ER within axons, which has 
the potential to translate proteins for mitochondrial biogenesis (Luarte et al., 2018). Alongside 
this, gene expression data has demonstrated that nuclear encoded mRNAs that target 
mitochondria were detected within the axons suggesting that mitochondrial proteins can be 
translated in distal axons (Willis et al., 2011, Spillane et al., 2013, Minis et al., 2014, Aschrafi 
et al., 2016, Shigeoka et al., 2018).  
The detection of thymidine analogues within axons, suggests perinuclear mtDNA replication 
followed by transport to distal regions of the neuron (Davis and Clayton, 1996, Calkins and 
Reddy, 2011). Thus, it is important to differentiate between mtDNA replication occurring at 
these two regions. While this is technically difficult to do, Amiri and Hollenbeck (Amiri and 
Hollenbeck, 2008) attempted to study this by separating the cell body from the axon via 
axotomy and suspension of transport in dorsal root ganglia neurons. This study showed that 
following both axotomy and transport suspension (via vinblastine treatment), mtDNA could 
be detected in distal axons in intact cells, 12% of axonal mitochondria showed BrdU 
incorporation which dropped to 4% of mitochondria in separated axons. In vinblastine treated 
cells, 25% of axonal mitochondria showed BrdU incorporation compared to 43% in untreated 
cells. This suggests that mtDNA biogenesis and replication was not limited to the cell body. 
However as mentioned before, this suggests that mtDNA replication can occur in distal 
regions, but not that this is the primary location for it, as it occurs at lower rate compared to 
the cell body.  
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 How is mtDNA replication affected by mtDNA damage? 
It is important to understand how the localisation of mtDNA replication and biogenesis 
changes in response to mtDNA damage and mutations, as neurons are post-mitotic and 
acquire these with age and in various diseases (section 1.6.5). Increased distal mtDNA 
replication was observed after 1 week of exposure to rotenone (1nM), however after 2 weeks, 
this increase was also present in cell bodies (Van Laar et al., 2018, Arnold et al., 2011). 
Conversely, damage induced by rotenone and H2O2 (25nM of both), was found to increase 
BrdU incorporation in the cell body, which was decreased in neurites compared to untreated 
controls (Calkins and Reddy, 2011). They also compared wild type mice to AβPP mice (model 
for AD by overexpressing the Aβ protein), which further demonstrated an increase in BrdU 
incorporation within the cell body of neurons, although there was a decrease in BrdU 
incorporation within neurites. This seemed to suggest that in the presence of stressors, there 
was a decrease in mtDNA replication in distal regions. This is contrary to the studies 
mentioned above. However it could be suggested that this is because the BrdU treatment 
lasted a maximum of 20 hours in the Calkins and Reddy study and lasted for up to 2 weeks in 
the previous study (Van Laar et al., 2018), therefore transport of mitochondria over time could 
affect the results.  
 Significance of this study 
Although still inconclusive, the majority of the studies mentioned above suggest that mtDNA 
replication within a neuron occurs perinuclearly or in the cell body, with data showing a 
decrease in BrdU incorporation with increasing distance from the nucleus (Calkins and Reddy, 
2011). This is also the same situation for mitochondria targeted for mitophagy, where data 
shows that such mitochondria are transported in a retrograde direction back into the cell body 
to be degraded (Sheng and Cai, 2012). Both replication and mitophagy could occur here due 
to the reliance of both of these processes on nuclear encoded factors. Based on this evidence, 
it could be suggested that the cell body is the primary location for mtDNA biogenesis and 
quality control of damaged mitochondria, suggesting that they both happen simultaneously 
and in close proximity to each other which could be beneficial in understanding mtDNA 
deletion formation. Due to this, it could be hypothesised that this increases the probability of 
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a damaged mtDNA potentially being replicated, and as a result, an increase in ΔmtDNA levels 
(figure 5.1). 
 
Figure 5.1 This figure presents the prime loci of mtDNA replication and mitochondrial degradation via mitophagy 
based on the current literature. Damaged mitochondria are targeted and transported in a retrograde direction 
back towards the nucleus, and cell body has been identified as the prime location of mtDNA replication suggesting 
that both processes happen in close proximity to each other. The transparent blue circle suggests the ‘hotspot’ 




 As discussed previously (section 1.6.5), neurons have a high energy demand and with ageing 
also show an increase in ΔmtDNA load. Since the formation of these deletions and their 
accumulation to high levels is still debated, it is important to identify any alterations in mtDNA 
replication that could explain the high levels of deletion observed. Subsequently different 
regions of the brain have varying levels of ΔmtDNAs (table 3.1 and 3.2), therefore it is 
important to understand how this perinuclear ‘hotspot’ could differ between different regions 
to investigate any relationship with ΔmtDNA. The study of mtDNA replication localisation in 
various regions of the brain is novel.  
This study aimed to understand the location of mtDNA replication in terms of distance from 
the nucleus. This would corroborate previous findings that suggest that the cell body is the 
primary loci for mtDNA replication, with minimal replication occurring in the distal regions of 
the neuron. CldU and IdU incorporation was used to quantify mtDNA replication in a 
transgenic mouse model with a mutation in Polγ (section 2.2.1) (Kujoth et al., 2005). 
Therefore, this model is an adequate model for studying the effect of mtDNA mutation on the 
location and rate of mtDNA replication. Using these four groups of mice; wildtype young, 
wildtype aged, PolgAmut/mut young and PolgAmut/mut aged provided information on how mtDNA 
replication loci change might change with advancing age and replication defects.  
5.2 Aim and objectives 
 Aim 
To identify the primary loci for mtDNA replication in neurons, in various brain regions, and to 
deduce how this is altered in the presence of mtDNA mutations and ageing.  
 Objectives  
The objectives of this study were; 
• To optimise analysis to identify mtDNA replication loci within a single cell 
• To compare mtDNA replication loci in different neuronal subtypes 
• To compare mtDNA replication loci between young and aged mice 
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• To compare mtDNA replication loci in neurons between WT and PolgAmut/mut ‘mutator’ 
mice 
5.3 Methods 
 In vivo analysis of mtDNA replication 
For details regarding the mice used, regions selected, confirmation of brain regions, 
identification of a specific subset of neurons via immunofluorescence, antibodies used, CldU/ 
IdU labelling in mice and visualisation via immunofluorescence and microscopy, refer to 
chapter 2 (section 2.2) and chapter 3 (section 3.2 and 3.3, table 3.3 and 3.5).  
 In vitro analysis of mtDNA replication 
For details regarding the cell line used, cell culture techniques, differentiation of stem cells 
into neurons, IdU labelling and visualisation via immunofluorescence and microscopy, refer to 
chapter 2 (section 2.3) and chapter 4 (section 4.2 and 4.3). 
 Analysis of mtDNA replication loci 
Confocal images were analysed in Image J (Fiji). The images were converted to a TIF format 
with a different image for each channel. The cell boundary based on the mitochondrial marker 
channel (tom20) was used to represent the cell area. The ‘straight’ line tool was used to draw 
a straight line through the cell (figure 5.2). If a straight line did not follow the trajectory of the 
neuron, multiple straight lines were drawn and presented as a single line. The spread of 
intensity for tom20 along each pixel of the line is produced as a histogram using the ‘plot 
profile’ function within the analyse option. The line drawn on the tom20 channel is then saved 
using the ‘ROI manager’ function in the ‘tools’ option of the ‘analyse’ option. This line is then 
added to the image for the Hoechst channel (nuclear marker) and IdU channel (mtDNA 
replication marker), and a spread of the intensity for each channel is produced using the ‘plot 
profile’ function. The values from the histogram are exported into Excel (Microsoft). The 
highest point of Hoechst intensity is then identified and this point is set as the middle of the 
cell or ‘0’ on the X axis (graph in Figure 5.2), which measures distance from the nucleus in 
pixels. This is because the highest point of Hoechst often produces a precise estimate of the 
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middle of the nucleus. In addition to this, the average diameter of the nucleus was obtained 
from these images and the final graphs were adjusted for this.  
The values of CldU and IdU are expressed as a ratio of the tom20 sign al to normalise the 
quantification of thymidine analogue incorporation. The spread of CldU or IdU values along 
the X axis or distance in pixel, in relation to the perinuclear region can then be identified.  
Multiple plot profiles were obtained from a total of at least 10 images from all the different 
mouse groups. The total number of neurons per region is presented in table 5. The number of 
neurons are different to chapter 3, as this study required identification of axons and dendrites 
which were not always visible in each analysed image.  
 
Age/Genotype Region Number of mice Number of neurons 
WY CER 4 12 
WY SN 2 11 
WY COR 4 31 
WY HIP 3 21 
PY CER 4 22 
PY SN 4 27 
PY COR 2 26 
PY HIP 1 21 
WO CER 4 14 
WO SN 3 27 
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WO COR 4 26 
WO HIP 4 21 
PO CER 4 16 
PO SN 3 27 
PO COR 4 28 
PO HIP 1 11 
Table 5.1 The total number of mice and neurons analysed per each age/genotype and region. 
 Classification of perinuclear and distal regions.  
Since the aim of this study was to understand the location of replication, it was important to 
classify the perinuclear and distal regions in order to quantitatively compare them. For this 
purpose, the radius of the nucleus for each group was measured and used to create a 
perinuclear region that starts from the value ‘0’, following on from this, any values 2 standard 
deviations from this was classified as distal (Figure 5.3). This was done to avoid any overlap 
between the regions and to truly make sure we were classifying two separate regions.  Due to 
its length, the full extent of the neuronal processes are generally not present within the same 
section as the cell body, therefore the ‘distal regions’ usually describes the initial lengths of 





Figure 5.2 Simplified cartoon of the analysis pipeline. A) This image presents a neuron, and as mentioned in section 5.2.3, 
a straight line is drawn through the cell (green line in cartoon, pink line in image). Using the plot profile function, this 
intensity of each pixel along this line, from each channel can be measure. The highest intensity of Hoechst is identified 
and set as the middle of the cell by setting that value as ‘0’ on the x axis which measures distance in pixels. The distance 
to the left side of the cell is identified with values from ‘-1’ onwards till the end of the line which is ‘-10’ in this case and 
vice versa, the right side of the cell is also identified with a value from ‘1’ until the end of the cell which is 25 in this case. 
B) Presents the method described in A but on one of the Purkinje cells used in this study. C) The graph produced from the 
histogram is represented on the X axis of the graph in the image. The tom20 and IdU intensity can also be measured 




 Statistical analysis 
Dr Conor Lawless (Wellcome Centre for Mitochondrial Research) undertook the statistical 
analysis. The perinuclear replication in vivo data was subjected to Loess smoothing (Jacoby, 
2000). This is because analysis yields a larger number of values for multiple profiles, hence a 
large amount of noise is produced, this smoothing function is used to reduce this noise. To 
analyse differences between the perinuclear and distal regions, the significant effects within 
the groups were analysed via ANOVA. This identifies any differences for a group, for example 
differences in CldU between the perinuclear and distal regions within each brain region. For 
each of the groups, a delta value was calculated by subtracting the median of the distal 
intensity of thymidine analogue values from their perinuclear counterpart for each neuron. 
This was performed for both CldU and IdU staining. Therefore the delta value measures the 
difference in perinuclear and distal cytoplasmic values for each genotype, age and brain region 
group. An equation for delta is presented in equation 5.1. Figure 5.4 presents an example of 
delta values calculated from four scenarios of CldU incorporation. The median was used as it 
Figure 5.3 Visual representation of the classification of the perinuclear and distal regions. This line presents a 
histogram as described in the previous figure. The nuclear radius is obtained and used to calculate a perinuclear 
region. 2 standard deviations (SD) away from this region is then calculated to give the area that will classified as 
distal. In doing so, this allowed quantification and comparison of the two regions. 
204 
 
correctly represents the range by catering for the high number of 0% in regions with a lack of 
thymidine analogue labelling.  
 
Significant effects between the groups (genotype, age and brain regions) were then 
determined using a Wilcoxon test, which compares data between the groups. This generated 
P-values that compared the median delta between the groups. These P-values were corrected 
using multiple testing to produce ‘Q-values’ which ultimately determined any significant 
differences between groups.  
Equation 5.1 Calculation of delta values 
 
Delta = (Average of perinuclear analogue signal)-(Average of distal analogue signal) 
Figure 5.4 Mock representation of delta calculation. This image presents four different scenarios of CldU 




 Distribution of thymidine analogues within single neurons 
Confocal images were obtained from four distinct brain regions, examining 3 specific neuronal 
types, namely Purkinje cells from the cerebellum, pyramidal cells from the frontal cortex and 
the CA1/CA2 region of the hippocampus, and dopaminergic neurons from the SN. After 
identification of neurons, the levels of CldU and IdU incorporation were measured following 
immunofluorescence (figure 5.5). The thymidine analogue staining was punctate and co-
localised with the mitochondrial marker, tom20. Detailed information on the choice of 
neurons is explained in section 3.4.1.  
At least 10 images containing multiple neurons (approximately 2-4) were analysed each brain 
region (figure 5.6 and 5.7 (including the number of neurons analysed), from the four 
experimental mouse groups which varied by age and genotype. The distribution of CldU and 
IdU labelling within these neurons is presented in Figure 5.6 (CldU) and 5.7 (IdU). The blue 
dotted lines differentiate the nuclear region from the distal regions based on the nuclear 
radius. CldU staining (figure 5.6) highlights that in the majority of the cases, there is an 
increased signal in the perinuclear region that reduces with distance from the nucleus. 
However, in the case of IdU (figure 5.7), no such pattern was observed. This could be due to 
low levels of incorporation of this analogue, into a small proportion of the neuronal 
populations, due to the shorter period of labelling (15 hours). It is also important to note that 
none of the CldU or IdU staining was noticed as being co-localised with the nucleus; hence the 
higher signal in the perinuclear region is not due to this. To statistically compare between the 
perinuclear and distal regions, the raw data from figures 5.6 and 5.7 was reclassified as 
described in section 5.3.4.  This was necessary to account for any variation due to difference 
in sizes of the neurons. Therefore, classification of the cell into perinuclear and distal regions 
is vital and allows the values to be averaged to find a median value, allowing quantification 
and comparison of the perinuclear region to the distal regions. To further analyse the 
replication pattern between brain regions, ages and genotypes, using a single value for each 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Site of mtDNA replication within single neurons 
A median value was calculated for each neuron from the perinuclear and distal regions to 
compare mtDNA replication between the brain regions for each mouse group studied (figure 
5.8). This demonstrated a significant increase in perinuclear incorporation of CldU, compared 
to the distal regions, in most cases (p<0.05), with the exception of wildtype young cerebellum 
and PolgAmut/mut old hippocampus. The lack of significance in these regions could be due to 
the low number of neurons studied (figure 5.6) due to lack of neurons and neurites visible in 
a section.  
In the case of IdU, the pattern of results showed more variability. A general pattern of a 
decrease in IdU signal within the perinuclear region was observed for the majority of regions 
when compared to the distal region. However this did not reach significance (p<0.05) in 
wildtype young cerebellum and hippocampus, wildtype aged cortex and hippocampus, 
PolgAmut/mut young cortex and PolgAmut/mut old cortex and SN. The only case with a significant 
decrease (p<0.05) in IdU levels in the distal regions compared to the perinuclear region was 
wildtype aged SN. This is interesting due to the high levels of deletion observed in this region 
in humans (tables.3.2 and 3.3) 
These differences in CldU and IdU pattern could be due to the labelling times used. CldU had 
been injected into the mice for 4 days, hence it represents total mtDNA CldU incorporation 
over this time. However IdU injection is conducted ~15 hours prior to death and hence, 
represent only the mtDNA incorporation that has occurred within this much shorter period. 
Although the timing is different, this is in concurrence with previous literature that 
demonstrated an increase in distal mtDNA replication one week after induced damaged, 
however, after two weeks, mtDNA replication was determined to have increased in the 

























Figure 5.8 Differences between CldU and IdU incorporation into perinuclear and distal regions in vivo. Image A presents 
CldU and B presents IdU.  The histograms were split into perinuclear and distal regions based on the nuclear radius. CER 
represents cerebellum, COR represents cortex, HIP represents hippocampus, SN represents Substantia nigra, PO 
represents PolgAmut/mut old, PY represents PolgAmut/mut young, WO represents wild type old, WY represents wild type 
young. The N is at least 10 neurons for case and the median plotted +/- SD. Wilcoxon test was used to identify significant 




 Variations in delta values between neuronal subtypes 
To compare the various brain regions, ages and genotypes, delta values were calculated giving 
a single value for each cell that could be analysed statistically (section 5.2.5, figure 5.3). Delta 
values calculate the difference between perinuclear and distal thymidine analogue signal, with 
a higher delta highlighting increased perinuclear incorporation. When comparing between the 
different neuronal subtypes, a general pattern observed for the CldU data (figure 5.9A) was 
increased delta values in the cerebellum with the lowest value for the SN. This pattern was 
consistent between all the mice groups used, although there were no significant differences 
(p<0.05) detected between brain regions, except between the cerebellum and the SN in the 
young PolgAmut/mut cohort. Therefore it can be suggested that the location of CldU 
incorporation does not differ between neuronal subtypes. However, the data suggests that in 
the cerebellum of young PolgAmut/mut mice, there is more perinuclear mtDNA replication than 
in the SN. Although not, significantly different, this pattern is also observed in the other mice 
groups, however to confirm, further investigations are required.  
In the case of IdU (figure 5.9B), the general pattern was that the lowest delta value was 
detected in the cerebellum and the highest in the SN, the opposite pattern to the CldU data. 
The majority of the cases were not significant, however the cerebellum had significantly 
decreased delta values compared to the other regions (p<0.05) in aged wildtype mice, young 
PolgAmut/mut mice and aged PolgAmut/mut mice. This suggests that the delta difference in the 
cerebellum is affected by ageing or replication defects, which will be discussed in the following 
section (section 5.4.4). This suggests that, due to the lower delta values, that the cerebellum, 
compared to the other regions, has an increased level of IdU signal in the distal mtDNA. This 
is particularly interesting when considering the previous literature, where a number of studies 
have identified the lowest number of ΔmtDNAs in the cerebellum compared to the other 
regions in mice and humans (refer to table 3.1 and 3.2). 
 Variations in delta values, the effect of age and a replication defect 
As significant differences were not detected, it could be concluded that age and replication 
defect do not affect mtDNA replication localisation, however patterns in the data could be 
observed between groups. With ageing and a replication defect, increased ΔmtDNA levels are 
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generally observed (table 3.1 and 3.2), the site of mtDNA replication between these groups 
were also compared (figure 5.9). With age, a pattern of increase in CldU and IdU delta was 
observed for all brain regions studied in the wild type mice (not significant). This suggests that 
with ageing, the site of mtDNA replication could shifts to the perinuclear region. However, 
these changes were not significantly different.  
When a replication defect is considered, an overall increase in CldU and IdU delta was also 
observed in the PolgAmut/mut mice compared to the wildtype. This also suggests that in 
PolgAmut/mut mice compared to the wildtype, there is an shift to perinuclear mtDNA replication. 
However, when PolgAmut/mut young mice are compared to PolgAmut/mut aged mice, there was a 
observed decrease in CldU and IdU delta in aged mice compared to young. This could suggest 
altered mtDNA replication localisation between healthy ageing and the PolgAmut/mut mice, 
However, these patterns are not statistically significant (p<0.05), therefore no firm 
conclusions can be drawn, although, a significant decrease (p<0.05) in delta was observed 


























































































































































































































































































































































































































































 Preliminary data – mtDNA replication site within neurons in vitro 
To further understand the influence of ΔmtDNA levels on the site of mtDNA replication, 
preliminary work was undertaken in cultured cells. The thymidine analogue labelling was 
optimised for cultured cells (as described in chapter 4), and differentiated neurons containing 
varying levels of heteroplasmy was used. Using cultured cells is also beneficial in identifying 
distal neurites further away from the cell soma, which are not necessarily observable in tissue. 
This allowed more accuracy regarding the distal region. As with the CldU data in vivo, a 
significant increase (p<0.05) in thymidine analogue incorporation was observed between the 
perinuclear region compared to the distal region (figure 5.10A).  
Since a high and low heteroplasmy cell lines were used the influence of ΔmtDNA on the site 
of mtDNA replication could be understood. Since these cell lines are isogenic controls, any 
differences are less likely to be due to other variables. The delta values demonstrated that 
there was no difference between the delta values with varying ΔmtDNA levels (figure 5.10B). 
















Figure 5.10 IdU incorporation in vitro. The data was split into perinuclear and distal regions based on the nuclear 
radius in the low and high heteroplasmy neurons.  Image A demonstrates the difference between the perinuclear 
and distal regions and image B demonstrated the delta values to compared the cell lines. The N is 107 for low 
heteroplasmy cells and 83 for high heteroplasmy cells  *** indicates p < 0.001 obtained using t-test.. 
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 Preliminary data – Detection of the site of mitophagy 
Since variation in delta values was observed between the different brain regions, suggesting 
variations in the location of mtDNA replication, it was important to study where mitophagy 
occurred. This would be beneficial in understanding not only the loci of mitophagy but also if 
this is related to the loci of mtDNA replication. Therefore, as a preliminary step, this study 
aimed to develop a method to analyse  the location of mitophagy in images from brain regions 
in the mitoQC mice (McWilliams et al., 2016). The images were a kind gift from Dr Ian Ganley 
(University of Dundee). The images (Figure 5.11) were analysed using Image J as described in 
section 5.2.3. Since the obtained images did not contain a nuclear marker, the analysis had to 
be modified. The nuclear region was identified by the region that lacked the anti-TH antibody 
and since the highest intensity was not visible, this anti-TH region was considered the 
perinuclear region. Data from an average of 33 cells from dopaminergic neurons of 2 wild type 
mice was collected and the difference in perinuclear and distal region calculated (figure 5.12). 
In concordance with the previous literature, although mitophagy did occur in distal regions, 
the perinuclear region had an increased level of mitophagy as observed via mCherry intensity. 
Since this was a preliminary study, there was no other region for accurate comparison, which 

















































































































































































































































































































































































































Figure 5.12 Localisation of mitophagic events in dopaminergic 
neurons from MitoQC mice. The spread of the bright mCherry spots 
were measured along the distance from the nucleus, and based on 
the nuclear radius, the values were separated into perinuclear and 
distal regions and the averages are presented here. N=33 neurons 




 Key results  
• In vivo CldU (4 days) shows increased perinuclear replication; however, IdU labelling 
(~15 hours) demonstrated variations. 
• No significant differences were noticed in delta values between brain regions for CldU 
in most groups, however significant differences were noticed in delta values between 
the cerebellum and the other regions for IdU. 
• Neither ageing nor the presence of a defective mtDNA polymerase altered the location 
of mtDNA replication, as measured with either CldU or IdU incorporation. 
• Preliminary in vitro study demonstrated no significant difference in delta between cell 
lines with high and low ΔmtDNA levels. 
• Preliminary mitophagy study demonstrated an increased signal intensity in the 
perinuclear region in dopaminergic neurons. 
 MtDNA replication occurs primarily in the perinuclear region  
In the in vivo study, with CldU, a significant increase in analogue signal and therefore mtDNA 
replication was observed in the perinuclear regions of neurons. This could suggest that, 
mtDNA replication is more abundant within the perinuclear region compared to the distal, 
when analogue presence is maintained over a long time frame (4 days). As mentioned in the 
introduction (section 5.1.1), distal regions did contain positive signals for mtDNA replication, 
however perinuclear regions had a significantly higher signal. This is in concordance with the 
previous literature (Amiri and Hollenbeck, 2008, Calkins and Reddy, 2011, Davis and Clayton, 
1996, Magnusson et al., 2003). For IdU, there was either no difference between the regions 
or a significant increase of IdU signal, and therefore mtDNA replication within the distal 
regions. This significant increase is only present in 8 out of the 16 cases trialled. These 8 cases 
were in different regions in different cohorts, therefore there appeared to be no pattern to 
these data. Although IdU produced different data to the CldU, this was also observed in 
previous literature when comparing between two time points. The study by Van Laar used 
two separate time points similar to this study. They also induced damage via rotenone and 
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noticed that at the shorted time point, the thymidine analogue was increased in the distal 
region compared to control, however with the longer time point, this was increased in the 
perinuclear region (Van Laar et al., 2018). They suggested that the rotenone damage led to 
axonal loss and therefore the mtDNA replication in distal regions was subsequently effected. 
However, in this study, no such difference was observed. Alongside this, another study using 
primary neuronal cultures demonstrated that between two time points of 4 hours and 20 
hours, there was no difference in mtDNA replication localisation (Calkins and Reddy, 2011). At 
both time points, mtDNA replication was higher in the cell body compared to the neurites. 
These differences could be due to the variable time points studied.  
The difference between CldU and IdU could suggest a time dependent variation in location, it 
could be considered that initially mtDNA replication occurs equally in the perinuclear and 
distal regions or in the distal region in some cases, however with time, these replicated mtDNA 
accumulate within the perinuclear region.  
Although the IdU data demonstrated inconsistencies, the CldU data demonstrated a 
significant increase in the perinuclear region. Therefore, to identify whether mitophagy also 
occurs in the same vicinity, mitoQC mice were used as part of a preliminary study (further 
detailed in section 5.4.5). After analysing dopaminergic neurons from three mice, the data 
demonstrated a significant increase (p<0.05) in basal mitophagy in the perinuclear region 
compared to the distal. This suggests that mtDNA replication and mitophagy could occur in 
the vicinity of each other further increasing the chances of a damaged mtDNA molecule being 
replicated. This has implications for ΔmtDNA formation and clonal expansion. Therefore, this 
preliminary study needs to be expanded to further study mitophagy in different regions of the 
brain. It is also important to consider the selection process of the template mtDNA for 
replication. Previous studies have demonstrated that the mtDNA template for replication is 
chosen randomly (Davis and Clayton, 1996). To study this, co-staining of damaged 
mitochondria and replicating mitochondria could be conducted, which would identify whether 
the two factors would co-localise. This could also be part of the future work of this study.  
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 The site of MtDNA replication does not alter with variations in ΔmtDNA levels 
Although the CldU and IdU data displayed variations between the perinuclear and distal 
regions, it was important to compare how the site of mtDNA replication is related to ΔmtDNA 
levels, to understand how mtDNA replication might be involved in this process. Therefore, the 
site of mtDNA replication was compared between different brain regions in aged, and 
PolgAmut/mut mice compared to the wildtype, as these generally present with varying levels of 
ΔmtDNA (table 3.1 and 3.2). In order to accurately compare the site of replication, delta values 
were calculated. These values provide a value based on the direction of change and the degree 
of change. By doing this, I successfully developed a method that allows comparison of how 
the site of replication changes in different cases.  
The results demonstrated no significant difference between the different regions of the brain 
or between aged and PolgAmut/mut mice compared to the wildtype. This suggests that mtDNA 
replication location does not have a correlation with the levels of ΔmtDNA. This is not in 
agreement with previous literature as a previous study using wildtype and AD mouse models 
(Calkins and Reddy, 2011), demonstrated that the site of mtDNA did alter between these mice. 
The location of mtDNA was also measured after damage induced by H2O2 and rotenone. This 
demonstrated that in cases with potentially higher mtDNA mutations mtDNA replication in 
distal regions is decreased, and increased in the perinuclear region. If delta values were 
calculated in these studies, I would predict that the group with mitochondrial damage would 
have significantly higher delta values than the wildtype mice. Although in this study, no 
significant differences were observed; the pattern of the data suggested an increase of delta 
values in regions typically associated with higher ΔmtDNA. For example, in both CldU and IdU, 
there is a slight increase in the delta value in the wildtype aged mice compared to the wildtype 
young which suggests more perinuclear and less distal mtDNA replication with ageing. This 
increase in delta was also observed in PolgAmut/mut mice compared to wildtype, and when 
comparing between the different brain regions. This pattern was not observed when 
comparing CldU in the different brain regions of PolgAmut/mut aged mice compared to 
PolgAmut/mut young mice  (figure 5.9A). Both these groups demonstrated the highest delta 
value in the cerebellum, which is associated with the lowest levels of ΔmtDNA.  
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The preliminary data from the in vitro study using cell lines of varying ΔmtDNA levels also 
demonstrated no significant difference in the delta values further supporting the in vivo data. 
A benefit to using in vitro neurons was the identification of neurites. This is particularly visible 
when considering the difference in X-axis values between the in vivo data where the distance 
in nucleus ranged from -150 to 100 while for the in vitro data, this ranges from -400 to 400. 
Since they were both imaged at the same magnification, and since the size of the cell body is 
not extensively variable, this suggests that the in vitro study was successful in capturing distal 
axonal regions. Therefore, the lack of significant difference in the delta values might be more 
reliable. However, this is preliminary and more replicates at various time points would further 
support these data.  
 Limitations of the study 
One limitation of this study is the definition of perinuclear and distal regions. As mentioned in 
section 5.4.2, within the in vivo tissue, distal regions of the cells are technically difficult to 
identify. Therefore the distal regions are more appropriately the distal regions of the cell body 
and the start of the axons and dendrites rather than distal axons, this would benefit from 
further modifications to the technique and analysis. Other techniques such as CLARITY could 
be used, where staining of sections with thickness of 200µm can be conducted (Morawski et 
al., 2018). This would allow identification of soma and axons appropriately and produce 
accurate results.  
Another limitation is the use of a line in image J to access the change in mtDNA replication 
with distance. Since mtDNA replication can occur in any loci of the cell, possible CldU or idU 
positive puncta might be neglected, as it does not fall in the trajectory of the line manually 
drawn. Introduction of an area larger than a line, e.g. a rectangle along the trajectory of the 
cell, would introduce another variable, the area of the rectangle. Alongside this, image J does 
not have the function to calculate distance along a rectangle.  Previous studies have opted to 
measure the spread of thymidine analogue labelling by classifying into categories based on 
the distance (Amiri and Hollenbeck, 2008, Magnusson et al., 2003).However this was done in 
in-vitro cells, and tissue contains more background which would decrease the reliability.  
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A further suggestion is that the thymidine analogue signal could be recognised as damage by 
the cells, and hence mtDNA molecules harbouring these analogues are transported to the 
perinuclear region over time for degradation or repair. This might suggest that replication 
occurs in all regions of the cell and the CldU data is due to thymidine analogue toxicity. As 
mentioned in section 4.1.1 (chapter 4), thymidine analogues could be considered as toxic at 
high levels. Other thymidine analogues, although structurally different to CldU and IdU, are 
used for antiretroviral treatment of HIV/AIDS patients and have been noticed to increase ROS 
production and mtDNA mutations (Kline et al., 2009, Stankov et al., 2013). Therefore further 
investigation would need to consider the effect of these analogues on mitochondrial 
dysfunction and mtDNA mutations. This also links to the previous theory of increased mtDNA 
repair in the perinuclear region, but these mtDNA molecules could also be targeted for 
mitophagy, which occurs predominantly in the perinuclear region, as suggested in section 
5.1.2.  
 Future work 
• One of the limitations of the analysis in vivo was the lack of axons identified. This could 
be repeated using Z-stacks of the sections captured by confocal microscopy. If this 
technique is not sufficient to identify axons, CLARITY could be used which can label 
sections up to 500µm in thickness and has been optimised with the Wellcome Centre 
(Phillips et al., 2016). 
• The in vitro work (section 5.4.5) would requires repeating. In addition to this, since 
high and low heteroplasmy neurons dependent on glycolysis for ATP production 
(Russell et al., 2018), substituting glucose with galactose, would force the cells to rely 
on the OXPHOS system, which might more accuratly predict any effect on mtDNA 
replication. Other methods of inducing mitochondrial dysfunction such as treatments 
with H2O2 or rotenone could also be useful for this purpose (Calkins and Reddy, 2011, 
Van Laar et al., 2018).  
• An increased number of time points, and longer time periods could be used to identify 
any differences in delta in vitro.  
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• Study mitochondrial motility between the different brain regions to consolidate the 
theory of increased transport. This is due to the differences in replication localisation 
pattern observed between the 15 hours (IdU) and 4 days (CldU). 
• Obtain mitophagy localisation data from the hippocampus, cerebellum and cortex of 
the mitoQC mice, stain for a nuclear marker and analyse in comparison to different 
brain regions to study how mitophagy could effevt this process.  
 Final conclusion 
Initially in the introduction (section 5.1.5), a theory of a replication ‘hotspot’ was discussed 
where the perinuclear region was identified as a region with high levels of mtDNA replication 
and mitophagy. By using CldU labelling (over 4 days), the majority of mtDNA replication was 
identified as being perinuclear. Studies on dopaminergic neurons from the MitoQC mice also 
observed higher levels of mitophagy in this region. Even though both data sets warrant further 
investigation, this is in support of a ‘hotspot’ region. This suggests that localisation of damaged 
mitochondria, mitophagy and mtDNA replication, are all present or occurring in close 
proximity to each other due to their dependence on nuclear factors. Therefore, it could be 
suggest that ΔmtDNA, present within damaged mitochondria, has an increased probability of 
being replicated, leading to the accumulation of ΔmtDNA with age.  However the IdU data did 
not correspond to this. A variation from this ‘hotspot’, with more distal mtDNA replication was 
also observed suggesting that this is not involved in progression of mitochondrial dysfunction 
or mtDNA damage. Other process that could be involved in this such as mtDNA transport 
needs to be analysed to further understand this difference.  
The delta calculation was developed to analyse between datasets as differences in mtDNA is 
observed between the brain regions and groups. There were significant differences noticed 
between the cerebellum and the other brain regions, and could possible suggest a 
compensatory mechanism in this region that leads to the lower ΔmtDNA. However, this 
requires further investigations. Alongside, there are no significant differences between the 
other regions, ageing or genotype, therefore it could be suggested that mtDNA replication 
localisation is not associated with the ΔmtDNA levels observed. However, patterns of variation 
were noticed between brain regions, ages and genotype, therefore a higher n number of 
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neurons and mice might increase the statistical power and highlight further significant 
differences. Variations between the two time points used in the in vivo study also suggests 
that maybe replication localisation could differ with time, however the in vitro data produced 
















Chapter 6:  Proof of concept study investigating the ultrastructure of 
mitochondria in dopaminergic neurons; implications for neurodegeneration 
6.1 Introduction  
 Electron microscopy advances 
Initially, electron microscopy (EM) was used to understand the basic structure of mitochondria 
(Palade, 1953). Due to the high resolution providing significant detail, this technique remains 
unparalleled for understanding mitochondrial structure. Initial techniques such as 
transmission electron microscopy (TEM) and scanning electron microscopy (SEM) can be used 
to analyse morphology and ultra-structures in a 2D format. However, since mitochondria are 
not isolated entities, but form complex reticular networks that are impossible to image in 2D, 
better techniques are required for studying mitochondria as 3D structures.  Due to this, a 
number of studies transitioned to using other technologies such as confocal microscopy with 
Z-stacking (Glancy et al., 2015, de Brito and Scorrano, 2008, Song et al., 2008). Although this 
does not provide the resolution offered by EM to study nanoscale structures, this in fact did 
allow the study of mitochondria in a 3D format.  
However, recent advances in EM have enabled 3D visualisation of minuscule structures, which 
allows the study of mitochondrial structure in a more dynamic way, taking into account their 
3D structure. Initially, these studies were performed using a technique called serial section 
transmission electron microscopy (ssTEM) where ultra-thin sections were manually sliced and 
imaged individually using TEM (Bang and Bang, 1957). Another technique employed was 
focused ion beam milling scanning electron microscopy (FIM-SEM) (Escovitz et al., 1975). This 
is a type of Focused ion beam-SEM (FIB-EM) and although this paper developed a method of 
high resolution image capturing, it was not used for 3D image analysis until later (Uchic et al., 
2006). Compared to the ssSEM, this is a more automated process. This uses two types of 
focused ion beam; low beam and high beam. Low beam is used to image the samples via the 
SEM, and high beam is then used to slices the section, which is them imaged again at the low 
beam. Both ssTEM and FIB-SEM are currently used and the studies using these techniques will 
be discussed in the forthcoming section (Rodriguez-Moreno et al., 2017, Fischer et al., 2018). 
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A disadvantage of these techniques is that with ssTEM, there is the lack of automation and 
FIB-SEM can only use smaller volumes of samples for imaging.  However, over the years, better 
techniques requiring less manual work and time, alongside with the ability to analyse large 
samples, have been developed (McEwen and Marko, 2001).  
The technique employed for this thesis is called serial block-face SEM (SBF-SEM) (Denk and 
Horstmann, 2004). SBF-SEM is described in detail in section 2.4.3 of this thesis. Briefly, this 
technique utilises a scanning electron microscope and a microtome. Initially, the sample is 
placed on the microtome, and an electron beam is used to scan the section and the 
backscatter is collected by a detector to produce an image. The microtome contains a 
diamond knife, which can be used to slice ultrathin sections of down to 25nm in thickness 
(Pfeifer et al., 2015). When the section is removed, the electron beam is illuminated again to 
produce a second image before the tissue is sectioned and imaged again. This process can 
continue sequentially and essentially produces a Z-stack of the images at a high resolution not 
offered by other microscopes. This will allow reconstruction of miniscule nanoscale structures 
including mitochondria, offering analysis of parameters such as mitochondrial volume, 
complexity or surface area that is not possible by 2D TEM (Eustaquio et al., 2018). This ability 
makes this technique vital for research investigating mitochondrial structural changes in 
response to various factors including age or neurodegeneration.   
 Significance of this study  
Understanding the 3D structure of mitochondria is very beneficial for the progression of 
research. A recent study conducted using SBF-SEM has demonstrated that there are variations 
in the mitochondrial network in the skeletal muscle fibres, which were not noticed before in 
the previous literature using 2D (Vincent et al., 2018). This highlights the importance of 
studying the ultrastructure of mitochondria in a 3D format, and identifying any difference in 
ageing and neurodegeneration.  
As discussed in the previous chapters, brain, similar to skeletal muscle, contains post mitotic 
cells which have been shown to have high levels of ΔmtDNA which are particularly prominent 
in the SN (Bender et al., 2006c, Kraytsberg et al., 2006b). Previous chapter in this thesis also 
discusses the formation and accumulation of these ΔmtDNA. The condition of the 3D 
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mitochondrial network could be a major factor in the accumulation of ΔmtDNA. This is 
because the fusion of mitochondria could lead to sharing of the contents between 
mitochondria. Therefore, a highly connected network could potentially present with an 
advantage in sharing these ΔmtDNA molecules which could beneficial for the accumulation of 
a mutated mtDNA species or for compensating for the mutation and therefore, cell survival. 
Due to this, it is vital to study the mitochondrial network in vivo.  
It is also important to understand if the ultrastructure of mitochondria changes under disease 
conditions, and if yes, how it is altered. Interrogation of these changes will provide more clarity 
with regards to the formation and accumulation of mtDNA deletions. In the previously 
mentioned study on human skeletal muscle study, mitochondria from three related 
individuals with the same m.8344A>G mutation presented differences in mitochondrial 
complexities based on the heteroplasmy of their mutation (Vincent, 2017). In a patient with 
low levels of heteroplasmy (~40%), increased mitochondrial connectivity was observed 
compared to control. When heteroplasmy was increased to ~63% and 97% in 2 other patients, 
the mitochondrial network appeared more fragmented than in controls. This suggested that 
in patients with the same mutation, mitochondrial complexity could potentially influence 
heteroplasmy, or vice versa, further suggesting a role in mtDNA mutation accumulation. Since, 
similar to skeletal muscle, neurons are also post-mitotic cells, and an accumulation in mtDNA 
deletions is observed in substantia nigra neurons (refer to table 3.1 and 3.2 for more details), 
the ability to study mitochondrial connectivity in the neurons may provide crucial information. 
This is a new area of research with a limited number of studies attributed to it (Park et al., 
2013, Tamada et al., 2017), and none of them have been conducted on human brain tissue. 
However, ssTEM has been performed in human brain tissue from control and individuals with 
Alzheimer’s disease (AD), which led to the model of ‘mitochondria on a string’ (MOAS) (Zhang 
et al., 2016). This model will be discussed in more detail in section 6.4.7. 
Another study has utilised FIB-SEM to study neuronal mitochondria (Tamada et al., 2017). This 
study used a DRP1 (mitochondrial fission protein) KO mouse, which demonstrated an increase 
in ‘enlarged’ mitochondria. Mitochondrion that have increased in size were also observed in 
a Drosophila melanogaster model of AD using FIM-SEM (Park et al., 2013).  
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The only study that has utilised SBF-SEM to study neuronal mitochondria was conducted in 
rats (Eustaquio et al., 2018). This study aimed to understand overall mitochondrial 
morphology in untreated control neurons and neurons treated with Ketamine, an inducer of 
apoptosis at high concentrations. This study also used TEM, which demonstrated ‘swelling’ of 
the mitochondria. This was also confirmed by SBF-SEM; however, this technique was also 
beneficial in identifying an increase in mitochondrial fragmentation, suggested to be due to 
mitochondrial fission, which could not be deduced from TEM.  
Due to the lack of available literature and the variation in the mitochondrial network observed 
in skeletal muscle between control and patients, it is necessary to understand how this feature 
of the mitochondria is effected in another post-mitotic tissue, which also shows increased 
mtDNA deletion load. By gathering data on the characteristics of the mitochondrial network 
in these cells inferences may be made (in a similar way to those in the muscle) as to how 
mitochondrial connectivity may lead to the accumulation of these mutations. In chapter 3, I 
have described how mitochondrial replication changes between different neuronal 
populations and the impact of these changes on the mutations we detect in the SN and so the 
study described here will add further information to complement these studies.  
Another novelty of the study detailed here is the comparison between perinuclear and distal 
region mitochondria in human dopaminergic neurons.  A similar study in ground squirrels and 
rats, have identified that mitochondria in the perinuclear region appear more connected, 
compared to axonal mitochondria that are fragmented and <3µM in length (Popov et al., 
2005). This can be looked in relation to the previous chapter of this thesis, which studied the 
mtDNA replication using thymidine analogue labelling in perinuclear and distal regions of the 
neuron.  
Although previous chapters focused SN with ageing and PD, in this chapter the focus is more 
on AD and DLB. This is due to the availability of fresh tissue. However, this is justified as AD 
and DLB are also age related neurodegenerative diseases and this thesis concentrates on 
mtDNA deletions, which is also found in patients with AD and DLB (Chinnery et al., 2001, 
Krishnan et al., 2012, Mawrin et al., 2004, Phillips et al., 2014). 
230 
 
6.2 Aim and objectives 
 Aim 
To provide a proof of concept study to understand whether SBF-SEM can be utilised to study 
mitochondrial complexity in 3D in single human substantia nigra neurons, and to understand 
if this changes in disease.   
 Objectives  
The following objectives were fulfilled in this study; 
• Identify a suitable methodology to image and analyse mitochondrial parameters 
• Provide proof of principle data on how the mitochondrial network is altered in disease 
conditions.  
• Provide proof of principle data to identify any alterations in mitochondrial morphology 
and connectivity in perinuclear and distal regions in dopaminergic neurons.  
6.3 Methods 
 Patient Cohort 










Cognitively normal control - 












secondary to COPD 
16 6.43 
C3 
81 F Metastatic liver cancer 19 6.09 NA 
87 F AD  21 6.35 NA 






79 M DLB  12 6.57 P3 
Table 6.1 List and details of individuals used for this study.  The pathology section describes the disease conditions 
present within the patient and for the controls the cause of death. AD indicates Alzheimer’s disease, DLB indicates 
Dementia with Lewy bodies. The PM delay is the time taken to remove the Substantia Nigra following the death 
of the patient. The pH of the sample before fixing is indicated. The case number given to the individual for the 
purpose of this study is indicated in the column ‘case’. NA in this column indicates that this sample was 
unavailable for analysis due to its quality. Certain individuals have two cases number because two different 
neurons were processed and analysed from the same individual, which were compared separately. The length of 
fixation represents the amount of time the tissue was present in the fixative. 
 Sample collection and preparation 
Substantia Nigra samples from human brain were collected and fixed by Dr Chris Morris 
(Medical Toxicology Centre, Newcastle University). The list of cases used, age, gender, any 
associated pathology, and the pH of the buffer are all detailed out in table 6.1. The tissue was 
fixed in 4% PFA +2.5%  EM grade glutaraldehyde in sodium cacodylate buffer at 4oC until 
processed for electron microscopy. The post mortem (PM) delay for each sample is listed 
alongside the sample list in chapter 6. This indicates the time after death where the tissue was 
removed and fixed. The processing of the samples, imaging using transmission electron 
microscopy (TEM) and serial block face sectioning/ scanning electron microscopy (SBF-SEM) 
was done by Dr Kathryn White and Tracey Davey at Electron Microscopy Research Services 
(EMRS) at Newcastle University. 
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 Transmission electron microscopy (TEM) 
TEM was conducted to identify dopaminergic neurons prior to SBF-SEM and was performed 
by Dr Kathryn White and Tracey Davey at Electron Microscopy Research Services (EMRS) at 
Newcastle University. 
Initially, the quality of the samples were visualised prior to SBF-SEM using TEM. The quality is 
referring to the heavy metal staining, the morphology of the samples and the amount of 
artefacts in the samples. In some cases there were areas of the tissue missing within the 
neuron which would skew the analysis. This also allowed identification of dopaminergic 
neurons present within the tissue. Dopaminergic neurons were selected with the presence of 
neuromelanin, which is a dark pigment found within these neurons in humans. If the quality 
was not up to standard or if dopaminergic neurons are not found within the sections, a new 
section was taken from the sample and analysed using TEM again.  
For TEM, the samples were post-fixed in 1% osmium. This is for useful for preservation of the 
cell membrane as it reacts with the lipid bilayer and also provides contrast for EM imaging. 
The tissue was subjected to heavy metal staining protocol as described (Wernitznig et al., 
2016, Wilke et al., 2013, Cocks et al., 2018). The protocol involves penetration of the samples 
with a number of heavy metals as SBF-SEM imaging requires backscattered electrons, which 
can only occur if the tissue is electron dense. After the final heavy metal solution, the tissue is 
dehydrated using increasing concentration of acetone from 25% to 100%. The acetone was 
then replaced with increasing concentrations of 812 epoxy resin. The embedding was done in 
100% resin at 60OC for 48 hours. The sections were cut using an ultra-microtome at a thickness 
of 1 µM and stained with toluidine blue, which is a basic dye and stains acidic components 
such as nucleotides which can be visualised under a light microscope. This was used to identify 
the relevant areas and then ultrathin sections (70nm for this study) were cut using a diamond 
knife on a Leica EM UC7 ultra-microtome. Following this, the compression in the tissue is 
removed by stretching in chloroform and the section was picked up on Pioloform-filmed 
copper grids. The sections were imaged using the Philips CM100 TEM and images obtained 
using AMT CCD camera. 
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The region of interest was identified at a magnification of 1400x. The magnification is relatively 
low due to the size of dopaminergic neurons being around 20-25 µM within the samples. More 
detailed images were captured at 13500x. If the tissue was adequate, the tissue was then 
imaged using SBF-SEM technique. 
 Serial block face scanning electron microscopy (SBFSEM) 
This was conducted to obtain the 3D structure of mitochondria in individual neurons and 
again, was performed by Dr Kathryn White and Tracey Davey at Electron Microscopy Research 
Services (EMRS) at Newcastle University. 
The serial block face /scanning electron microscopy (SBF-SEM) technique has been described 
previously in the literature (Denk and Horstmann, 2004, Peddie and Collinson, 2014). The 
resin-embedded samples were glued onto a metal pin, trimmed to approximately 0.5 x 0.5mm 
and coated with gold. 
This technique provides a 3D model of the tissue using a Z-stack. This uses a Zeiss Sigma 
Scanning Electron Microscope incorporating the Gatan 3view, which is a microtome and a 
diamond knife inside the SEM chamber. An image is taken using an electron beam that scans 
the tissue block surface and the backscattered electrons are detected to produce the image. 
An ultrathin section (of 50nm for this study) is cut using the diamond knife, and another image 
is taken. The resolution of the images was 3000x3000 pixels or 3500x3500 pixels. These 
variations are due to the variations in size of individual neurons. This process of section, image, 
section, and image is repeated until the necessary depth is acquired to produce the Z-stack 
required.  For the purpose of this study, stacks of 150-300 images were collected.  A specific 
region of interest can be chosen, and based on the number of cells within a section, a 
maximum of 4 regions of interest were selected per section.  
 Analysis of the 3D structures 
The stack of tiff images were manually reconstructed in microscopy imaging browser (MIB) 
(Belevich et al., 2016). A guide to using this software has been published (Cocks et al., 2018). 
The resolution that was optimised and used allows visualisation of the cristae, through which 
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mitochondria are identified.  Mitochondria were randomly chosen from a single slice based 
on the proximity to nucleus. The Z-stack was then analysed to see if the mitochondrion is fully 
included within the stack. If it is not the case, the mitochondrion is discarded and another is 
chosen at random so that its structure is entirely contained within the Z-stack. The chosen 
mitochondrion is then manually traced on consecutive slices and reconstructed based on the 
3D slices in MIB. A total of 32 mitochondria from the perinuclear region and 32 from the distal 
regions were reconstructed producing a total of 64 mitochondria from an individual neuron. 
A larger number of mitochondria was available but was not analysed as this is a preliminary 
study. The definition of perinuclear and distal regions are as described in the previous chapter 
section 5.3.4. To identify these regions based on the distance from nucleus, the nucleus was 
also reconstructed. The images were exported to IMARIS 9 and AMIRA and the parameters of 
surface area and volume were obtain from both software allowing comparison between them. 
Using IMARIS to obtain these parameters has been described previously in this thesis (section 
2.2.7) and using AMIRA has been presented in the above mentioned study (Cocks et al., 2018). 
An additional parameter used to quantify mitochondria branching and connectivity was the 
mitochondrial complexity index (MCI). This parameter allows in depth analysis of the 
mitochondrial network. The equation used for this is presented in equation 6.1 and is has been 
previously developed and validated by Dr Amy Vincent (Wellcome centre for mitochondrial 
research, Newcastle University) (Vincent, 2017).  
 
Equation 6.1 The MCI equation used to calculate mitochondrial branching. The SA refers to the area of the surface 
and V refers to the volume of the surface. 
Equation 6.1 The MCI equation used to calculate mitochondrial branching. The SA refers to the area of the 




 Optimising methodology  
Due to the novelty of this study, optimisation of certain parameters were required. Small 
regions of the substantia nigra (SN) were collected from individuals and fixed by Dr 
Christopher Morris (Newcastle Brain Tissue Resource).  These specific neurons were targeted 
due to the large levels of ΔmtDNA deletions observed in this region, data I had collected in 
previous studies and their importance for Parkinson’s disease (Kraytsberg et al., 2006b, 
Bender et al., 2006c). A comparison of the levels of ΔmtDNA within different regions of the 
brain is also provided in tables 3.1 and 3.2.   Within the SN, dopaminergic neurons were 
distinguished from other neuronal populations by their size and the due to the presence of 
neuromelanin. Figure 6.1 presents an image of a neuron with and without neuromelanin.   
Since Dr Kathryn White and Tracey Davey at Electron Microscopy Research Services (EMRS) at 
Newcastle University, provided expert knowledge and vast amounts of experience in 
processing and imaging samples, the technique of SBF-SEM did not require any additional 


























































































































































































































































































































Following successful identification of dopaminergic neurons, the resolution had to be adjusted 
to correctly identify the whole neuron without compromising this resolution. This is because 
a higher resolution would require higher magnification, which would render the already big 
dataset, even bigger. This could cause computational problems. This study aimed to 
investigate the connectivity of the mitochondrial population within dopaminergic neurons, 
there was a need to be able to confirm the neuronal membrane to ensure analysed 
mitochondria were within this. Furthermore, as highlighted in figure 6.1, the dopaminergic 
neurons are large cells. A few different magnifications were trialled and a magnification of 
3000-3500x was set as the standard as it allowed visualization of the cristae within the 
mitochondria allowing appropriate identification of mitochondria, however, other smaller 
structures such as nucleoids could not be properly distinguished at this magnification. 
However, it did allow representation of the whole neuron. A range of 3000-3500x was used 
as a standard and the magnification was set individually for each case based on the size of the 
dopaminergic neurons.  
Previous studies on skeletal muscle identified a section thickness of 30-50nm (Cocks et al., 
2018, Vincent, 2017). Due to issues with the section variations at 30nm, the thickness of the 
section in this study was trialled at 50nm as it appropriately identified the same mitochondria 
in sequential stacks, and the end of a mitochondrial network was identified more accurately. 
SBF-SEM has the capacity to reduce section thickness to 25nM, however, a lower thickness is 
also associated with other technical difficulties such as the section not being properly sliced 
or removed by the microtome or sectional variation. 
The number of sections (depth of dataset) was then optimised for SBF-SEM. This feature also 
depended on the individual case and the size of the neuron. For this study, at least 100 
sections were used to identify the whole mitochondria. In this case, none of the stacks had a 
complete dopaminergic neuron cell body, again due to the size of this cell. Therefore a 
minimum of at least 100 sections are required for appropriate identification of the 
mitochondrial population. A range of sections from 100-200 per neuron was collected in this 
pilot study.  
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 Comparison between IMARIS 9 and AMIRA 
IMARIS was initially considered for use in this study for continuity reasons following on from 
previous chapters. However, a number of computational problems were encountered due to 
the size of the dataset. This could be a computational processor problem rather than the 
actual software. When this occurred, Amira was chosen due to in-house experience by Ross 
Laws (EMRS) and previously optimised techniques to analyse SBF-SEM data in this software 
(Cocks et al., 2018). IMARIS was preferred for analysis due to the added parameter of distance 
between each surface created. This allows quantification of the distance between the nucleus 
and each surface. This measurement was calculated as the distance between the midpoints 
of both surfaces. In Amira, this requires manually drawing a line and measuring it on the 
software, and in a large-scale study, such as this which aimed to examine a large number of 
mitochondria, this is not feasible to do. However, due to the processing problems in IMARIS, 
AMIRA was chosen for this study. The distance from nucleus was compared manually, as 
presented in figure 6.2.  
The parameters of surface area and volume were obtained from Amira. This was also 
compared to the few of the cases that successfully worked on IMARIS 9. One-way ANOVA 
showed no significant differences in both these parameters in an individual case between both 
these software, further validating the data obtained. The graph comparing IMARIS 9 and 







































































































































































































































































































































 Comparing variability between controls 
All the controls were compared to analyse any variability between each other in each of the 
parameter tested, which were mitochondrial surface area, mitochondrial volume and MCI. 
Previously in the literature, a ‘form factor’ was calculated from 2D images of mitochondria, 
which provided the degree of branching (Mortiboys et al., 2008, Koopman et al., 2005). This 
was calculated based on the length and aspect ratio of the mitochondria. This equation was 
modified for use in 3D structures and is presented in equation 6.1. This equation took into 
account the 3D nature of these structures by using the surface area and volume of each 
mitochondrial surface. This equation has been systematically evaluated and validated to study 
mitochondrial branching (Vincent, 2017). 
One-way ANOVA was used to test any significant differences between the cases. No significant 
differences were observed between the controls, except in the case of MCI. This is presented 
Figure 6.3 Comparing mitochondrial volumes obtained from IMARIS 9 and AMIRA. This was conducted to 
validate the data between the two software suggesting that the data is reliable as there were no significant 




in the graphs in figure 6.4. Significant differences in the MCI between C3 and some of the 
other cases could potentially be due to biological variation, which could be confirmed by 




Figure 6.4 Testing the variability between controls. This was conducted to validate that the controls were in fact 
controls. The details of the cases are highlighted in table 6.1. The data was tested using a one-way ANOVA and * 
indicates p>0.05 and *** indicates p>0.001. 
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 Comparing mitochondrial parameters with healthy ageing and disease conditions 
Mitochondrial surface area, volume and MCI was also compared between healthy ageing and 
patient tissue. The controls were pooled together and compared to the patient tissue. The 
graphs are presented in figure 6.5.   
In the case of mitochondrial surface area and volume, there is no significant difference 
between the control neurons and the patients, in both the perinuclear and distal group.  
The MCI data showed significant differences (p<0.001), however, all these differences were 
between the case P3 and all the other data. All the other cases did not show any significant 
differences from the control.  In the distal region, P2A was also not significantly different from 
the P3 region. An image of P3 compared to one of the control, C1A, is presented in figure 6.6. 
This highlights the clear difference in the mitochondrial branching.  
The significant differences observed in MCI that was not present in the mitochondrial surface 






Figure 6.5 Comparing mitochondrial parameters between healthy ageing and disease conditions. This figure 
presents the mitochondria surface Area (A), mitochondrial volume (B) and MCI (C). The data was tested using a 





 Comparing mitochondrial parameters in neurons with Lewy bodies  
As mentioned above, in some cases, multiple neurons from the patient were reconstructed. 
In one of the DLB patients, two separate dopaminergic neurons from the same patient were 
analysed: P2A and P2B. One of these neurons presented with Lewy bodies, however the other 
did not show evidence of a Lewy body within the stack analysed. An image of both the 
neurons, along with the 3D reconstructions is presented in figure 6.7. Although significant 
differences (p<0.05) were not noticed when the datasets were compared, there are 
observable differences. In the neuron without the Lewy bodies (P2B), the mitochondria 
appeared elongated and branched and in the neuron with the Lewy bodies, the mitochondria 
appeared more fragmented. However, an increased number of mitochondria will need to be 
analysed to study this in more detail. 
Figure 6.6 Comparing mitochondrial MCI (degree of branching) between healthy ageing and DLB. This figure 
presents the 3D reconstructions of the mitochondria in in a control case C1A and in the DLB case P3. P3 has 
significantly different (p<0.001) MCI values from most of the controls and other disease individuals used. The blue 





Figure 6.7 Comparing cells with and without Lewy bodies from the same patient. This figure presents the 3D 
reconstructions of the mitochondria in two neurons from the same DLB patient. One cell contained lewy body 
heighted by the red arrow, and the otherdid not. The blue surface highlights the nucleus, red highlights 
perinuclear mitochondria and the yellow highlights distal mitochondria. 
  Comparing mitochondrial parameters with perinuclear and distal mitochondria  
There were no significant differences (tested for p<0.05) between the perinuclear and distal 
regions in all the three mitochondrial parameters tested. This is presented in figure 6.8. This 
could be due to two main factors, one of which is the number of mitochondria studied. A total 
of 32 mitochondria per region could not be a large enough ‘n’ number to see any significant 
differences. A high total number of neurons analysed could be beneficial. Alongside this, due 
to the technique, there were difficulties in establishing a perinuclear or distal region. In the 
majority of the neurons studied, axonal regions were not visible. This could suggest that all 
the mitochondria studied in these cases were actually perinuclear. This will have to be 
improved in further studies.  
 
 
Figure 6.7 Comparing cells with and without Lewy bodies from the same patient. This figure presents the D 
reconstructions of the mitochondria in two neurons from the same DLB patient. One cell contained lewy body 
heighted by the red arrow, and the otherdid not. The blue surface highlights the nucleus, red highlights 





Figure 6.8 Comparing mitochondrial parameters between perinuclear and distal mitochondria. This figure 
presents the mitochondria surface Area (A), mitochondrial volume (B) and MCI (C). The data was tested using a 




 Nanotunnels or Mitochondria on a string (MOAS)  
Two of the studies mentioned in the introduction have noticed certain structures of 
mitochondria where two bodies of mitochondria are connected by a long tubular structure 
(Zhang et al., 2016, Vincent et al., 2017). Initially, these structures were identified in studies 
in cardiomyocytes and kidney cell with Confocal imaging and TEM respectively (Huang et al., 
2013, Gupta et al., 2008). In the study on kidney cells, these thin microtubular structures were 
termed ‘mitochondrial extensions’. The study on cardiomyocytes coined the term 
‘nanotunneling’ and suggested this to be a mechanism of communication between static 
mitochondria to exchange contents or signals between the network (Huang et al., 2013). 
Following this, a study on skeletal muscle identified these structures using SBF-SEM (Vincent 
et al., 2017). They identified a number of features of these structures including the presence 
of a double membrane, a diameter of 40-200nM and a length of up to 30µM. This study also 
suggested these structures to aid the sharing of contents between mitochondria. Following 
this, nanotunnels were also found to be at an increased frequency in patient tissue compared 
to controls (Vincent, 2017). These nanotunnels are consistent with the bacterial origin of 
mitochondria as nanotubes are used by bacteria for the purpose of communication (Dubey 
and Ben-Yehuda, 2011).  
However, a similar structure has also been identified from the brain of Alzheimer’s patients 
using ssTEM (Zhang et al., 2016). They termed this structure ‘mitochondria on a string’ (MOAS) 
due to its appearance. They suggested that this structure was due to arrested fission of the 
mitochondria in a damaged tissue, developed as a compensatory mechanism to counteract 
the biochemical defect and protect from mitophagy. They also found this structure in wild 
type mice when damage was induced by hypoxia or in an ageing cohort. Following this study, 
ssTEM was also used on rhesus macaques where this structure was also observed with ageing 
(Morozov et al., 2017). They suggested this could be a result of a malfunction in dynamics with 
ageing.  
Another study in mice using FIB-SEM also recognised tubular mitochondria. In this case, these 
mice were transgenic with an inducible Drp1 ablation, specific for neurons (Tamada et al., 
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2017). Drp1 is involved in fission of the mitochondria. This study discovered that, when the 
Drp1 mutation was induced, after one week it lead to various tubular mitochondria, however 
after two weeks, these resulted in enlarged mitochondria. It has been suggested that, due to 
the lack of Drp1, the mitochondria fused together. In this scenario, the fission arrest lasted for 
a week and lead to enlarged mitochondria. If MOAS theory is true, a large number of enlarged 
mitochondria would be observed in the cases presenting a large number of nanotunnels. 
However, this cannot be confirmed since the mice used in this study specifically had a DRP1 
knockout. However, in patients, fission arrest could be temporary, hence it does not lead to 
enlarged mitochondria.  
These structures were identified in this study in single substantia nigra neurons and images of 
them are present in figure 6.9. The sequential images (A-N) presents the reconstruction of two 
mitochondria which are connected via a nanotunnel highlighted in red. Due to the number of 
stacks through which this extends, a few sections were omitted in the figure, and thus a 
representative reconstruction is presented in this figure. Another mitochondrion with a 
nanotunnel is presented in figure 6.10, which also contains the measurement of its diameter. 
Both of these were from case P2B (DLB), where a large number of tunnels were observed. 
Nanotunnels were also observed in both patient and control tissue, however, none compared 
to the number in the case P2B. These nanotunnel structures were also observed frequently in 
P1 which is a patient with AD. This is in concordance with the paper stating the MOAS theory 
(Zhang et al., 2016). The presence of nanotunnels were cell dependent as they were noticed 
in some disease and control cases, and were also equally absent from other disease and 
control cases. This is presented in figure 6.11. However, as mentioned before, this could be 
the effect of using aged controls, however this is a pilot study with a small sample size and 











Figure 6.9 sequential sections highlighting the tubular structure. This image presents a 3D reconstruction of the 




Figure 6.10 Mitochondrial nanotunnel. The diameter of this structure is presented in the image. A 3D reconstruction 
of this mitochondrion with the nanotunnels is also presented in this image. The images were obtained using SBF-





 Comparing mitochondrial parameters between healthy ageing and patients 
In this study, I successfully used the SBF-SEM to reconstruct mitochondria from single 
dopaminergic neurons from human tissue in healthy aged controls and a small cohort of 
patients with neurodegenerative diseases including AD and DLB. We also undertook the first 
assessment of the mitochondrial 3D network in this tissue in humans. The technique needed 
optimisation, which was undertaken and is detailed in the results section. A fully optimised 
Figure 6.11 Mitochondrial nanotunnels in patient and control cells. This figure presents the 3D reconstructions of 
the mitochondria with nanotunnels in the cases P1 and C1A and mitochondria without nanotunnels from the 
cases P3 and C3. The details of each case are highlighted in table 6.1. The blue surface highlights the nucleus and 
the red highlights perinuclear mitochondria. The cytoplasmic mitochondria are not presented in these cases. 
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method to study mitochondria in human dopaminergic neurons has been developed in this 
study.  
Four neurons from patients with neurodegenerative diseases and four controls were used in 
this study. The controls were tested for variability. No significant differences (p<0.05) were 
noticed between the control in the mitochondria surface area and volume, however, there 
were a few significant differences (p<0.05) in the MCI values. This could be due to biological 
variation or due to the age of this control. This is potentially the effect of a small sample size, 
as it renders the statistical power weak. Since this is a pilot study, it was useful to investigate 
any statistical differences. A larger number of neurons would of course have to be studied to 
validate this and statistical power.  
When these parameters were compared between patients and between patients and the 
controls, significant differences (p<0.05) were noticed in mitochondrial surface area and MCI, 
but not in volume. This suggests that mitochondrial volume remains same in healthy ageing 
and in neurodegenerative conditions, however, the surface area and MCI changes suggests 
that the mitochondria may become more tubular and branched, but the overall volume 
remains the same. This might suggest that the mitochondria are altering their shape, but not 
their volume. In support of this is work that suggests that fission and fusion proteins such as 
drp1, mfn1 and mfn2 are altered in AD models (Westermann, 2010, Manczak et al., 2011, 
Wang et al., 2009). Changes in the shape of mitochondria are also linked to neurodegeneration 
as it affects cell physiology and signalling (Campello and Scorrano, 2010). However, as 
mentioned before, detailed analysis need to be performed here due to the small sample size 
and in order to make firm conclusions more cases and neurons require analysis 
 Comparing mitochondrial parameters between perinuclear and distal mitochondria  
Unlike the previous chapter and previous literature using ground squirrels and rats (Popov et 
al., 2005), all of the mitochondrial parameters tested were not significantly different between 
the perinuclear and distal mitochondrial populations. This could be due to three main reasons. 
Since the controls used were aged individuals, maybe ageing could influence this similarly in 
control and disease models. Previous studies on brain tissue from healthy ageing and PD 
patients have demonstrated that the levels of mtDNA deletions and COX-deficiency were 
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similar in PD and age-matched controls, which were significantly different from a younger 
group (Bender et al., 2006c, Kraytsberg et al., 2006b). However, the result from the previous 
chapter highlight no significant differences in thymidine analogue incorporation and therefore 
mtDNA replication between these regions in a young and aged cohort.  
Another reason for the lack of any significant difference could be due to the regions in this 
study that were termed perinuclear and distal. Since the Z-stacks were based on the cell body, 
the majority of the neurons did not produce an axon. Due to this, the mitochondria termed 
‘distal’ could in fact be perinuclear. A number of the Z-stacks, along with the cell body of a 
dopaminergic neuron, also contains axons from nearing cells. These are myelinated and easily 
identified, Therefore, to combat this, mitochondria within nearby axons could be studied. 
However, this presents another problem that the mitochondria studied will be from different 
cells and as noticed before, there could be cell to cell differences (figure 6.7). Alongside this, 
the sample size is too small and hence, the statistical power is weak. Therefore, this required 
a higher number of neurons analysed. 
 Variability between cells from the same patient 
This study also noticed variability in two different neurons from a patient with DLB. These 
were observational and not significantly different for the parameters tested. From this patient 
I investigated a neuron which contained a Lewy body and one which did not. In the neuron 
without the Lewy body, the mitochondria appeared highly tubular and elongated, whereas in 
the presence of Lewy body, mitochondria appeared fragmented (figure 6.7). 
GBA1 is a gene which is highly variant in individuals with PD, which is a disease that presents 
with Lewy bodies. Mutations leading to loss of functions in this GBA1 gene in a mouse model 
demonstrated accumulation of α-synuclein which is the main component of Lewy bodies 
(Osellame et al., 2013). This study also demonstrated an increase of fragmented mitochondria 
in this case. Increased fragmentation of mitochondria has also been demonstrated in vitro 
upon the over-expression of α-synuclein (Nakamura et al., 2011). This suggests that the 
fragmented mitochondria could be the result of the Lewy bodies. However, mitochondria have 
also been suggested to influence α-synuclein accumulation as they can release a protease 
enzyme called neurosin that can cleave the α-synuclein aggregation or the Lewy body, but can 
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also release cytochrome C which is suggested to be involved in the accumulation of α-
synuclein (Iwata et al., 2003). 
However, this requires further work, since the neuron without Lewy body could actually in 
fact contain Lewy bodies, which were not present in the Z-stack taken. In addition to this, the 
lack of significant differences could be due to the parameters tested or due to the small 
sample size. 
 Nanotunnels  
As mentioned before, although the presence of these long tubular structures were observed 
in AD from neurons in the hippocampus, cortex and cerebellum, this study is the first to 
observe this within dopaminergic neurons from patients with AD, DLB or in healthy ageing. A 
number of the reconstructed mitochondria were presented with these nanotunnels. These 
structures were frequent in P1 and P2B. P1 is a patient tissue affected by AD and these 
structures were observed on the case of AD tissue previously and was suggested to be due to 
fission arrest (Zhang et al., 2016). This is a novel discovery in the case of a neurons affected by 
DLB. However another neuron from the same tissue was presented with no nanotunnels, 
although this neurons contained Lewy bodies (refer to figure 6.7), therefore the nanotunnel 
could potentially be a compensatory mechanism present at low levels of cellular stress. 
However, neurons from control also demonstrated an absence of nanotunnels which could be 
due to the specific control used. Nanotunnels were observed in C1A where the age of the 
patient was 54, but absent from C3 where the patient was 94 years old. This is preliminary and 
the differences were observed but not quantified, therefore, the study needs to be extended 
to a larger dataset in order to test for a relationship between these nanotunnels and ageing 
and disease state.  
 Accumulation of ΔmtDNA  
This pilot study has identified a technique through which variations within the ultrastructure 
of the mitochondria could be observed from the SN, which also possess high levels of ΔmtDNA. 
Since the sample size is small, these variations are not significant between healthy ageing and 
individuals with AD and DLB. Alongside this, variations between the perinuclear and distal 
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mitochondria were also not observed as discussed above. However there were observational 
differences in both groups which could potentially be significant with a larger sample size. 
In addition to this, nanotunnels were noticed in some cases. If the mitochondria, due to these 
nanotunnels, are more connected within the mitochondrial network, this could potentially 
provide a route for the accumulation of ΔmtDNA. However, unpublished data from our group 
suggests that nanotunnels are unlikely to transport nucleoids since only 4% of nanotunnels 
are actually wide enough in muscle. Therefore, this would also require further analysis by 
measuring the lumen diameter of these structures in neurons. 
 Future work 
The aim of this chapter was to provide a proof of concept data in studying mitochondrial 
network and connectivity in a 3D format in human dopaminergic neurons. A large amount of 
future work remains. 
• One of the criticisms against this technique could be the post-mortem (PM) delay 
variation highlighted in table 6.1. The PM delay is unavoidable as this study was 
conducted in human tissue. Although no specific association of post-mortem delay was 
observed in this study, and the quality of the samples was not affected with a higher 
length of PM delay, this would still require validation. These can be conducted in vivo 
potentially using mice models. The same mice can be used for this purpose. The brain 
could be sliced down the midline. The SN can be extracted from one half and fixed 
immediately, and the SN from the other half can be fixed with a stimulated delay. 
Conducting SBF-SEM on these two sections would allow comparison for any 
differences associated with the PM delay.  
• Since this study is on human, brain tissue from young controls would be more difficult 
to obtain. Therefore, in order to study an effect on ageing on mitochondrial network 
and connectivity, in vivo studies on mice could be conducted.  
• The analysis for this technique is time consuming as the reconstruction is conducted 
manually. Therefore, 32 mitochondria was selected from each region. However, when 
expanding, all the mitochondria within a neuron could be studied for an increased N 
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number. These could be classified based on distance after the reconstructions by 
obtaining the distance from IMARIS for each mitochondria from the nucleus. With 
further optimisations and machine learning, this time consuming process could also be 
automated. 
• Since axons are myelinated, SEM easily identifies them. Therefore, this analysis could 
be extended to axons rather than solely to the cell body. This would be a better 
representative of the distal mitochondria. However, this might not be reliable due to 
the different population of neurons present, which would suggest that the axon does 
not belong to a dopaminergic neuron.  
• The previously mentioned study using FIB-SEM has defined and described various 
structures of mitochondria (Tamada et al., 2017). Classifying mitochondria based on 
their structure would provide a good comparison between disease and patients and 
will provide an extra parameter to compare, which could take into account the 
nanotunnels; however this will be observational and could lead to bias.  
 Final conclusion 
This technique is feasible in human SN neurons. This technique is also sensitive enough to 
notice ultrastructure variations within the mitochondria. Manual reconstruction of the 
mitochondria is time-consuming, however this ensures the accuracy of this technique as each 
mitochondrion is studied. Since variations were noticed in this small sample set, this should 









Chapter 7:  Final discussion 
7.1 Introduction 
Mitochondrial DNA deletions (ΔmtDNA) have been implicated to be important for ageing as 
well as a number of disease conditions, including Parkinson’s disease and mitochondrial 
disease. Although they lead to mitochondrial dysfunction and COX-deficiency, the 
mechanisms by which these deletions form and accumulate to high levels remains unknown. 
The suggested pathways for deletion formation are through error prone replication or 
inadequate repair (section 1.6). This study aimed to investigate the role of alterations in 
mtDNA replication in this process. Although many post mitotic cells present with high levels 
of ΔmtDNA, the brain was studied in this thesis since it is a vital tissue affected in both 
mitochondrial disease and PD, and the highest levels of ΔmtDNA reported in the literature are 
found within this tissue (Cortopassi et al., 1992, Meissner et al., 2008).   
7.2 Major findings and further work 
 Variations in mtDNA replication with neuronal type, age and genotype.  
Using thymidine analogue labelling, mtDNA replication levels in various brain regions, ages 
and genotypes were successfully compared in mice. Double thymidine analogue labelling was 
used, with CldU labelling mtDNA for 4 days and IdU for 15 hours. These timings were optimised 
as part of another study (Stamp, 2016). Four specific neuronal subtypes and regions were 
chosen: Purkinje neurons (from cerebellum), Pyramidal neurons (cortex and hippocampus) 
and dopaminergic neurons (SN). These regions were studied in four groups of mice; wildtype 
young, PolgAmut/mut young, wildtype aged and PolgAmut/mut aged. 
The original hypothesis of the study was that if the mechanism of ΔmtDNA formation was 
through mtDNA replication as suggested (section 1.6), then an increase in mtDNA replication 
would be associated with an increased level of ΔmtDNA. However, this was not observed, 
when replication levels from this study was correlated with a previous study in the literature 
(Perrier et al). This would suggest that ΔmtDNA could potentially be forming via another 
mechanism, for example, mtDNA repair. However, evidence supporting an association of 
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mtDNA replication with ΔmtDNA was also uncovered, in that there is an inverse relationship 
between mtDNA replication levels and ΔmtDNA in different brain regions, ages and 
genotypes. For example, mtDNA replication was found to be increased in the cerebellum and 
decreased in the SN, whereas levels of ΔmtDNA is comparably lower in cerebellum and highest 
in SN (table 3.1 and 3.2). Similarly, aged PolgAmut/mut mice also demonstrated lower levels of 
mtDNA replication, but high levels of ΔmtDNA (table 3.1 and 3.2). This suggests that in regions 
with high levels of ΔmtDNA, there are lower levels of mtDNA replication. 
My data suggests a general pattern of an increase in mtDNA replication in regions associated 
with a decrease in ΔmtDNA. Therefore, it could be suggested that increased mtDNA 
replication results in increased mtDNA copy number, which could function as a compensatory 
mechanism, whereby the levels and biochemical defect produced by ΔmtDNA appear minimal 
in these situations. This increased copy number acting as a compensatory mechanism against 
ΔmtDNA has been suggested previously in the literature (Dölle et al., 2016). On the contrary, 
some studies have found comparably lower mtDNA copy number in the cerebellum, which is 
a region with high mtDNA replication and low ΔmtDNA (Fuke et al., 2011b). Other factors 
which might have an on mtDNA replication levels in association with ΔmtDNA are mtDNA 
transcription, transport of mitochondria and mitophagy as discussed in chapter 3.  
However, there are exceptions to this idea of ‘increased ΔmtDNA in regions showing lower 
mtDNA replication’. For example, the SN generally presents with a higher level of ΔmtDNA 
with advancing age (table 3.1 and 3.2), however, there was no age associated decrease in 
mtDNA replication either in the aged wild type or aged PolgAmut/mut mice. It could be suggested 
that since the mtDNA replication levels were low to begin with in these neurons, further 
reduction was not observed with ageing. However, since the mtDNA replication levels are low 
to begin with, this increase in ΔmtDNA could also be explained by clonal expansion of 
mutations over time. As suggested in the previous paragraph, due to a lack of compensatory 
effect by wildtype mtDNA, the ΔmtDNA have an increased chance of replicating and clonally 
expanding (Dölle et al., 2016). 
When considering IdU incorporation, the pattern of replication was as demonstrated with the 
CldU, however not all the cases are significantly different to each other. There were also a few 
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differences, notably within the SN. With CldU, the total mtDNA replication level was the 
lowest in SN, however with IdU, the SN had the second highest mtDNA replication levels after 
cerebellum. This suggests that mtDNA replication occurs at a higher level compared to 
hippocampus and cortex in the short term (15 hours), which reduces to the lowest level of all 
the brain regions within the 4 days. This implies that the CldU incorporation over the 4 days 
could be effected by other mechanisms, such as mitophagy. Therefore, to test this theory, 
MitoQC mice, donated by Dr Ian Ganley (University of Dundee), were used to analyse the 
levels of mCherry positive puncta (mitophagic events) in a cell. Images of dopaminergic 
neurons (SN) and Purkinje neurons (cerebellum) were obtained and compared to each other. 
A significantly higher level of mitophagy was observed in the SN compared to the cerebellum. 
However, validation would require further investigation, such as the study of more brain 
regions.  
 Relationship between ΔmtDNA and mtDNA replication 
Since an association between regions and groups with high levels of ΔmtDNA and low levels 
of mtDNA replication was noticed, it was vital to study the correlation between these two 
cases. Published data regarding ΔmtDNA and mtDNA copy number in different brain regions 
was kindly shared by Dr Celine Perier (Vall d’Hebron Institute of Research, Spain)(Perier et al., 
2013). Their study was similar to this study as several regions of the brain were investigated 
in wild type and PolgAmut/mut mice. No association was observed between the mtDNA 
replication levels and corresponding ΔmtDNA levels in the various brain regions studied or in 
PolgAmut/mut mice. There was also no association between the mtDNA replication levels and 
the mtDNA copy number in these regions, suggesting that ΔmtDNA are not caused by 
replication, rather, by other mechanisms, such as repair.  
Although the studies were similar, there are a number of limitations between the two. This 
study analysed individual cells from these regions, however Perier et al. studied homogenate 
tissue samples. The use of homogenate data could be contaminated by other cell types (for 
example astrocytes or interneurons) which could skew the data. Variations in mtDNA copy 
number have been demonstrated in studies investigating the same tissue but in homogenate 
and individual neurons (Coxhead et al., 2016, Dölle et al., 2016, Pyle et al., 2015). Furthermore, 
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since an average value per mouse was obtained, and not the raw values per replicate, this 
saturates the statistical power. In addition to this, Perier et al. reported that the cerebellum 
contained a higher ΔmtDNA load than the midbrain (where SN is located) which contradicts 
other studies in the literature (refer to Table 3.1 and 3.2 in Chapter 3). Due to the differences 
between the two studies, further investigations are required. To accommodate future work in 
this area, half of each mouse brain used in this study was snap frozen. Individual neurons could 
be isolated via laser-microdissection, and molecular analysis could be conducted using 
quantitative real-time PCR to study the total levels of ΔmtDNA as described previously (He et 
al., 2002).   
 Developing thymidine analogue labelling for use in vitro 
Thymidine analogue labelling has been used previously to study mtDNA replication in vitro, 
however single analogues were commonly used (Section 4.1.1). Until very recently, double 
thymidine analogue labelling had not been used in vitro to study mtDNA, likely due to the 
technical optimisation required (Phillips et al., 2017). The initial idea was to develop a pulse 
chase experiment to study the turnover of mtDNA replication, and for this reason the 
methodology was developed on HeLa cells. The optimum concentration of both analogues 
was deduced separately, based on cell viability and level of mtDNA incorporation of each 
analogue. Although the concentration was optimised for each individual analogue, the 
combination of analogues was toxic, and therefore a single analogue was selected. IdU was 
chosen due to the higher level of incorporation within the mtDNA. Since nuclear genome 
replication was also incorporating IdU, aphidicolin was used to block this to ensure that only 
mtDNA replication was being labelled. Following this, appropriate analysis was also developed 
for future use. 
Following optimisations in HeLa cells, this methodology was successfully employed in iPS cells 
and differentiated neurons generated from fibroblasts containing a single, large-scale mtDNA 
deletion. This technique can successfully label mtDNA replication and was then used to obtain 
preliminary data for chapter 5.  
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 Localisation of mtDNA replication within neurons in vivo 
Thymidine analogue labelling was also used to study the localisation of mtDNA replication. 
Successful analysis was optimised to study this, and compared between each cohort of mice 
using delta values produced by Dr. Conor Lawless (Wellcome Centre for Mitochondrial 
Research). This was achieved by identifying perinuclear and distal mtDNA replication based 
on the nuclear radius, allowing comparison of mtDNA replication localisation between groups 
(in depth explanation in chapter 5).  
Differences were noted between the time points of IdU (15 hours) and CldU (four days) in vivo. 
At 15 hours, a large number of data sets from the mouse cohorts demonstrated increased 
mtDNA replication in the distal regions. However after four days, the majority of the mtDNA 
replication was present within the perinuclear region. This pattern of increased mtDNA 
replication in the distal region at the shorter time frame and increase in the perinuclear region 
at the longer time frame was previously observed (Van Laar et al., 2018). This shift from the 
distal to the perinuclear region of mtDNA replication localisation could be to aid quality 
control or due to increased anterograde transport. However, this requires further 
investigation. When the delta values were compared, significant differences were only 
observed between the cerebellum and other regions when analysed for IdU incorporation. 
The cerebellum had significantly lower delta values compared to the other regions, suggesting 
an increase in distal replication compared to the other regions. Since damaged mitochondria 
are targeted and transported anterograde into the perinuclear region, this could be a 
compensatory mechanism to avoid replicating ΔmtDNA. Localisation of mitophagy was also 
analysed in dopaminergic neurons of MitoQC mice, donated by Dr Ian Ganley (University of 
Dundee) as part of a preliminary study to identify localisation of mitophagy. These data 
suggest an increased perinuclear localisation of mitophagy within the SN. However, other 
regions of the brain would require analysis to make firm conclusions. 
 Could mitochondrial structure affect the clonal expansion of mtDNA deletions? 
As differences in mtDNA replication localisation were observed, it was important to study the 
ultrastructure of mitochondria to investigate mitochondrial network and interconnectivity, 
which would shed more light on spread of ΔmtDNA. This was performed via SBF-SEM as it 
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reveals the mitochondrial structure and connectivity in a 3D format without compromising 
the resolution. This was a ‘proof-of-concept’ study on dopaminergic neurons from both 
human healthy aged controls and patients with Alzheimer’s disease (AD) or dementia with 
Lewy bodies (DLB).  Imaging was conducted to obtain a 3D model allowing measurements of 
parameters not available from a 2D image. This allowed identification of alterations to the 3D 
structure such as volume and variations in the structural connectivity of the mitochondrial 
network.  
Although variations between the perinuclear and distal mitochondria were not observed, this 
was mainly due to the limitations discussed in chapter 6 and were likely due to the small 
sample size included in this study. Variation was observed between the healthy ageing 
controls and the patients in terms of mitochondrial surface area. Variations between patients, 
concerning mitochondrial branching were also observed. Since a small number of neurons was 
analysed, a greater number will need to be analysed to statistically compare between patients 
affected by neurodegenerative diseases and those who are unaffected.  
An interesting observation from this study was the identification of two neurons from the 
same DLB patient, one with Lewy bodies and one without. Variations were noticed between 
the two neurons from the same patient. The mitochondria within the neuron containing Lewy 
bodies appeared more fragmented, with reduced mitochondrial branching. Alongside this, 
elongated tubular structures were noticed (highlighted in figure 6.9 and 6.10). Previous 
literature has suggested that these could be nanotunnels between mitochondria that will 
allow communal sharing of contents between mitochondria (Vincent et al., 2017). 
Nanotunnels might be forming to compensate for the limited movement of mitochondria, 
which might be blocked by Lewy bodies in this case. This is the first time nanotunnels have 
been noticed within neurons and could be functioning as a compensatory mechanism as this 
was noticed in both patients (DLB and AD) and healthy ageing. On the other hand, it could also 
aid in the accumulation of ΔmtDNA, as these molecules could be shared throughout the 
network. However, measurements of these nanotunnels in muscle suggest that only 4% of the 
nanotunnels have sufficient diameter to allow transport of nucleoids (Vincent et al., 2019). 
Alternatively, these structures could be ‘mitochondria on a string’ (MOAS) as described by 
another study which suggested that they occur due to fission arrest (Zhang et al., 2016). In the 
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study by Zhang et al, these structures were noticed in AD patient, which was also the case 
with this study. However, these structures were also noticed in a healthy ageing individual in 
this study. Therefore further steps to confirm these structures and their function could 
provide the required information on disease progression and ΔmtDNA accumulation.  
 Role of ΔmtDNA replication in mtDNA formation and accumulation 
An increase in mtDNA replication was not observed in brain regions with an increase in 
ΔmtDNA, suggesting that mtDNA replication does alone not directly lead to formation of 
ΔmtDNA. However, a pattern of association, specifically a decrease in mtDNA replication in 
regions of high ΔmtDNA was observed, suggesting a relationship between these two 
processes. In addition to this, variations were also noticed in the location of mtDNA replication 
with respect to neurons both in vivo and in vitro. This was particularly noticeable between the 
two time points of 15 hours and 4 days in vivo, suggesting that another mechanism could 
function to effect both mtDNA replication and ΔmtDNA. This could be altered transport, 
mitophagy, transcription or mtDNA repair.  
7.3 Final conclusion  
The aim of this study was to further our understanding of the role of mtDNA replication in 
deletion formation and accumulation within the brain. The main findings were as follows; 
• This study was the first to identify variation in mtDNA replication levels within different 
neuronal populations in vivo and found associations with ΔmtDNA levels, however this 
requires further work to successfully establish a relationship.  
• A methodology was developed to study mtDNA replication turnover in vitro. 
• The location of mtDNA replication localisation was identified as being increased in the 
perinuclear region. The localisation of mtDNA deletions did not alter between 
neuronal subtypes, or in ageing or replication defect.  
• The feasibility of using SBF-SEM on human post mortem brain tissue, to understand 
mitochondrial ultrastructural changes in disease was proven. 
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This study has uncovered potential compensatory mechanisms present within different brain 
regions to protection against ΔmtDNA. Analysis of ΔmtDNA levels in single laser micro-
dissected neurons could be used to correlate with these findings as most studies in the 



















Chapter 8:  Appendix 
8.1 Thymidine analogue incorporation – cell death  
Figure 4.8 displays images of IdU labelled HeLa cells at 2.5µg/ml and also highlights the cell 
death that was observed and the morphology of the dead cells. Cell death was noticed in these 
cases; however, they were not as elevated as in the previous tries with the combination of the 
thymidine analogues (data not presented). The cell death was quantified using Image J and is 
presented in supplementary figure 8.1 for each of the concentrations and times trialled. These 
were identified based on the morphology as indicated in figure 4.8. An untreated control was 
used to compare the level of cell death. Since this control was only left for 24 hours, 
statistically this was not compared to the concentrations at 48 hours, as the cell death could 
























































































































Supplementary figure 8.1 The effect of CldU and IdU labelling on cell survival in HeLa cells. The cells were treated 
for either 24 or 48 hours with concentrations ranging from 3-6µg/ml for the CldU and 1µg/ml for the ldU. A 
control was used which was an untreated well which was fixed after 24 hours. Since this was fixed with the 
concentrations at 24 hours, these were compared to each other statistically. The N=10 images for each thymidine 
analogue label. Each 24 hour concentration was compared to the untreated cells ** indicates p < 0.01 and *** 
indicates p < 0.001 
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With the CldU, the number of dead cells were similar for all the concentrations and time points 
that were all significantly different from the untreated (p < 0.01 and p < 0.001). These were 
also decreased compared to the IdU cells but this could be due to the dead cells detaching 
and being removed during washing. This is reflected in the fact that the total cell count is 
reduced. For the IdU labelled cells, the lower concentrations showed reduced cell death 
compared to 2.5µg/ml and above. At 6µg/ml, the number of dead cells appear reduced 
compared to the lower concentrations; however, this was due to the detachment of dead 
cells, which could potentially have been removed along with the media prior to fixation. A 
limitation of attempting to measure toxicity is the detachment of the cells following steps 
during immunofluorescence. Due to this, the number of dead cells not be accurately 
represented since these are not accounted for and hence may not correctly measure toxicity. 
8.2 Analysis of thymidine analogue labelling in vitro using IMARIS 9 
The correct quantification and analysis of IdU incorporation into cells was vital for the success 
of this project. Analytical approaches used the mitochondrial marker to normalise the IdU 
incorporated into mtDNA since each cell is different in terms of size and abundance of 
mitochondria. Two methods of analysis were considered. The first method of analysis used 
ImageJ (Fiji). In this case, the images were exported as TIFFs exporting each individual channel 
as a separate file. The images were then opened in ImageJ (Fiji). The ‘Freehand selection’ 
function was used to draw around the cell region based on the Tom20 channel to create a ROI. 
This was then duplicated on to the IdU channel using the ‘ROI manager’ function, wh ich can 
pick up this exact region based on the loci in multiple images. The mean intensity for each ROI 
in each channel was then produced by the ‘measure’ function. The intensity of the IdU channel 
is then expressed as a percentage of the Tom20 channel.  
Since this method produces the mean intensity per unit area, this is not completely accurate, 
as the range of intensities within the cell cannot be obtained from the software. If individual 
mitochondrion in a cell had a very high incorporation of IdU into the mtDNA, this might 
produce a similar mean intensity as another cell with multiple mitochondria with IdU 
incorporation but with a lower intensity. In this way, the data may not accurately reflect the 
total number of mtDNA molecules that have replicated in a single cell. For this reason, another 
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analysis method using Image J was also considered, such as choosing multiple ROI’s within a 
single cell based on the Tom20 channel. This was randomized and identified multiple 
mitochondrial regions within a single cell allowing calculation of the sum of total intensity and 
range, however this also had the problem of not including every mitochondria.  
To overcome this problem, IMARIS (bitplane) was used. In IMARIS, a surface is created by 
manually drawing around the cell boundary in the Tom20 image to produce an ROI. This is 
then masked on to the Tom20 channel to produce a surface only within the area where there 
is positive staining for Tom20. The Tom20 mask was then used to select a new channel that 
detects only the IdU staining within the Tom20 surface created (i.e. only IdU incorporated into 
mitochondria). This allows the creation of a surface that accurately represents the total 
number of IdU positive areas within the Tom20 positive population. The sum of the volumes 
for the Tom20 and IdU channel are then obtained from the software. The total IdU values are 
then expressed as a percentage of the total Tom20 values. This way, all the individual IdU 
positive puncta are considered individually unlike the previous analysis. The systematic guide 
to conduct this analysis is presented in Supplementary figure 8.2. With the surface creation, 
background subtraction was a function that was used to choose positive staining for 
mitochondria based on their size. Since IMARIS provided was the most accurate method, this 












































































8.3 Determination of nuclear size 
The CldU and IdU labelled mouse brains were stained and imaged using the Nikon A1R 
confocal system. Initially it was determined to identify the diameter of nucleus based on the 
intensity of the Hoechst channel. This can be identified using a threshold value for positive 
staining within this channel an d any values above this value would determine the presence 
of nucleus and any values below, an absence of a nucleus. However due to the high level of 
noise and saturated pixels in this channel, it was difficult to accurately determine the nuclear 
membrane as suggested by a threshold value. Therefore, this led to development of other 
techniques to identify the perinuclear and distal cytoplasmic regions. 
When the data was obtained, since the highest point of Hoechst was designated as the centre 
of the cell, the perinuclear region differed between cells, especially since the neurons have 
varying sizes. However, since a large number of cells from at least 10 images (per region/per 
genotype/per age) were analysed (at least 160 images), this should average out the intensities 
in the perinuclear region. To increase the accuracy of this calculation, the diameter of the 
nucleus in pixels was also measured manually using image J, and the radius calculated. This 
was conducted for a minimum of 10 neurons per region per group. The nuclear radii for each 
region from each group is plotted in supplementary figure 8.3. When comparing between 
regions, there are significant differences (p<0.05) in nuclear radius between all the neuronal 
types. This was expected due to the differences in neuronal size. When comparing between 
ages and genotype, there were no significant differences detected (p<0.05) except in the case 
of PolgAmut/mut old, which was significantly increased to the other cohorts. The reason for this 
in unknown. However, since this method was developed for classifying the regions of the cell, 
and this was conducted successfully and this method was carried forward for further 
experiments. This step of validation was also conducted for the in vitro study as well, with no 
significant differences detected in nuclear radius between the low and high heteroplasmy 











Cerebellum Cortex Hippocampus SN 
Supplementary figure 8.3 Variations in nuclear radius diameter (in pixels). The graph presents the spread of 
nuclear radii from which the average nuclear radius is calculated to separate the perinuclear region from the 
distal regions of the cell. Ce represents cerebellum, co represents cortex, hi represents hippocampus, sn represents 
substantia nigra, PO represents PolgAmut/mut old, PY represents PolgAmut/mut young, WO represents wild type old, 
WY represents wild type young and px  represents pixels. 
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8.4 Immunofluorescent image analysis optimisation 
 Since IMARIS provides analysis of various parameters, four parameters were selected and 
compared. These included area, volume, fluorescent intensity and number of voxels. IMARIS 
surfaces are constructed by triangular shaped objects called voxels which are the equivalent 
of a pixel in an image, therefore, ‘number of voxels’ gives the number of said voxels used to 
construct the image. All of the different parameters produced similar results with no 
significant differences (at a p value of 0.05) in terms of the level and pattern of replication. 
Since there were no significant differences, the number of voxels was carried forward for the 
future analysis. This was suggested by the manufacturer due to the 2D nature of the images.  
Other studies have also analysed thymidine analogue labelling using Fiji (Image J) (Van Laar et 
al., 2018, Schindelin et al., 2012). A subset of the data from this study was also analysed this 
way to test for any differences to IMARIS to allow the selection of the most appropriate 
technique. This analysis was undertaken on at least five images from the young wild type and 
young PolgAmut/mut groups (Supplementary figure 8.4). The approach using Fiji revealed 
differences to previously obtained results from IMARIS in terms of the levels of CldU and IdU 
within each region. In these graphs, there was a significant difference between the four 
different brain regions in terms of CldU and IdU labelling as highlighted in the graph 
(Supplementary figure 8.4A and B). However, there were also differences in the number of 
puncta of the Tom20 and area, which demonstrated an increase in the cerebellum compared 
to the other areas for both the wild type and the PolgAmut/mut mice (Supplementary figure 8.4C 
and 8.4D). This highlights a flaw with this analysis when used to compare different cell types, 
as it does not take into consideration the size of the cell. Cell size can account for the increase 
in puncta per cell and per area within the cerebellum and SN, since the Purkinje cells and 






Supplementary figure 8.4 Analysis optimisations: IMARIS vs Image J – The puncta per cell values are obtained 
from Image J. Images A and B presents the puncta per cell values for the CldU and the IdU channel. Images C and 
D presents the variation in the Tom20 channel for the puncta for cell values and the area of cell within each tissue 
type. The tissue type is indicated by colour with the key. All these mice were from the young group, W indicates 
wild type mouse and P indicates PolgAmut/mut mice. The N is at least 5 images for each area. * indicates p < 0.05, 




Due to these variations, to normalise the data, the Tom20 puncta per cell was divided by the 
area of the cell (Supplementary figure 8.5A), this generated similar patterns between the 
regions for all cell types suggesting normalisation to area as a valid step in this analysis. The 
values from CldU and IdU in the young group of wild type and PolgAmut/mut mice were 
normalised to the area of the cell and produced a similar pattern to the IMARIS analysed data. 
Image J and IMARIS analysis of CldU (Supplementary figure 8.5B and D) and IdU signal 
(Supplementary figure 8.5C and E) were then compared. The range of values are different 
from the two image analysis packages: 0-30 for Image J and 0-100 for IMARIS. This was 
because, in Image J, the values are divided by the area of the Tom20 puncta and in IMARIS, 
the values are expressed as a percentage of the Tom20 values. 
There are still notable variations, for example between the wild type cerebellum CldU signal 
compared to the hippocampal data from the same group. This could be due to the number of 
values for each group. In the image J group, the maximum number of cells analysed was 40 
and for the IMARIS, this was 106. This is because, only a subset of 5 images were selected for 
analysis via Image J. It is however, reassuring that all the significant differences identified by 
the Image J values were also identified by IMARIS values. However, again potentially due to 
the higher number of cells, IMARIS identified more significant differences and was therefore 
















































































































































































































































































































































































































































































































8.5 Differentiating between replication and repair 
One of the concerns against using thymidine analogue labelling to study DNA replication is 
that thymidine incorporation is not exclusive to replication. Thymidine and its analogues can 
be incorporated into the mtDNA during repair. This is particularly important for this study due 
to the use of PolgAmut/mut mice, since polγ is involved in both replication and repair.  
Although it is experimentally difficult to distinguish between incorporation due to replication 
or repair, this may be partially investigated by examining CldU and IdU signal intensities for 
each individual mitochondria. Analogue incorporation via replication will give a significantly 
higher signal intensity compared to repair due to the larger number of base pairs involved in 
replication compared to repair. In replication, 16kbp of mtDNA is available for thymidine 
analogue incorporation, compared to a single or few nucleotides via repair. To differentiate 
between the two, intensities of CldU and IdU signal in each mitochondrial surface were 
analysed. CldU and IdU values were compared from two wild type and two PolgAmut/mut mice 
from the aged group, within the cerebellum and cortex. The ageing cohort was selected as it 
was hypothesised that more mtDNA repair might be occurring due to age related mtDNA 
mutations. The graphs in Supplementary figure 6.1 show that the intensities are similar within 
all surfaces created per mouse. The difference in range is due to the different levels of 
analogue incorporated into the mtDNA. There were two mice within the CldU graph 
(Supplementary figure 8.6A): P1 cerebellum and P2 cortex, and 1 mouse within the IdU: P2 
cerebellum that produced signal intensities at a much reduced level. These values could 
potentially represent mtDNA incorporation via repair. This is reiterated by the even further 
reduction observed in IdU incorporation compared to the CldU as the IdU is labelled for a 
shorter time period. It is also important to mention that these lower values were observed in 
PolgAmut/mut mice. This could be due to an increase in error prone replication which could 
result in a higher demand for repair. 
All values were <1 in both graphs, hence a threshold value for the intensity was set as 10 per 
unit area for subsequent analysis. This would potentially eliminate any thymidine analogue 






Supplementary figure 8.6 mtDNA replication vs repair – The signal intensity produced by the CldU (A) and 
IdU (B) channel for each individual Tom20 surface created. This was to distinguish between replication and 
repair. The yellow boxes represents the values likely due to be incorporated via repair, since they are low. 
The tissue type is indicated by colour with the key in the Figure. All these mice were from the young group, 
W indicates wild type mouse and P indicates PolgAmut/mut mice. N=10 images for each area with the total 
mitochondrial surfaces ranging from 300-4000. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates 
p < 0.001. 
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8.6 Normalising datasets 
Since the replicates were not normally distributed, as confirmed by Kolmogorov-Smirnov 
testing (p<0.05), quantile normalisation was undertaken to compensate for this. This is a 
process by which data can be made comparable by rearranging the dataset in numerical 
ascending order, each value is then given a position within the dataset depending on where it 
appears on the ascending order. Each value is then averaged by its counterparts in the other 
datasets. For example is the lowest value is 3,5,and 7 in the three datasets, the average 
become 5 and the lowest value is all the data sets are then set as three. By doing this, this 
makes each value comparable, however any differences in the high values and low values 
between the datasets are still considered. A graphical representation is provided in 




Supplementary figure 8.7 Data normalisation. These scatter plots demonstrates the spread of data prior to and 
following normalisation to make them comparable between experimental repeats. More details regarding the 
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